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Von Hippel–Lindau (VHL) is the E3 ubiquitin ligase targeting hypoxia-inducible 
transcription factor-alpha (HIF-α) for proteasomal degradation. The crucial function of 
VHL in response to hypoxia and cellular oxygen sensing are well established, owing to 
the use of genetic tools through knockout and knockdown that inactivate VHL. 
However, the functional consequences of specifically interrupting the interaction 
between VHL and HIF-α remain to be elucidated. The development of a chemical probe 
that unambiguously blocks the VHL:HIF-α interaction downstream of HIF-α 
hydroxylation by prolyl hydroxylase domain (PHD) enzymes, would address biological 
questions about VHL molecular targets and functional consequences of disrupting the 
interaction. 
Here, small molecules inhibiting the VHL:HIF-α interaction were shown for the first 
time to stabilise HIF-α and elicit HIF transcriptional activity in cells. The most potent 
VHL inhibitor identified is VH298. VH298 is potent, cell-permeable, selective, and not 
toxic at the concentration required for HIF-α stabilisation. Further characterisation 
shows that VHL inhibitor exclusively induces HIF-dependent changes in global gene 
and protein expression, demonstrating the specificity of the inhibitor. VHL protein level 
was found to increase in the presence of VHL inhibitor, which in turn promotes the 
degradation of HIF-α in prolonged inhibition. 
The work herein characterises the VHL inhibitor as a chemical probe of the hypoxia 
signalling pathway with great potential to address biological questions regarding the 
roles and regulation of VHL. The VHL inhibitor is a unique tool due to its on-target 
selectivity and specificity in inducing HIF activity, without affecting HIF-independent 
response, and exerts its effect further downstream than PHD hydroxylation. This work 




therapeutic potential of VHL inhibitor in diseases, such as chronic anaemia, ischaemia, 
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G2 – Gap phase 2 
GFP – Green-fluorescent protein 




GSK3β – Glycogen synthase kinase 3β 
HECT – Homologous to E6AP C-terminus 
HFF – Human foreskin fibroblast 
HIF – Hypoxia inducible factor 
HK2 – Hexokinase 2 
HRE – Hypoxia response element 
Hpx - Hypoxia 
HSP70 – Heat shock protein 70 
HSP90 – Heat shock protein 90 
IBD – Inflammatory bowel disease 
IgG – Immunoglobulin G 
iNOS – Inducible-nitric oxide syntase 
IPAS – Inhibitory PAS domain 
IRE1 – Inositol-requiring enzyme 1 
IKKβ – Inhibition of κB kinase β 
ITC – Isothermal titration calorimetry 
Kd – Dissociation constant 
LZIP – Leucine zipper domain 
M Phase – Mitosis 




MCT4 – Monocarboxylate transporter 4 
MS – Mass spectrometry 
mTOR – Mammalian mechanistic target of rapamycin 
NAE – NEDD8-activating E1 enzyme 
NHE1 – Sodium-hydrogen exchanger 1 
NF-κB – Nuclear factor κ-light-chain-enhancer of activated B cells 
NODDD – N-terminal oxygen dependent degradation domain 
NOG – N-oxalylglycine 
NTAD – N-terminal transactivation domain 
O2 – Molecular oxygen 
ODD – Oxygen degradation domain 
OTUB7B – Ovarian tumour protease DUB 
PAS – Per/Arnt/Sim domain 
PCC - phaeochromocytoma 
PDK1 – pyruvate dehydrogenase kinase 
PER2 – Period circadian clock 2 
PERK – PKR-like ER kinase 
PHD – Prolyl hydroxylase domain 
PI3K – Phosphoinositide-3-kinase 




PKR – Protein kinase R 
PPI – Protein–protein interaction 
PROTAC – Proteolysis targeting chimera 
pO2 – Partial pressure of oxygen 
RACK1 – Receptor for activated protein kinase C 
RBR – RING-in-between-RING 
RCC4 – Renal cell carcinoma 4  
RGC32 – Response gene to complement 32, also known as RGCC 
RGCC – Regulator of cell cycle, also known as RGC32 
RING – Really interesting new gene 
S Phase – Synthesis phase 
SGC – Structural genomics consortium 
Spry2 – Sprouty 
SRS – Substrate recognition subunit 
STUB1 – STIP1 homology and U-box containing protein 1 
TCA – Tricarboxylic cycle 
TCP1 – T-complex protein 1 
TMT – Tandem mass tag 
TriC – TCP1 ring complex 




TXNIP – Thioredoxin interacting protein, also known as VDUP1 
UPR – Unfolded protein response 
UPS – Ubiquitin–proteasome system 
VDUP1 – Vitamin D upregulated protein 
VEGF – Vascular endothelial cell growth factor 
VBC – VHL:Elongin B:Elongin C 





1.1.  Hypoxia 
Oxygen is required for the survival of metazoan organisms. It is an essential molecule 
for many cellular processes, primarily the oxidative–phosphorylation system, which 
utilises oxygen to generate cellular adenosine triphosphate (ATP), energy for the cell, in 
mitochondria (1). Therefore, a tight control on oxygen homeostasis is important to 
maintain proper cellular functions. Importantly, the demands of oxygen level in an 
organism differ depending on the tissue. The normal physiological level of oxygen, 
termed normoxia, is therefore specific to each tissue (2). While the atmospheric oxygen 
concentration at sea level is 20.95% (760 mmHg), the micro-environmental oxygen 
level in adult human tissues varies between 7-100 mmHg (Figure 1.1). When oxygen 
levels drop below the physiological level in tissues, it is termed as hypoxia; whereas the 
opposite case makes the tissue hyperoxic. 
 
Figure 1.1 – Oxygen partial pressure (pO2) found in various human tissues in situ. 
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Hypoxia occurs when oxygen demand exceeds supply. Hypoxia has been shown to 
contribute to many physiological and pathological processes. Hypoxia is involved in 
physiological adaptation to high altitude (3,4), embryonic development (5), and 
angiogenesis (6,7). For instance in embryonic development, hypoxia triggers 
angiogenesis via vascular endothelial cell growth factor (VEGF) that is induced in 
hypoxia. The stimulation of angiogenesis subsequently affects the development of the 
labyrinth layer of placenta, vascularisation of heart and formation of bone of the embryo 
(5). 
Hypoxia also plays a role in several pathophysiological conditions, such as cancer (8,9), 
anaemia (10) and ischemia including both cerebral and myocardial (11). The association 
of hypoxia in some of these are further discussed in section 1.2. As oxygen homeostasis 
is important for survival, as well as being physiologically and pathologically relevant, 
organisms have developed mechanisms to tightly regulate oxygen levels in cells. A 
major regulator of oxygen sensing and response is the family of transcription factors 
called hypoxia-inducible factors (HIFs). HIFs are activated in response to hypoxia to 
initiate a transcriptional program, and ultimately restore oxygen homeostasis and 
promote cell survival. This is achieved as cells switch off energy demanding processes 
in hypoxia such as cell proliferation, DMSO replication and translation (12-14), and 
trigger metabolic switch to glycosis (15). Besides HIF, there are also other hypoxia 
responsive transcription factors, including NF-κB, Myc, p53 and AP-1 [reviewed in 
(16)]. 
1.1.1. Hypoxia-inducible factor (HIF) 
The response to hypoxia is transcriptionally regulated at the molecular level largely, but 
not exclusively, by HIFs. HIF was first identified in 1995, in work trying to identify the 




DNA sequence in the enhancer of EPO gene was found to interact with HIF-1 through 
biochemical assays. The study led to the identification of HIF-1 and a consensus motif 
termed the hypoxia response element (HRE, ‘5 – RCGTG – 3’) that interacts with 
HIF-1. The transcription factor was found be composed of two different subunits: an 
oxygen-labile α-subunit and a constitutively stable β-subunit (17,18). 
1.1.1.1. HIF-α 
The transcription factor HIF family has since been found to be composed of three HIF-α 
subunits: HIF-1α, HIF-2α (also known as endothelial PAS (Per/Arnt/Sim) domain 
protein-1 [EPAS-1]) (19), and HIF-3α (20); encoded by three different genes. Amongst 
the three-α subunits, HIF-1α is the most studied and characterised. HIF-1α is 
ubiquitously expressed in nearly all cell types, while HIF-2α is detected only in specific 
tissues, including endothelium, lung, kidney, liver, heart, and brain (21). In contrast to 
the restricted pattern in vivo, almost all transformed cell lines express HIF-2α (22). In 
recent years, there has been increasing interest in studying HIF-2α due to the association 
of elevated HIF-2α levels and poor patient survival in multiple tumours (23,24). HIF-1α 
and HIF-2α are the most structurally similar and contribute to the majority of HIF 
transcriptional responses to hypoxia. The two HIFs each transcriptionally regulate both 
a unique and an overlapping set of target genes. HIF-1 transcriptional activity begins 
early in response to hypoxia, whereas HIF-2 governs the adaptation in prolonged 
hypoxia (25-27). Although HIF-1 and HIF-2 are both known to attribute to poor 
prognosis of many cancers, only one of the HIF-α seem to be driving the progression in 
some tumours. For instance, HIF-2α acts as a tumour suppressor in the lung tumour, 
whereas HIF-1α is important for supressing tumour progression in the renal cancer 
[reviewed in (24)]. The opposing roles of HIF-1 and HIF-1 in cancers will be further 




development as the knockout of either subunit in mice is embryonic lethal, albeit at 
different stages [reviewed in (28)]. 
HIF-3α is still very poorly understood. The protein expression of HIF-3α is restricted to 
a subset of tissues [reviewed in (29)]. HIF-3α was initially identified as a dominant 
negative regulator of HIF-1α and HIF-2α through one of its splice variant, termed as 
inhibitory PAS domain protein (IPAS). IPAS binds to the PAS domain of HIF-1α and 
HIF-2α, and prevents their dimerisation with HIF-1β, and thus the interaction with HRE 
of target genes. This negative regulator was later found to be the product of alternative 
splicing (30), and since, at least six splice variants of HIF-3α have been identified with 
different functions and response to hypoxia, as well as transcriptional activity [reviewed 
in (31,32)]. Recent studies showed that HIF-3α also functions as transcriptional 
activator in the zebra fish – it binds to HREs of target genes to induce their expression, 
indicating that HIF-3α is more than a HIF negative regulator (33). However, the 
association between HIF-3α expression and patient prognosis has not been established, 
or conclusively characterised in mammalian systems. 
Structurally, HIF-α proteins are characterised by the presence of an N-terminal 
transactivation domain (NTAD) and an oxygen-dependent degradation domain (ODD), 
which contains conserved proline residues important for mediating the sensitivity of 
these proteins to changes in oxygen levels (Figure 1.2). Additionally, HIF-1α and 
HIF-2α, which share a sequence identify of 48%, also contain another domain not found 
in HIF-3α, the C-terminal transactivation domain (CTAD). CTAD is required for HIF 
transcriptional activity through the interaction with the co-activators CREB-binding 
protein/p300 [CBP/p300] (34).  
The α- and β-subunits of HIF belong to the bHLH/PAS (basic helix–loop–helix/PAS) 




(Figure 1.2). Each subunit is characterised by the presence of bHLH and PAS domain, 
required for DNA binding, and heterodimerisation between the α- and β-subunits, 
respectively, and several crystal structures of these domain regions of HIF-1α/HIF-1β 
and HIF-2α/HIF-1β heterodimers have been solved (35). 
1.1.1.1. HIF-1β 
HIF-1β is also known as aryl hydrocarbon receptor nuclear translocator (ARNT). 
Unlike the α-subunits, HIF-1β does not have an ODD domain, rendering it unaffected 
by changes in oxygen, such as hypoxia (Figure 1.2). In addition, its gene and protein 
expressions are constitutively active in normoxia (36). In hypoxia, HIF-1β can protect 
the hypoxia-induced HIF-1α from being degraded by the proteasome and is required for 
HIF transcriptional activity. Through the bHLH/PAS domains present in both proteins, 
 
Figure 1.2 – HIF subunits domain structure: bHLH – basic helix–loop–helix domain; 
PAS  – Per/ARNT/Sim domain; ODD – oxygen-dependent degradation domain; NTAD 
– N-terminal transactivation domain; CTAD – C-terminal transactivation domain; TAD 
– terminal transactivation domain; NLS – nuclear localisation signal; LZIP – leucine 
zipper domain. Hydroxylation sites by PHDs and FIH for HIF-1α and HIF-2α are noted. 
Adapted from (16).  
bHLH PAS NLS CTAD ODD NTAD 
Pro402 Pro564 Asn803 
bHLH PAS NLS CTAD ODD NTAD 
Pro405 Pro531 Asn847 












HIF-1β interacts with HIF-α to form a transcriptionally active HIF dimer to regulate 
responses to hypoxia. HIF-1β also forms heterodimer with aryl hydrocarbon receptor 
(AhR) through the PAS domain of each protein (37), and binds to the dioxin response 
element (DRE), required for the activation of drug-metabolising enzymes (38).  
Importantly, similar to the α-subunits, HIF-1β is essential for embryonic development. 
The knockout of HIF-1β in mice has been shown to develop abnormal vascular and is 
embryonically lethal [reviewed in (28)]. 
1.1.2. Canonical regulation of HIF in hypoxia 
Unlike the constitutively expressed HIF-1β that is not affected by oxygen changes, 
HIF-α proteins are extremely labile. In the presence of normal oxygen level, HIF-α is 
rapidly degraded by the proteasome with a short half-life of 5 min (39). The ODD 
domain of HIF-α is subjected to hydroxylation by a family of dioxygenase enzymes 
called prolyl hydroxylases (PHDs). PHDs use 2-oxoglutarate (2OG), Fe2+, ascorbate, 
and molecular oxygen as co-factors to hydroxylate two proline residues within the 
HIF-α ODD domains (40,41). The hydroxylated prolines create a recognition site with 
1000-fold increased affinity, over the parent protein containing unmodified proline, for 
the E3 ubiquitin ligase, von–Hippel Lindau (VHL) tumour suppressor (42), which 
polyubiquitinates HIF-α, rapidly targeting it for degradation by the proteasome (Figure 
1.3) (43). at the protein levels. The accumulated HIF-α dimerises with HIF-1β and binds 
to the consensus motif HREs of HIF-target genes in the nucleus to activate the 
transcription of genes in order to adapt to the hypoxic stress (Figure 1.3) (44). In 
hypoxia, due to the insufficient oxygen molecules, PHDs are unable to efficiently 





In addition to the regulation by the PHDs, another 2-oxoglutarate-dependent oxygenase, 
factor inhibiting HIF (FIH), is involved in regulating HIF-α (45). FIH is part of another 
hydroxylase family different to PHDs, the Jumonji-C family, and was the first of the 
family shown to have the 2OG oxygenase activity (46). In normoxia, FIH utilises Fe2+ 
to bind molecular oxygen, as well as 2OG as co-factors to hydroxylate a conserved 
asparagine residue (Asn803 of HIF-1α) within the CTAD, preventing the recruitment of 
transcriptional co-activators CBP/p300 (47). FIH is less sensitive to oxygen changes 
compared to PHDs; hydroxylation activity of FIH occurs in the presence of much lower 
oxygen levels than the required for PHDs, and becomes inactive in extreme hypoxia 
(48). The differential response of the two hydroxylases provides an additional HIF 
control in response to hypoxia. 
 
 
Figure 1.3 – Canonical HIF regulation pathway. In normoxia, PHDs use oxygen 
molecules to hydroxylate two proline residues within the HIF-1α subunit. Hydroxylated 
prolines allow the binding of VHL and ubiquitination by the E3 ubiquitin ligase, 
targeting HIF-1α/ HIF-2α for proteasomal degradation. As the oxygen level decreases to 
hypoxia, PHDs are gradually inhibited and this leads to the accumulation of HIF-1α, 
which dimerises with HIF-1β. HIF dimer interacts with endogenous HREs to drive the 




1.1.3. Prolyl hydroxylase (PHD) enzymes 
HIF prolyl hydroxylase (PHD) enzymes are 2OG-dependent dioxygenases that 
hydroxylate HIF-1α at two proline residues (Pro402 and Pro564) within the ODD 
domain (49,50). The two proline residues are found in consensus sequence LXXLAP, 
where P is the proline subjected to hydroxylation (51). While HIF-1α and HIF-2α have 
the LXXLAP motif, there are other PHD substrates found without this motif (discussed 
further in section 1.1.3.2). This suggests that substrate recognition for PHD 
hydroxylation is more than the consensus motif. 
1.1.3.1. PHD isoforms 
There are three known PHD isoforms: PHD1, PHD2, and PHD3; or EGLN 2, EGLN1, 
and EGLN3, respectively (51). All three isoforms display high sequence homology in 
the C-terminal catalytic domain, but not the N-terminus. A fourth isoform has been 
identified, but not well-characterised (52). Amongst the isoforms, PHD2 is the most 
studied and characterised, and is thought to be the most important oxygen sensor (47). 
The three PHDs regulate HIF-1α and HIF-2α in a non-redundant manner (53). PHD1 
shows a preference for HIF-2α over HIF-1α in normoxia, while PHD2 shows the 
opposite specificity; but both PHDs hydroxylate the two prolines of HIF-α. On the other 
hand, PHD3 hydroxylates exclusively Pro564, and acts equally on HIF-1α and HIF-2α 
under normoxia, but preferentially HIF-2α in hypoxia (53). In addition, the subcellular 
and tissue localisations for the three PHDs are different (Table 1.1). PHD2 is the most 
abundant of the three isoforms and expressed in all tissue types, while PHD1 and PHD3 
expressions are more restricted (54,55). PHD2 and PHD3 are also induced in response 
to hypoxia. PHD2 is specifically induced by HIF-1α, whereas PHD3 is a target of both 




Table 1.1 – PHD isoforms. Preferred target, cellular and tissue localisation, as well as 


















Nucleus Mainly in testes, 
also in heart, 
brain, liver and 
kidney 
Viable offspring (57), tolerance 





Cytoplasm All tissues, 
abundant in 
heart 
Embryonic lethal due to cardiac 
and placental defects (57). 
Conditional knockout is viable 
with increased angiogenesis 
(59), and polycythaemia (60,61). 








Viable (57), with reduced 
resting blood pressure and 
distinct CNS changes in 
innervation (57) (62) 
 
Given the differential localisation patterns and activities towards HIF-α, the PHD 
isoforms may have distinct functions. Unlike HIF knockouts, PHD knockout mice are 
not as lethal, except for PHD2 knockout, which are embryonically lethal due to 
developmental defects (57). However, conditional knockout mice of PHD2 are viable, 
but show increase in angiogenesis (59) and are polycythaemic (60,61). Although the 
knockouts of PHD1 and PHD3 produce viable offspring, they display cardiovascular 
defects (61). 
1.1.3.2. PHD-targets 
Beyond HIF-1α and HIF-2α, PHDs have been shown to have other substrates, including 
inhibition of κB kinase β (IKKβ), Cep192, RNA polymerase II subunit Rpb1, and the 
β-adrenergic receptor II (63-66). These proteins also contain the motif LXXLAP 




The IKKβ plays a role in the activation of the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB), a transcription factor that is constitutively active in some 
cancer and associated with inflammatory and innate immune responses (67). Under 
hypoxia, IKKβ has been shown to be inhibited by PHD1 and PHD3 (68), presumably 
mediated by their prolyl hydroxylase activities within the evolutionarily conserved 
LXXLAP motif on IKKβ, leading to reduced NF-κB activity (68,69). However, another 
study has found that PHD3 inactivates the phosphorylation activity of IKKβ in a 
hydroxylation-independent manner by preventing the interaction between IKKβ and the 
heat shock protein 90 (HSP90) (70). The centrosomal component Cep192, essential for 
cell-cycle regulation, is hydroxylated specifically by PHD1 on proline residue within 
the LXXLAP motif. Hydroxylation lead to Cep192 degradation as the hydroxylated 
protein is polyubiquitinated by Skp2 E3 ubiquitin ligase, resulting in proteasomal 
degradation (63). The RNA polymerase II subunit Rpb1 and the β-adrenergic receptor II 
also contain the same hydroxylation motif and hydroxylated by PHD1 under oxidative 
stress (65,71), and PHD3 (66), respectively, for degradation in a VHL- and subsequent 
proteasome-dependent manner (65,71). 
Interestingly, PHDs have recently been found to also hydroxylate another motif that is 
not consensus LXXLAP, called the ‘FOXO3a-like’ motif. An in vitro hydroxylation 
screening assay identified FOXO3a protein as a substrate of PHD1, but FOXO3a does 
not have the LXXLAP consensus motif. PHD1 hydroxylates two proline residues within 
‘GPSS’ and ‘GSPT’ sequences on FOXO3a, and this triggers the degradation of the 
protein by the proteasome (72), and may be in a manner independent of VHL (73). 
Another protein with similar motif to the FOXO3a prolyl hydroxylation motif is Akt, a 
serine/threonine kinase that promotes growth and survival of various cancers (74). Akt 
is frequently activated in VHL-defective ccRCC patients (75) and this is later on found 




PHD2 on two proline residues within ‘GSPS’ and ‘GTPE’ motifs, and subsequently 
recognised by VHL, which inhibits Akt activity and promotes tumorigenesis and cell 
survival (74). 
1.1.4. Other HIF regulators 
In addition to the canonical regulation of HIF through the proteasomal degradation 
system mediated by hydroxylation and polyubiquitination, HIF is also controlled via 
other mechanisms, and can be induced by other stimuli including growth factors, viral 
proteins, cytokines, hormones and inflammation.  
Several chaperone proteins have been shown to regulate HIF-1α stability. The heat 
shock protein 90 (HSP90) is a molecular chaperone that binds to HIF-1α. This 
interaction prevents HIF-1α from misfolding and subsequent degradation as it protects 
HIF-1α from the receptor for activated protein kinase C (RACK1)/Elongin-C-mediated 
degradation (76). HSP70 also regulates HIF-1α degradation not by the proteasome, but 
by the lysosome via the chaperone-mediated autophagy (CMA). HSP70 interacts with 
the E3 ubiquitin ligase STUB1 (STIP1 homology and U-Box containing protein 1) and 
promotes STUB1 to catalyse K63 polyubiquitination of HIF-1α and subsequent 
degradation by the lysosomal machinary (77). Besides RACK1 and STUB1, other E3 
ligases that regulate HIF-1α are MDM2, HAF, and TRAF6 (77). Interestingly, the 
deubiquitinase (DUB) enzymes that catalyse the removal of ubiquitin linkages have also 
been shown to regulate HIF-1α. One example is the ovarian tumour protease (OTU) 
DUB (OTUD7B [also known as Cezanne]) that has been shown to modulate the 
expression of both HIF-1α (78) and HIF-2α (79), in a proteasome-independent manner. 
HIF is also regulated at the translational levels by the phosphoinositide-3-
kinase/mammalian mechanistic target of rapamycin (PI3K/mTOR) and ERK mitogen-




subsequent protein levels (80). Although HIF is the master regulator of the hypoxia 
signalling, other transcription factors have been shown to play a role in concert with 
HIF in cellular response to hypoxia. Examples are NF-κB, Myc, p53 and AP-1 
[reviewed in (16)]. Furthermore, chromatin remodellers including SWI/SNF and ISWI 
complex also affect HIF-1α mRNA levels, as well as acting as transcriptional 
co-activators of in the HIF pathway (81). The multiple mechanisms and regulators 
highlight the importance of controlling HIF-α. 
1.1.5. HIF-target genes 
In response to the hypoxic stress, HIF activates a large number of genes required for 
many cellular processes including metabolism, angiogenesis, autophagy, apoptosis, and 
cell differentiation, with the ultimate aim to restore oxygen homeostasis. These 
pathways promote tumour growth and progression, and therefore HIFs are considered as 
attractive targets for therapeutic approach for cancer (73). To date, more than 100 
HIF-target genes have been identified (Figure 1.4) (82), and there are estimates that 
HIFs could regulate up to 2% of human genes (83). These genes then mediate the 
response to hypoxia. The roles of some of these genes are further discussed in section 
1.2.1. In addition to direct upregulation of genes by HIF, HIF can also repress gene 
expression indirectly through its interaction with other transcription factors, such as 
Myc and p53 [reviewed in (16)]. 
A computational study that integrates gene expression profiles from several cell lines 
and computational binding-site analyses identified hundreds of potential HIF-targets 
and interestingly, 70% of genes altered in hypoxia do not contain the canonical HRE 
motif (5’- [A/G]CGTG -3’) in their proximal promoters, important for transcriptional 
activation by HIF (84). A narrower and highly reliable list of 217 genes was generated 




immunopreciptation (ChIP) analysis (85). Through this study, the authors compiled a 
list of 100 known and validated HIF-1 target genes (Appendix Table 9.4). 
 
Figure 1.4 – HIF-target genes. HIF upregulates many genes involved in many 
biological processes. Figure is adapted from (82). 
 
1.1.6. HIF-independent hypoxia responses 
In addition to the transcriptional programme induced by HIF, cells also utilise other 
signalling pathways independent of HIF to mediate cellular responses to hypoxia. 
Examples of these HIF-independent oxygen-sensitive pathways are the mTOR and 
unfolded protein response (UPR). 
HIF 
Angiogenic signalling 
VEGF – vascular endothelial growth factor A 
EG-VEGF – endothelial gland derived-VEGF 
VEGFR1 – VEGF receptor 1 
PAI1 – plasminogen-activator inhibitor-1 
UPAR – urokinase plasminogen activator receptor 
Energy metabolism 
GLUT1 – glucose transporter 1 
CA9 – carbonic anhydrase 9 
HK1 and 2 – hexokinase 1 and 2 
PFKL – 6-phosphofructo-1-kinase L 
 6-phosphofructo-2-kinase 
GAPDH – glyceraldehyde-3-P dehydrogenase 
ALDA – aldolase A 
ALDC – aldolase C 
Eno1 – enolase 1 
PGK1 – phosphoglycerate kinase-1 
LDHA – lactate dehydrogenase A 
PKM – pyruvate kinase M 
Adenylate kinase 3 
Transglutaminase 2 
Matrix and barrier functions 
Pro-collagen prolyl hydroxylase α1 
TFF – intestinal trefoil factor 
Ecto-5’-nucleotidase 
CATHD – capthepsin D 
FN1 – fibronectin 1 
MMP2 – matrix metalloproteinase 2 
Hormonal regulation 
EPO – erythropoietin 
LEP - leptin 
Cytoskeleton formation 
KRT14 – Keratin 14 
KRT18 – Keratin 18 
KRT19 – Keratin 19 
Vimentin 
Cell migration 
CXCR4 – chemokine receptor 
c-Met 
AMP/GPI – autocrine mobility factor 
LRP1 – LDL receptor related protein 1 
TGF-α – transforming growth factor-α 
Cell proliferation 
TGF-α – transforming growth factor-α 
TGF-β3 – transforming growth factor-β3 
IGF-2 – insuline-like growth factor 2 
















ET1 – endothelin 1 
ADM – adrenomedullin 
Tyrosine hydroxylase 
α1B-adrenergic receptor 
iNOS – inducible nitric oxide synthase 
eNOS – endothelial NOS 
Heme oxygenase-1 
Atrial natriuretic peptide 
Growth and apoptosis 





ENG – endoglin 
Wilms’ tumour suppressor 
α-Fetoprotein 




The mTOR pathway is important for the activation of several biological processes, 
including metabolism, ribosomal biogenesis, mRNA translation, apoptosis and 
autophagy (86). Under hypoxia, particularly prolonged (chronic) hypoxia or in 
combination with other stresses, the mTOR signalling is inhibited in order for cell to 
adapt and survive the stressful condition (16). The downstream signalling of mTOR is 
inhibited through multiple pathways mediated by the activation of the tuberous sclerosis 
protein 1 and 2 (TSC1/2) complex (86). The complex can be activated via the 
hypoxia-inducible AMP-activated protein kinase (AMPK) or REDD1. Under hypoxia, 
AMPK phosphorylates the TSC1/2 complex to inhibit mTOR activity (13), whereas the 
induction of REDD1 releases TSC2 from a complex to allow the re-activation of 
TSC1/2 (87). The inhibition of mTOR activity also leads to reduced phosphorylation of 
S6K, S6 ribosomal protein and 4E-BP1 important for mRNA translation, inhibiting 
translation initiation (13). 
The UPR is a pathway that activates transcriptional and translational changes in 
response to endoplasmic reticulum (ER) stress (86). The ER is a cellular organelle 
important for the maturation of membrane or secreted proteins. Under severe hypoxia, 
ER stress occurs, and this leads to the accumulation of unfolded or misfolded proteins, 
which act as sensors to rapidly activate the UPR. The activation of UPR is essential for 
regulating several downstream processes, including cell metabolism and cell death, 
protein maturation and degradation, and protein production that collectively promote 
hypoxia tolerance and cell survival (88). The UPR activation in hypoxia is mediated by 
PKR-like ER kinase (PERK) that inhibits overall mRNA translation, presumably to 
relieve ER function and promote overall survival (89). Besides PERK, there are two 
additional ER stress sensors: activating transcription factor 6 (ATF6) and inositol-
requiring enzyme 1 (IRE1) that mediate the UPR; however their regulation in hypoxia is 




1.2.  HIF and disease 
The HIF transcription factor is involved in many pathological diseases including cancer, 
myocardial ischaemia, chronic anaemia, and gastrointestinal diseases. Although HIF 
activation in cancers can promote cancer progression, it is also therapeutically 
beneficial for the other diseases, and also aids in medical treatments including wound 
healing and organ transplantation. 
1.2.1. Cancer 
The HIF pathway regulates many biological processes including metabolism, 
angiogenesis and cell proliferation required for the survival of fast-proliferating 
tumoural cells. Therefore it is not a surprise that HIFs are induced in many tumour types 
(90). Owing to the rapid cell proliferation in tumour, oxygen supply is quickly 
exhausted from poor vascularisation, and this results in intra-tumour hypoxic regions 
(91). Hypoxic environment, and in turn, HIF activation, have been associated with 
increased metastasis and patient mortality in many human cancers. Furthermore, 
increased HIF-1α and/or HIF-2α levels have been observed in brain, head/neck, breast, 
lung, colon, gastric, kidney, pancreas, stomach, skin, endometrium, bladder, rectum, 
cervix, ovarian, and prostrate cancers (92). 
HIF regulates processes in response to hypoxia via its target genes. For instance, HIF 
promotes angiogenesis, a process that renews blood vessels, required for the poorly-
vascularised intra-tumour via the regulation of many pro-angiogenic genes including 
vascular endothelial cell growth factor (VEGF) and inducible-nitric oxide synthase 
(iNOS) (93). HIF also reduces oxygen demand by promoting glycolysis through 
upregulation of glucose uptake via glucose transporter 1 (GLUT1), increasing glycolytic 
enzymes such as aldolase A and phosphoglycerate kinase, and induction of pyruvate 




Furthermore, HIF upregulates proteins involved in cellular pH regulation; as such the 
carbonic anhydrase 9 (CA9) that reversibly hydrates carbon dioxide to form bicarbonate 
and hydrogen ions (94); sodium-hydrogen exchanger 1 (NHE1) that pumps hydrogen 
ions into extracellular space (95); as well as, monocarboxylate transporter 4 (MCT4) 
that pumps lactate out of tumour cells (96). Collectively, these proteins promote an 
alkaline intracellular environment required for cell proliferation and acidic extracellular 
environment for invasion (90). 
Hypoxic tumour activates both HIF-1α and HIF-2α, and both have been associated with 
poor clinical outcomes in patients with cancers. Interestingly, the functions of HIF-1α 
and HIF-2α can vary depending on the cancer types. In some cancers, HIF-1α promotes 
cancer progression, while HIF-2α acts as tumour suppressor, and the opposite is also 
found in other cancers. For instance, HIF-2α has been shown to contribute to disease 
progression and mortality in the renal clear cell carcinoma, whereas HIF-1α is 
suppressed due to gene deletion and the absence of HIF-1α is associated with worse 
patient prognosis (97,98). On the other hand, the two HIF-α act oppositely in colon 
cancers, where HIF-1α is overexpressed, while HIF-2α is silenced (99). The loss of 
HIF-2α expression was strongly correlated with advanced cancer stage, but not HIF-1α 
(99). Thus, the effect of HIF-α activation is dependent on the tumour type. Importantly, 
selective stabilisation or inhibition of either isoforms may be therapeutically beneficial 
for cancer treatments. 
1.2.2. Anaemia-associated chronic kidney diseases 
Patients with chronic kidney disease (CKD) often suffer from anaemia, a condition of 
red blood cell deficiency as their kidneys fail to produce adequate erythropoietin (EPO), 
and hepatic EPO production cannot compensate. EPO is a hormone required for the 




is often linked to increased morbidity and mortality (101). Recombinant human EPO 
has been used to treat anaemia associated with kidney failure since 1989 (102). Since 
then, many other EPO analogues have been made and used for correcting anaemia. 
However, these treatments have shown several issues including high cost, resistance and 
side-effects (103), such as increased risk of cardiovascular events and blood pressure as 
the intermittent treatment may result in excessive EPO levels (104).  
In recent years, HIF stabilisers have been explored as new strategy for treating anaemia. 
HIF-1α is known to transcriptionally activate EPO (17), thus stimulating EPO 
production. Examples of HIF stabilisers for this therapeutic approach are PHD 
inhibitors. Five PHD inhibitors are currently in clinical trials for anaemia associated 
with CKD, with FG-4592 (Roxadustat) as the most advanced in phase III (105); these 
PHD inhibitors will be discussed in 1.4.2.5.  
1.2.3. Myocardial ischaemia-reperfusion injury 
Myocardial ischaemia-reperfusion injury is a condition with initial restriction of blood 
supply to the heart muscle (myocardium), causing tissue hypoxia, followed by the 
restoration of blood flow (perfusion) and concomitant re-oxygenation that associate 
with reperfusion injury (tissue injury and profound inflammatory response) (106). 
Several studies have shown that ischaemic preconditioning (pre-exposure to short, non-
lethal episodes of ischaemia) reduces myocardial tissue injury during subsequent 
ischaemia-reperfusion injury, in which HIFs play a functional role. Studies have shown 
that HIF-1α was stabilised in preconditioning of the myocardium in mice, and the 
knockdown of HIF-1α by siRNA abolished this cardioprotection effect. Similarly, 
cardioprotection was also achieved with HIF activator DMOG (107). In addition, the 
role of HIF-1α in myocardial ischaemia was found to be dependent on its interaction 




anaerobic glycolysis, important for preconditioning to myocardial ischaemic tissue 
(108). 
1.2.4. Inflammatory bowel disease 
Inflamed tissues are often hypoxic owing to increased metabolism required by the 
inflamed resident cells and infiltrating immune cells. These processes decrease blood 
flow within the tissue (109). An example of inflammatory diseases associated with 
hypoxia is the inflammatory bowel diseases (IBDs). IBD is an inflammatory disorder 
due to deregulated mucosal immune system, and is divided into two types according to 
their distribution patterns: ulcerative colitis that is limited to the colon, and Crohn’s 
colitis that affects any part of the gastrointestinal tract (110). The hypoxic environment 
and pro-inflammatory molecules enhanced in the inflamed tissues can induce HIF 
stabilisation (103). Activation of HIF-1α and HIF-2α has been observed in IBDs, and 
shown to protect against the intestinal inflammation in several ways. The stabilised 
HIFs can promote tissue reparation by inducing and inhibiting apoptosis in neutrophils 
and epithelial cells, respectively (109,110). In addition, HIF-1α also enhances the 
production of anti-inflammatory molecules including adenosin and netrin-1, to protect 
the intestinal mucosa (111). 
Due to the protective role of HIF in IBD, pharmacologic activation of HIF has been an 
attractive therapeutic approach. Several studies have shown that HIF stabilisation 
induced by PHD inhibitors greatly improves intestinal inflammation in mice (112,113). 
The PHD inhibitor dimethyloxalylglycine (DMOG) displayed protective adaptation in 
an in vivo model of chemically induced murine colitis (112,114). Other PHD inhibitors, 





1.2.5. Wound healing 
During wound healing, the metabolism of tissue is significantly shifted to the site of 
vascular damage, and tissue oxygen demand increases, resulting in hypoxia (106). HIF 
is stabilised during re-epithelialisation at the site of wounds and promotes mucosal 
barrier. HIF stimulates angiogenesis (the budding of new blood vessels from pre-
existing vessels) and vasculogenesis (the de novo formation of blood vessels from 
precursor cells) required for wound healing through its targets including VEGF and 
iNOS (116). Furthermore, HIF also mediates the recruitment of bone marrow-derived 
angiogenic cells (BMDACs) to the wound. BMDACs are involved in angiogenesis or 
vasculogenesis, thus play an important role in wound healing (92). HIF-1 activation, by 
the use of PHD inhibitors has also been shown to improve impaired wound healing in 
diabetic mice (117-120). Therefore, therapeutic approach to stabilise HIFs would be 
beneficial for the treatment of conditions with defective wound healing. 
1.2.6. Organ transplantation 
Many solid organ transplantations display chronic rejection, resulting in graft failure 
and are associated with high rates of mortality and morbidity (106). Ischaemia-
reperfusion injury has been shown to contribute to chronic rejection and early graft 
failure in liver transplantation (121), as well as the recurrence of hepatitis after 
transplantation in patients with the liver failure of hepatitis C (122). Owing to the role 
of HIF in ischemia-reperfusion injury, HIF activator may prevent early graft failure 
during solid organ transplantation (106). Studies have also suggested that HIF activators 
may be used to improve the outcomes of β-cell transplantation in diabetic patients with 




1.3.  Von Hippel–Lindau (VHL) 
The von Hippel–Lindau (VHL) E3 ubiquitin ligase is part of a multi-subunit Cullin 
RING ligase, acting as the substrate-recognition subunit of the complex. The VHL 
complex mediates polyubiquitination of HIF-α, important for targeting HIF-α for 
proteasomal degradation (43). 
1.3.1. The ubiquitin–proteasome system (UPS) 
The molecular machines responsible for catalysing almost all processes inside the cells 
including signalling, regulation, transport, movement, catalysis, membrane fusion and 
many more, are composed of proteins. Cellular proteins are continuously synthesised 
and degraded to maintain protein homeostasis (also known as proteostasis). Proteostasis 
is an important process, as deregulated proteins would lead to the destabilisation of 
entire networks and pose a danger to cells (124). For instance, many cancers occur 
primarily due to mutations in genes, which affect proteins and ultimately the molecular 
networks involved. Furthermore, as amino acids are limited recourses in the cells, and 
the energy required for amino acid synthesis is high, recycling them via degradation 
contributes to proteostasis maintenance (125). 
Protein degradation in eukaryotic cells is mediated by two major protein degradation 
systems: the ubiquitin–proteasome system (UPS) and lysosomal proteolysis (124). 
While lysosomal pathway mainly degrades long-lived proteins, aggregated proteins, and 
cellular organelles, the UPS targets short-lived, regulated proteins, as well as abnormal, 
damaged or denatured proteins for degradation, degrading up to 80-90% cellular 
proteins (125).  
The ubiquitin–proteasome system (UPS) is an essential biological pathway that 




degradation of proteins (126). The UPS is involved in regulating many cellular 
processes including protein quantity control, cell cycle progression, transcription, DNA 
repair, apoptosis, stress response, and endocytosis (127), and therefore deregulation of 
the UPS is associated with many diseases (128). Proteins targeted for the UPS are 
tagged with a highly conserved 76-residue polypeptide, ubiquitin, an important post-
translational modification that can guide a protein to the degradation machinery. This 
tagging process is catalysed in a stepwise mechanism primarily by three enzymes: E1 
(ubiquitin-activating enzyme), E2 (ubiquitin-conjugating or carrier enzymes) and E3 
(ubiquitin ligase). Briefly, E1 activates the C-terminus of ubiquitin by catalysing a 
thioester linkage to a Cys residue of E1 in an ATP-dependent manner. Activated 
ubiquitin is then transferred to a conserved active site Cys of E2 that prepares ubiquitin 
for conjugation. Lastly, E3 recognises a target protein substrate, and catalyse the 
transfer of ubiquitin from the loaded-E2 to substrate protein by forming an isopeptide 
bond between C-terminal of ubiquitin and a ε-amino group of a specific lysine of 
substrate, either directly or via an additional E3-ubiquitin thioester bond (126). 
The human genome encodes two E1s, approximately 40 E2s, and more than 600 E3s 
ubiquitin ligases (129). As the E3 ligases confer substrate specificity to the UPS for 
degradation, it is not a surprise that there are so many E3s. The eukaryotic E3 ligases 
divided into three different types: homologous to E6AP C-terminus (HECT) E3s, really 
interesting new gene (RING) E3s, and RING-in-between-RING (RBR) E3s, that 
transfer ubiquitin to substrate via different mechanisms (130). Ubiquitin can be added 
on target substrates in the form of monoubiquitin/multi-monoubiquitin, and 
polyubiquitin chains. With seven lysine residues and the ε-amino group of ubiquitin, 
further ubiquitin molecules can be attached to form polyubiquitin chain that is linear, 
mixed or branched. The types and length of the ubiquitin chain greatly determine the 




degradation, to regulate protein function, interaction and localisation (131,132). 
Ubiquitination can also be reversed by a class of enzymes called deubiquitinases 
(DUBs), of which over 100 have been identified in the human genome . 
1.3.2. Cullin RING E3 ubiquitin ligases 
VHL is the substrate-recognition subunit (SRS) of a Cullin RING E3 ubiquitin ligase 
(CRL), a superfamily of RING E3s. CRL is the largest class of ubiquitin ligases, and is 
involved in regulating diverse cellular processes (133,134). Each CRL is characterised 
by: 1) a Cullin protein (Cullin1, 2, 3, 4a, 5 or 7), which is a scaffold protein that 
functions as a docking platform for assembling E3 ligase complex; 2) a small RING 
protein (examples are Rbx1, Roc1, and Hrt1) that recruits an ubiquitin-loaded E2 to 
promote the transfer of ubiquitin to substrate; 3) an adaptor protein that interchangeably 
binds the SRS to the Cullin complex (examples are Skp1, Elongin B:Elongin C 
[EloB/C] complex, damage-specific DNA-binding protein 1 [DDB1]); and finally, 4) a 
SRS that confers substrate specificity (133,135). 
CRL is activated by a post-translational modification called neddylation, occurring on 
the Cullin protein. The neddylation process covalently attaches the ubiquitin-like 
protein NEDD8 onto a lysine residue in the Cullin C-terminus, leading to 
conformational changes on the Cullin and RING proteins, in order to promote ubiquitin 
transfer (136). Cullin can also be de-neddylated by COP9 signalosome (CSN) and de-
neddylated CRL is sequestered by the interaction with Cullin-associated NEDD8-
dissociated protein 1 (CAND1) that keep the CRL in an inactive state (137). 
1.3.3. The VHL E3 ubiquitin ligase 
1.3.3.1. The history of VHL – VHL disease 
VHL is a known tumour suppressor. The gene encoding VHL was first identified in 




associated with VHL disease, an autosomal-dominant, hereditary disease caused by 
germline inactivating mutations in the VHL gene, which is associated with various types 
of cancers. In 1894, Treacher Collins first described familial retinal angiomatosis, now 
identified as a VHL-associated tumour, and in 1906, Eugen von Hippel also reported 
similar patients (139,140). Later in 1927, Arvid Lindau described patients with central 
nervous system haemangioblastomas, and recognised how it linked to the retinal 
angiomas reported by Collins and von Hippel. Thus, the name von Hippel–Lindau was 
derived and first used in 1936 (139,140). 
Retinal angiomatosis and cerebellar haemangioblastomas are two of the most frequent 
tumours related to VHL disease, alongside with clear-cell renal cell carcinomas 
(ccRCCs), phaeochromocytomas (PCCs), endolymphatic sac tumours and pancreatic 
islet tumours. Visceral cysts in kidney, epididymis and pancreas are also common, but 
rarely affect the function of organ (141). Clinically, VHL disease is divided into type 1 
characterised by the absence of PCCs, and type 2 with the presence of PCCs (142). 
Type 2 is further classified into three: type 2A (with PCCs, but not RCCs); type 2B 
(presence of PCCs and RCCs); and type 2C (only PCCs) (143). VHL disease and 
associated tumours occur in patients with biallelic inactivation of VHL (139). Despite 
being a familial disease, approximately 20% of VHL patients do not have a family 
history and VHL inactivation occurs due to de novo mutations (144). 
1.3.3.2. The VHL gene and VHL isoforms 
The VHL gene is located on chromosome 3p25 with three exons (138). VHL encodes 
two major VHL isoforms: a 213 amino acids isoform (pVHL1-213), and a protein 
containing 160 amino acids (pVHL54-213) (Table 1.2). These two isoforms are often 
referred as pVHL19 and pVHL30, respectively, based on their apparent molecular masses 
upon protein electrophoresis. pVHL19 arises from an internal translation initiation from 




pentameric acidic repeat domain (145-147). pVHL30 was first identified in 1995 and 
displayed tumour suppression activity, and thus was described as tumour suppressor 
(148). Further studies later on showed that both isoforms are functional tumour 
suppressors as the reintroduction of either protein suppressed tumour formation in nude 
mice (148). In addition, both isoform are believed to have the E3 ligase activity as they 
are able to bind to components of VHL E3 ubiquitin ligase (Cullin2, Elongin B and 
Elongin C) (145-147). VHL also encodes another transcript that is produced by an 
alternative splicing of exon 2, and found to be low in abundance (149,150) with no 
tumour suppression capability (149). 
1.3.3.3. Expression and subcellular localisation of VHL 
The VHL protein is evolutionarily conserved across species and ubiquitously expressed 
in embryonic and adult human tissues (150,151). Biallelic inactivation of VHL is 
embryonic lethal in mice (VHL –/–) owing to placental vasculogenesis deficiency, 
whereas heterozygous VHL mice (VHL +/–) are phenotypically normal and do not 
develop tumours in their short life spans (152). A conditional deletion of VHL in the 
liver of mice resulted in steatosis, formation of blood-filled vascular cavities and foci of 
increased vascularisation, depicting the role and importance of VHL in regulating 
angiogenesis (153). 
pVHL30 and pVHL19 differ slightly in their subcellular localisation (Table 1.2). pVHL30 
is localised primarily in the cytosol, and less in the nucleus or associated with the 
endoplasmic reticulum (ER), whereas pVHL19 is distributed equally in the cytosol and 
nucleus, but not found associated with the ER (145,154). The association with ER is 
thought to be related to the binding of pVHL30 with fibronectin as both localised to the 




Table 1.2 – VHL isoforms. Protein length, apparent molecular weight, subcellular 






















pVHL30 213 30 Mainly cytosol. 
Little in nucleus or 
associated with ER 
(145,154) 
Yes Yes 
pVHL19 160 19 Nucleus and 




1.3.3.1. VHL as E3 ubiquitin ligase 
VHL associates with Cullin2, EloB/C, Rbx1 to form an E3 ubiquitin ligase complex 
(156,157), primarily known for polyubiquitinating HIF-α to form K48-linked ubiquitin 
chain (77), which directs HIF-α  for degradation by the 26S proteasome (Figure 1.3). 
Cullin2 functions as a scaffold core of the complex, important for the docking of 
EloB/C, Rbx1 and a cognate E2 ubiquitin-conjugating enzyme (158). Rbx1 is a RING 
box protein containing catalytic activity of the E3 complex, and assists the recruitment 
of the ubiquitin-loaded E2, whereas EloB/C bridges the Cullin2 scaffold and the VHL 
SRS. VHL interacts with EloB/C via a conserved sequence motif in EloB/C called BC 
box (159). VHL is divided into two functionally distinct domains: an α domain at the 
C-terminus (amino acid 155-192) and a β domain at the N-terminus (amino acid 63-154 
and 193-204) (Figure 1.5) (160). The α domain contains three α-helices and directly 
interacts with EloB/C to form the multi-protein complex with Cullin2 and Rbx1, 
whereas the β domain is comprised of two β-sheets arranged as a sandwich with a 
α-helix on top (140), importantly, contains binding pocket for target proteins, such as 





Figure 1.5 – The VHL protein. (A) The VHL gene encodes two proteins: pVHL30 and 
pVHL19. pVHL19 is a product of alternative translation initiation sites (ATG coding for 
Met 54) and lacks an N-terminal acidic domain. The structure of pVHL reveals two 
structural subdomains: α and β. The α domain contains three α-helices and binds to 
EloB/C. The β domain contains a surface region that is required for binding substrates 
such as HIF-1α. Figure was adapted from (139). (B) Crystal structure of VHL54-
213:EloB:EloC (VBC) in two orientations. VBC is coloured according to the following: 
VHL is in yellow; EloC is in light green; EloB is in cyan. The surface region on VHL 
that is required for binding HIF-1α is highlighted in orange. The surface region on VHL 
that interacts with Cullin2 is highlighted in blue, whereas the surface region on EloC 
that interacts with Cullin2 is in dark green. Crystal structures of figure B is provided by 
Guilherme Castro. 
 
1.3.3.2. HIF-independent VHL-targets and functions 
Apart from HIF-α subunits, several other proteins have been identified as potential 
substrates of VHL E3 complex. Sprouty (Spry2), a protein associated with tumour 
growth and progression, was found to be hydroxylated on proline residues by PHDs in 
normoxia, and subsequently recognised by VHL for polyubiquitination and degradation 
(161). VHL was also shown to polyubiquitinate several atypical protein kinase C 
Cullin2     




β α β 
ATG 
54 63 155 192 204 
pVHL 




















(PKCs) involved in the tight junction structure formation and maintenance of cell 
polarisation (162). VHL was also found to mediate the polyubiquitination and 
degradation of epidermal growth factor receptor (EGFR), presumably to suppress 
tumour growth induced by prolonged signalling of EGFR (163). The largest subunit of 
RNA polymerase II, Rpb1, is also polyubiquitinated by VHL for protein degradation 
(71). However, in another cell context, RCC cells, Rpb1 was polyubiquitinated, but not 
degraded. The same study also discovered that Rpb1 possess an ODD-like domain, 
which contains the LXXLAP motif, and the proline residue of this motif was 
hydroxylated by PHD1 under oxidative stress (65). 
In addition to these substrates, VHL was also found to associate directly with 
fibronectin to promote proper fibronectin matrix assembly, a process important for cell 
growth and differentiation (154). Dysregulation of the matrix formation is often 
associated with tumour. Interestingly, this interaction between VHL and fibronectin is 
impaired in VHL type 2C VHL disease, but the VHL E3 ligase activity is still 
functional (143). In addition, VHL has also been shown to regulate tight junctions and 
integrins, adherin, MMP and collagen IV important for the assembly of the extracellular 
matrix [reviewed in (140)]. 
It is also claimed that VHL appears to regulate other functions, including transcription 
regulation via the binding to SP1 transcription factor in a HIF-independent manner; 
regulation of apoptosis; cell senescence control via SWI2/SNF2 chromatin remodeller 
p400, independent of HIF; and cell cycle through regulation of cyclin D1 in a HIF-
dependent manner [reviewed in (140,164)]. 
1.3.3.3. VHL regulation 
The regulation of VHL protein is still not well studied and characterised. The formation 




(HSP70) (165) and hetero-oligomeric chaperonin TCP1 ring complex (TriC; also called 
as chaperonin-containing TCP1 [CCT]) (165,166). The newly synthesised VHL is 
shuttled from the ribosomal machinery by HSP70, and the formation of VHL with 
EloB/C (VBC) is mediated by TriC. TriC associates with VHL to facilitate the folding 
of VHL, and thereby promotes the assembly of VHL into EloB/C complex (165). 
Failure of protein folding or formation of VBC leads to VHL degradation via the UPS, 
and this process requires another chaperone protein, heat shock 90 kDa protein 
(HSP90), which is involved in protein folding (167). 
1.4.  Pharmacology modulation of oxygen sensing 
As HIF plays a key role in regulating many cellular processes and is implicated in 
diseases, it is a very attractive therapeutic target. Depending on the context and the role 
of HIF in the disease, activation or repression of HIF activity can be beneficial for the 
treatment of the disease. For instance, as HIF often promotes tumour growth, inhibition 
of HIF might be ideal for therapy against certain cancer types. However, as HIF-1α and 
HIF-2α can play opposing roles to promote tumour progression or suppression, 
therefore, inhibition of a specific isoform is important. On the other hand, activation of 
HIF would be beneficial for the treatment of chronic anaemia, ischaemia, 
gastrointestinal disease, and aiding wound healing process and organ transplantation. 
Below are examples of HIF activators and repressors, activating or repressing HIF via 
pharmacological modulation of protein components involved in regulating HIF activity. 
In addition to these, there are many small-molecules targeting different components or 
pathways affecting oxygen sensing that are not mentioned or discussed here. 
1.4.1. HIF repressors 
Pharmacological inhibition of HIF has been challenging owing to its intracellular 




targeted for small-molecule inhibition (168). Nonetheless, there are several HIF 
inhibitors available that inhibit HIF via different mechanisms; including targeting 
mRNA expression, protein translation, and more recently, direct small-molecule 
inhibition. Below are a few examples of HIF inhibitors: digoxin and acriflavine that 
inhibit both HIF-1α and HIF-2α, bortezomib that inhibits HIF transcriptional activity, 
and PT2399 that selectively inhibits HIF-2α. 
1.4.1.1. Digoxin – inhibits HIF-1α and HIF-2α 
A study identified digoxin and other cardiac glycosides (including proscillaridin A and 
ouabain) as inhibitors of HIF-1α through a high-throughput cell-based screen of drugs 
that are in clinical trials or approved for use (169). These drugs were shown to inhibit 
translation of HIF-1α and HIF-2α, as well as the induction of HIF-1α target genes in 
tumour cells, but their mechanisms of action remained elusive and found to be in an 
mTOR-independent manner (169). In addition, digoxin treatment inhibited growth of 
subcutaneous xenografts and established tumours in mice (169). Digoxin and the other 
cardiac glycosides are used in patients with congestive heart failure to inhibit the 
Na+/K+ ATPase, but the HIF-α inhibition by digoxin is not dependent on this 
mechanism (169). Digoxin and acriflavine (also a HIF inhibitor; 1.4.1.2) have been 
shown to block early step of breast cancer metastasis in mice (170). A phase II breast 
cancer trial begins evaluating HIF-1α level in tumour tissues of patients on daily oral 
digoxin for two weeks before surgery compared to no drug study (NCT01763931). 
1.4.1.2. Acriflavine – inhibits HIF-1α and HIF-2α 
Another HIF inhibitor, acriflavine, was also identified in a cell-based screen of drugs 
approved by FDA or previously in clinical use (171). Through in vitro pulldown assays, 
acriflavine was shown to bind directly to the PAS-B domains of HIF-1α and HIF-2α, 
preventing the dimerisation of the α-subunits to HIF-1β, thereby inhibiting HIF 




xenografted with prostate cancer or hepatocellular carcinoma, and also arrested tumour 
growth in established prostate cancer, presumably mediated by its anti-angiogenic 
effects as acriflavine inhibits tumour vascularisation, expression of angiogenic cytokine 
and mobilisation of angiogenic cells (171). Other studies have shown that acriflavine 
also induces anti-cancer effects in murine breast cancer model (172) or mice with 
human breast cancer xenografts (170). It has also been shown that pre-treatment of 
acriflavine improves photodynamic therapy (a cancer therapy that induces cell death) in 
cultured cells (173). A very recent study shows that acriflavine reduces the maintenance 
of leukaemia stem cells and leukaemia development in chronic myeloid leukaemia in 
vitro and in vivo (174).  
1.4.1.3. Proteasome inhibitor: bortezomib, carfilzomib and 
MG132 
Bortezomib (Velcade™) is a 26S proteasome inhibitor approved by the FDA for 
treating multiple myeloma and mantle cell lymphoma (175). Bortezomib can induce 
opposite effects in cells regarding HIF regulation: bortezomib inhibits the proteasome 
and leads to the accumulation HIF-α and proteins degraded by the proteasome when 
used at sufficiently high concentrations; but it also inhibits HIF transcriptional activity 
by blocking the interaction between HIF-α and p300, a HIF transcriptional co-activator, 
when used at nanomolar concentrations (176,177). The activity and cytotoxicity of 
bortezomib also seems to differ depending on the cell lines tested [discussed in (176)]. 
Another FDA-approved proteasome inhibitor is carfilzomib (Kyprolis), also used for 
the treatment of multiple myeloma. Carfilzomib has been shown to be more potent than 





MG132 is another proteasome inhibitor, but has never been tested clinically due to rapid 
oxidation. MG132 is widely used in research and has proved to be a valuable research 
tool (179). 
1.4.1.4. PT2399 – inhibits HIF-2α 
As HIF-1α and HIF-2α are structurally similar and regarded as undruggable, there was 
no inhibitor that could bind to HIF-α protein directly, let alone that could selectively 
inhibit a particular isoform. However, early structure-guided medicinal chemistry led to 
the development of artificial small molecules targeting a cryptic pocket in the HIF-2α 
PAS domain (180). As this pocket adopts a different size in HIF-1α, it could be possible 
to selectively bind the small molecule to HIF-2α over HIF-1α (181). More recently, two 
recent studies simultaneously revealed an optimised HIF-2α-selective inhibitor – 
PT2399 (182,183), demonstrating that it is possible to selectively inhibit a single 
α-subunit. PT2399 was optimised through structure-guided design, and shown to 
directly inhibit HIF-2α by binding to its PAS-B domain, thereby disrupting the 
interaction between HIF-2α and HIF-1β and inhibiting HIF-2 transcriptional activity 
(183). PT2399 inhibits HIF-2 dimerisation in mice with patient-derived xenografts of 
VHL-null ccRCCs, renal carcinoma that are commonly associated with HIF-2α 
accumulation. Furthermore, the inhibitor suppresses tumorigenesis in 56% of these 
tumourgrafts, validating HIF-2α as therapeutic target in ccRCC (182). PT2399 has also 
been shown to minimally affect a group of 68 enzymes, receptors, and ion channels 
(183), thus may require further optimisation. 
An additional analogue of PT2399, PT2385, which also selectively inhibits HIF-2 via 




1.4.2. HIF activators 
As discussed in 1.2. , inducing HIF activity can be therapeutically beneficial. Below are 
examples of HIF activators via modulating different components that are involved in 
HIF regulation. 
1.4.2.1. 2-oxoglutarate mimics: dimethyloxalylglycine 
(DMOG), N-oxalylglycine (NOG) and 
N-oxalyl-D-phenylalanine 
2-oxoglutarate (2OG) is a co-factor required by all 2OG-dependent dioxygenases 
including PHDs and FIH. 2OG binds to the catalytic domain that docks an essential Fe2+ 
ion, important for enzymatic activity of these dioxygenases. N-oxalylglycine (NOG) 
and dimethyloxalylglycine (DMOG, a pro-form of NOG) have been shown to inhibit 
both the prolyl and asparaginyl hydroxylation of PHDs and FIH, respectively (185). 
DMOG and NOG are structurally similar to 2OG, mimicking 2OG and binding to the 
active site of PHDs and FIH. NOG has been shown to also inhibit other 2OG 
oxygenases, and deemed unlikely to be suited for medicinal use (186). A study showed 
that 2OG dioxygenase inhibitors display similar transcriptional profile to hypoxia, as 
compared to selective PHD inhibitors (187). N-oxalyl-D-phenylalanine is another 2OG 
mimic, designed based on crystal structures of FIH–Fe2+–2OG/NOG with fragments of 
HIF-1α CTAD, and shown to be a selective inhibitor of FIH by competing with 2OG, 
but it could not inhibit PHD2 at 1 mM concentration (186). 
DMOG has been extensively used and reported to induce HIF activities in cells and 
animals. As mentioned in the previous section (1.2. ), DMOG has been shown to have 
protective roles in many diseases, including ischaemia (heart, brain and kidney), 





1.4.2.2. Fe2+ substitutes: Co2+, Ni2+ and Cu2+ 
Fe2+ substitutes including Co2+, Ni2+ and Cu2+, replace Fe2+ in the active site of Fe2+-
containing dioxygenases including PHDs and FIH, resulting in the inhibition of their 
enzymatic activity and subsequent HIF stabilisation. The most commonly used 
substitute is CoCl2. CoCl2 is a water-soluble compound that was traditionally used for 
anaemia treatment in infants and pregnant women. CoCl2 has been shown to induce 
EPO in cells and in vivo, elicits hypoxia response, and has cardioprotective effect via 
HIF-1α (189,190). 
1.4.2.3. Fe2+ chelators: deferoxamine/desferrioxamine and 
AKB-4924 
In addition to substituting Fe2+, chelating Fe2+ also induces HIF stabilisation. There are 
many Fe2+ chelators known to stabilise HIFs, including deferoxamine/desferrioxamine 
(DFX/DFO), AKB-4924, L-mimosine, hydralazine, FG-2229, and TM-6008 [reviewed 
in (106)]. Fe2+ is crucial for enzymatic reaction of PHDs and FIH. Therefore enzymatic 
activity of these enzymes would be inhibited with the sequestering of Fe2+. 
DFO was the first FDA-approved iron chelator, and has been systematically used to 
treat chronic iron overload since 1970s (191). DFO has been commonly used in 
stabilising HIF-1α in cells, and known to stabilise HIF-1α in almost every cell type. 
DFO was first shown in 1993 to induce HIF-1α by chelating iron and also activate gene 
expression of EPO (before the discovery of HIF as the transcription factor of EPO) 
(190). DFO has been shown to aid wound healing in diabetic mice (120) and possess 
neuroprotective effects (192,193) via its HIF stabilisation activity. 
AKB-4924 (Aerpio Therapeutics) is a PHD inhibitor that predominantly targets HIF-1α 
and not HIF-2α (194). AKB-4924 was originally identified in a screen for antimicrobial 




group similar to the iron-chelator L-mimosine, suggesting similar mechanism of 
inhibition on PHDs by chelating iron bound on the active site (194). A study shows that 
AKB-4924 stabilises HIF-1α to enhance host cell immunity and indirectly induces anti-
microbial activity through promoting the bactericidal capacity of host cells (194). 
Recently, a phase I clinical trial using AKB-4924 for treating IBD has commenced 
(NCT02914262), since the inhibitor has been shown to regulate innate immune 
response and maintain epithelial barrier function in murine colitis, mediated by the 
stabilised HIF-1α (195). 
1.4.2.4. Inhibitors of Cullin neddylation: MLN4924 
MLN4924 inhibits NEDD8-activating E1 enzyme (NAE) and prevents the neddylation 
of Cullin1 and Cullin2 (196). MLN4924 is structurally related to adenosine 5’ 
monophosphate (AMP), a tight binding product of NAE. In the first step of the 
neddylation cascade reaction, AMP binds to the nucleotide-binding site on NAE, which 
catalyses the formation of NEDD8 adenylate (NEDD8-AMP). The mechanism of 
neddylation inhibition by MLN4924 is similar – MLN4924 competes with AMP for the 
binding to NAE, and NAE subsequently catalyses the formation of a covalent adduct of 
MLN4924 with NEDD8, thereby preventing the activation and conjugation of NEDD8 
to target proteins (197). The action of MLN4924 on Cullin2 results in stabilisation of 
HIF-α (198), and other CRL substrates (199). Many studies have shown the anti-cancer 
effects of MLN4924 (196-198), and the inhibitor is currently in clinical trials for 
patients with acute myeloid leukaemia and myelodysplastic syndromes (200). In 
addition, MLN4924 also decreases inflammation and disease severity in murine model 
of colitis (199). 
1.4.2.5. PHD inhibitors 
Most HIF activators mentioned above inhibit PHDs by blocking their 2OG- and Fe2+-




Fe2+-containing enzymes resulting in off-target effects from deregulating HIF-
independent hydroxylase pathways. Below are examples of compounds that inhibit 
PHDs directly. 
1.4.2.5.1. Roxadustat/FG-4592 
Roxadustat/FG-4592 is an oral PHD inhibitor that induces erythropoiesis (red blood cell 
production), and regulates iron metabolism (54). FG-4592 inhibits all three PHD 
isoforms (201). FG-4592 is currently in phase III clinical trial for the treatment of 
anaemia associated with CKDs (NCT01750190) – the most advanced PHD inhibitor in 
clinical trial. The inhibitor could be a first-in-class treatment option – FG-4592 may be 
a better treatment than the purely-EPO based therapy ones as HIF stabilised in the 
presence of PHD inhibitor could induce cellular processes such as iron metabolism to 
promote erythropoiesis (202). Another potential advantage of PHD inhibition is that 
endogenous EPO is induced instead of administering recombinant EPO, and thereby 
might have reduced side effects (202). No serious drug-related side effects have been 
observed with in the clinical trials of FG-4592 (201). 
Beside FG-4592, there are more PHD inhibitors in clinical trials: vadadustat/AKB-6548 
(phase III), daprodustat/GSK1278863 (phase III), molidustat/BAY 85-3934 (phase II), 
JTZ-951 (phase II), and JNJ-42905343 (preclinical). A recent detailed review on these 
inhibitors can be found in (201). 
1.4.2.5.2. IOX2 
IOX2 was reported as a selective PHD inhibitor (203). Although there is no crystal 
structure of IOX2 itself bound to PHD2, a close analogue of IOX2 has been shown to 
bind to the active site of PHD2, replacing 2OG in the active site (203). This was the 
expected binding mode, given IOX2 was designed to mimic closely the structure of 




fact that they all bind 2OG similarly, it is considered likely that IOX2 also potently 
inhibits PHD1 and PHD3 (204). IOX2 inhibits PHD2 with IC50 of 22 nM in an in vitro 
binding assay (203), and is at least 431-fold more selective for PHD2 over a panel of 
2OG dioxygenases (204). A more potent inhibitor than IOX2, IOX4, has also been 
described recently (204), but is not discussed here. 
 
1.5.  VHL inhibitors as HIF stabilisers 
Chemical intervention in the ubiquitin–proteasome system (UPS) has therapeutic 
potential, demonstrated by the clinical success of proteasome inhibitors (128). However, 
this approach is not specific to a given substrate as proteasome inhibitors affect all 
processes that exploit the UPS for regulation. In contrast, the E3 ubiquitin ligases (>600 
E3 predicted in humans) confer substrate specificity to the UPS for degradation (205), 
and are associated with many diseases (128), therefore E3 ubiquitin ligase would 
potentially provide more attractive targets and a more selective chemical intervention 
than the proteasome. 
As mentioned previously, the tumour suppressor von Hippel–Lindau (VHL) is a 
biologically relevant E3 ubiquitin ligase that targets hypoxia-inducible factor-α (HIF-α) 
transcription factor for degradation via the UPS. Inhibition of VHL would be expected 
to prevent polyubiquitination and subsequent degradation of HIF-α, resulting in HIF-α 
stabilisation. Development of a potent inhibitor of the interaction between VHL and 
HIF-α would allow intervening in the HIF pathway downstream of prolyl hydroxylases 
and potentially in a more selective fashion. Most importantly, this would provide a tool 




1.5.1. Targeting protein–protein interactions 
Protein–protein interactions (PPIs) are ubiquitous in nature. Owing to the diverse and 
crucial roles of PPIs in regulating many biology processes, the therapeutic targeting of 
PPIs is of great interest (179,206). However, the development of drug-like small 
molecule modulators that targets PPIs has proven challenging as the interacting surfaces 
between proteins are generally large and involve flat surface or shallow grooves, not 
suitable for small molecule to bind; this includes targeting the UPS (179). A variety of 
strategies have been employed to identify hits and leads against PPIs including: high-
throughput screening of a library of compounds; fragment screening and optimisation; 
rational design of mimicking peptides; computational approaches to analyse 
‘druggability’ (the likelihood of modulating a target protein by small-molecules) and 
predict possible small-molecule binding pockets; and lead optimisation [reviewed in 
(207)]. 
1.5.2. Chemical probes 
A chemical probe is a small-molecule modulator of the function of a target protein that 
allows addressing mechanistic and phenotypic questions on the target protein in 
biochemical, cell and animal studies (208). In order to serve as a powerful tool for 
research, a chemical probe has to be of high-quality – potent, selective and 
cell-permeable. Evidence for target engagement, and an understanding of the 
mechanism by which the compound modulates the target should be ideally provided. 
The recent development of high-quality chemical probes has facilitated substantial 





1.5.2.1. Requirements for high-quality small molecule 
A small molecule is different to chemical probe. The low molecular weight small 
molecule is a modulator of a target protein. However, to be approved as a chemical 
probe, the small molecule has to be fully assessed and meets a number of minimal 
requirements, or so-called “fit-for-purpose criteria”. The followings are guidelines set 
by the Structural Genomics Consortium (SGC) (http://www.thesgc.org/chemical-
probes): 
• In vitro binding affinity towards target protein of <100 nM 
• Displays >30-fold selectivity compared to other proteins of the same family 
• Exhibits on-target effects in cells at 1 µM 
• Screened against ‘industry standard’ off-targets and against large protein 
families relevant to drug discovery (208) 
• Preferably accompanied by an inactive close analogue of the small-molecule as 
negative control 
These are ideal criteria of a chemical probe and others have put together a more 
thorough review on factors to be considered in assessing the small molecules (210). It is 
advocated and well acknowledged that these criteria should not be rigid, and could vary 
depending on the specific target and pathway in question. 
A chemical probe is different to a small-molecule drug in terms of their purposes and 
characteristics. For instance, whilst selectivity profile is very important for chemical 
probe, it may be less important for a drug; and indeed many drugs manifest their clinical 
effects through affecting multi-targets or disease pathways (208). Furthermore, a 
chemical probe does not need to possess optimised pharmacodynamics or oral 




probe has to be potent, selective, and with defined on-target mechanism of action, in 
order to be a useful tool to address biological questions (208). 
1.5.2.2. Advantages 
Chemical probes have proven to be very impactful in modulating target protein due to 
following [reviewed in (208)]: 
• Complementary to genetic tools including RNAi, and more recently, 
CRISPR-Cas9, specifically because a chemical probe typically inhibits a 
particular function of the target protein rather than removing the entire protein 
• Able to inhibit a protein or a protein domain in cells or organisms rapidly and 
reversibly 
• Can be used in any type of cell 
• Uncover temporal characteristics of target inhibition 
• Comparison with RNAi would help dissect between effects due to scaffolding 
(abolished in protein knockdown with RNAi) and inhibition of protein 
interaction or catalytic activity (blocked by small molecule) 
• Combination with other chemical probes in synthetic lethal screens can be 
useful to study the link between separate pathways involved 
• Crucially, the results from chemical probes can be applicable to clinical studies 
because chemical probes are often starting points, and provide the core scaffold 
to a drug, thus they likely behave similarly to small molecule drugs 
1.5.2.3. Limitation 
As of any approaches, chemical probe may also have off-target effects. Unbiased 
transcriptome and proteasome profiling may provide valuable means to analyse on- and 
off-target effects of a chemical probe in cells (210). In addition, a negative control, 




chemical scaffold would help to distinguish between effects from on- and off-target 
(210). 
As small molecule is not part of the endogenous system, the compound may face issues 
with regards to transport out of cells by efflux pumps and metabolism/stability 
liabilities, which could limit its applicability despite being cell-permeable. In addition, 
the molecule may also be toxic to cells. However, a small molecule that is deemed as 
chemical probe should not have these issues if well-characterised. 
1.5.3. VHL inhibitors 
The first series of VHL inhibitors was first described in collaborative research between 
the Ciulli group and scientists from Yale University (211-213). The inhibitors contain a 
hydroxyproline fragment, designed rationally based on the hydroxyproline residue on 
HIF-1α, which makes key interactions with VHL. Thus the inhibitors were expected to 
compete with hydroxylated HIF-1α to bind to VHL, and lead to HIF-1α stabilisation. 
However, these inhibitors were ineffective in inducing HIF-1α stabilisation in cells, 
owing to their limited potency and suboptimal physiochemical properties (211-213). 
The Ciulli group later reported a series of VHL inhibitor developed by stepwise 
structure-guided design, with in vitro nanomolar binding affinities (214). The most 
potent inhibitor according to the in vitro binding affinity measured was VH032 (also 
called ligand 7 in the published article), however no cellular data was reported (214). 
This thesis describes the characterisation of VH032 in cells and the discovery of the 
most potent VHL inhibitor so far, VH298, which was first disclosed by the Ciulli group 
in 2016 (215). In addition, a suitable negative control was also generated for each of the 
two inhibitors – cisVH032 and cisVH298. The two compounds maintain the chemical 




stereochemistry at the carbon atom bearing the hydroxyl group on the hydroxyproline 
ring (Table 3.1 and Table 3.2). 
1.5.4. The use of VHL inhibitors in proteolysis targeting chimeras 
(PROTACs) 
Besides stabilising HIF-1α, VHL inhibitors have been used in a novel strategy that 
recruits a degradation system such as the VHL E3 ubiquitin ligase to degrade a specific 
target protein. This approach is commonly called proteolysis-targeting chimeras 
(PROTACs) (216). PROTAC compounds contain two recruiting ligands connected via 
a linker: one ligand specifically binds to a target protein that is to be degraded and the 
other ligand recruits an E3 ubiquitin ligase (217). PROTACs thus recruit the two targets 
in close proximity and promote the polyubiquitination, and subsequent proteasomal 
degradation of the target protein by the E3 ubiquitin ligase (217). 
VHL inhibitor VH032 has been used as the VHL-recruiting moiety in several reported 
PROTACs. VH032 is linked to different target ligands to induce proximity-driven 
ubiquitination of a specific target protein by VHL and subsequent proteasomal 
degradation. Target proteins that have been degraded via this mechanism are: BET 
proteins (217,218), ERRα and RIPK2 proteins (219), and intracellular green-fluorescent 
protein (GFP) fused to HaloTag7 (220). 
1.6.  Aims and objectives 
A series of small molecules that disrupts the interaction between VHL and HIF-α (VHL 
inhibitors) with nanomolar binding affinities have been developed and more potent 
VHL inhibitors were also designed by the Ciulli group, but the biological and functional 




We hypothesise that the VHL inhibitor is able to disrupt the interaction between VHL 
and HIF-α, leading to the stabilisation of HIF-α in cells. The binding of the small 
molecule on the VHL pocket for HIF-α would also indicate that the inhibitor may 
manipulate only the function of VHL on targeting HIF-α. The inhibitor is potentially 
able to also inhibit VHL rapidly and reversibly, and therefore a better tool to repress 
VHL function than genetic or RNAi knockdown. 
To test this hypothesis, we describe the following aims: 
1.6.1. To characterise VHL inhibitors as chemical probes of the 
hypoxia signalling pathway. 
Poorly characterised chemical probe may have major off-targets, and their usage may 
lead to misrepresentative or incorrect conclusions (208). Therefore, it is important to 
characterise a small molecule for its potency, selectivity, and mode-of-action. To do so, 
a biased approach was initially employed to assess the ability of VHL inhibitors in 
stabilising and activating HIF, followed by unbiased gene and protein expression global 
profiling of representative inhibitors via RNA-sequencing and TMT-labelling proteomic 
approaches, respectively. 
1.6.2. To determine the regulation of VHL using VHL inhibitors. 
The VHL E3 ubiquitin ligase is not well characterised with regards to how it is 
regulated. Usage of a VHL inhibitor that binds specifically to the binding pocket 
recognised by hydroxylated HIF-α as chemical tool may shine light into the regulation 
and function of VHL, in the context of the blockade of this specific interaction site. In 
addition, there have been small molecules that bind to an E3 ligase and de novo “hijack” 
the ligase activity toward a new substrate as a new binding site is created and exposed 




valuable information on changes on VHL interactome in the presence and absence of 




2. Methods and Materials 
2.1.  Cell Culture 
2.1.1. Cell lines and growth conditions 
Human cervix carcinoma cells HeLa, human osteosarcoma cells U2OS, human 
embryonic kidney cells HEK293, human foreskin fibroblasts HFF, renal carcinoma 
cells RCC4-HA and RCC4-HA-VHL were obtained from the American Type Culture 
Collection (ATCC). All cells were propagated in Dulbecco’s Modified Eagle Medium 
(Gibco) supplemented with 10% fetal bovine serum (Gibco), l-glutamine (Lonza), 
100 mg ml-1 of penicillin/streptomycin (Lonza; DE17-602E) at 37°C and 5% CO2. 
RCC4-HA and RCC4-HA-VHL were maintained in the same condition with the 
addition of 400 mg ml-1 G418 (ForMedium; G4181). Stable cell lines HeLa-HRE and 
U2OS-HRE luciferase cells were generated previously by others as described (222) and 
maintained in 0.1 mg ml-1 puromycin (Fisher; P8833). All cell lines were routinely 
tested for mycoplasma contamination using MycoAlert kit from Lonza every three 
months and discarded if tested positive for mycoplasma contamination.  
2.2.  Treatments 
2.2.1. Hypoxia treatment 
For hypoxia induction, cells were incubated at 1% O2 (5% CO2 and 94% N2) in an 
InVIVO 300 hypoxia workstation (Ruskin Technologies). To prevent reoxygenation, 
cells were lysed for protein extract (refer to section 2.1. ) or RNA extraction (refer to 
section 2.4. ) in the hypoxia workstation. Normoxic control was included by placing 




2.2.2. Compound treatments 
DMSO was used as vehicle control at 1% v/v. Hypoxia mimetic agents cobalt chloride 
(CoCl2) was obtained from Sigma (catalogue number C8661) and used at a final 
concentration of 100 µM for 4 h. The proteasome inhibitor MG132 was obtained from 
Merck (474790) and mostly used at the final concentration of 20 µM for 3 h unless 
indicated otherwise. PHD inhibitors IOX2 and FG-4592 were purchased from Sigma 
(SML0652) and Selleckchem (S1007), respectively. Drugs were added to cells at 
indicated concentration and for indicated length of time. 
VHL inhibitors used were synthesised by Pedro Soares from Alessio Ciulli Group 
(Dundee) and used in a stock concentration of 25 mM. 
2.3.  Cell transfections 
2.3.1. siRNA transfections 
Small interfering RNA (siRNA) oligonucleotides were purchased from Eurofins/MWG, 
and used in a stock concentration of 20 µM. siRNAs were transfected using Interferin 
from Polyplus according to the manufacturer’s instructions with some modification. 
Briefly, HeLa cells were seeded at 1.5 × 105 cells per well in a six-well plate one day 
prior to transfection. A mixture of 200 µL Opti-MEM reduced serum medium 
(Invitrogen; 51985-026), 3 µL INTERFERin (Polyplus; 409-50) and 3 µL of 20 µM 
siRNA was incubated at room temperature for 15-20 min. Meanwhile, medium was 
aspirated from the plate of cells and replaced with fresh pre-warmed medium. The 
transfection mixture was then transferred to cells in drop-by-drop. Media was changed 
after 24 h of transfection and transfected cells were incubated for another 24 h before 





Table 2.1 – Oligonucleotide sequences used for siRNA knockdown 
siRNA Sequence (5’ → 3’) 
Control AAC AGU CGC GUU UGC GAC UGG 
VHL GGA GCG CAU UGC ACA UCA ACG 
 
2.4.  RNA extraction and quantitative PCR analysis 
2.4.1. RNA extraction and quantification 
Following treatment, medium was removed from each well or plate, and cells 
were washed with 1 × PBS twice. Total RNA from mammalian cells was 
extracted using the RNeasy Mini Kit (Qiagen; 74104/74106) according to 
manufacturer’s protocol. Note that a total of 250 µL or 400 µL of RLT buffer 
(part of the RNeasy Mini Kit) supplemented with 40 mM mL-1 of DTT 
(ForMedium; DTT010) was used to lyse cells in 24-well plate or 12-well plate, 
respectively. RNA was quantified using NanoDrop™ 2000c spectrophotometer 
(Thermo Scientific), using the elution buffer (RNase-free H2O) as blank.  
2.4.2. cDNA synthesis 
A total of 500 ng of RNA was reverse transcribed in a total volume of 20 µL 
mixture per reaction using the iScript™ cDNA Synthesis Kit (BIO RAD; 
170-8891) according to the manufacturer’s protocol. RNA was reverse 
transcribed in the Applied Biosystems 2720 thermal Cycler. Following reverse 





2.4.3. Real time quantitative PCR 
Real time quantitative PCR (RT qPCR) was performed in triplicates in 96-well 
plate using PerfeCTa SYBR Green FastMix (Quanta Biosciences; 733-1378) in 
C1000 Touch Thermal Cycler (Bio-Rad Laboratories). RT qPCR was performed 
according to manufacturer’s protocol with the modification that 6 µL of the 
diluted cDNA was used in a total of 15 µL mixture per reaction. For all primers 
used in this study, an annealing temperature of 60 °C was used. mRNA levels 
were calculated based on averaged CT values and normalised to β-actin mRNA 
levels. The primers used for RT qPCR are shown in Table 2.2. 
2.1.  Protein lysis 
2.1.1. Whole cell protein lysis 
Following treatment, medium was removed from each well or plate, and cells were 
washed with 1 × PBS twice. Cells were harvested using whole cell protein lysis buffer 
(20 mM Tris pH 7.6, 150 mM NaCl, 1% Triton X100, and one protease inhibitor 
cocktail tablet [Roche; catalogue number 11873580001] per 10 mL of buffer). Lysis 
buffer containing protease inhibitor was stored in fridge (4 °C) and used for no longer 
than 3 months. A total of 90 µL of lysis buffer was used for a six-well plate, 200 µL for 
10 cm plate, and 300 µL for 15 cm plate. Cells were collected and kept on ice for 15-30 
min before centrifugation at 17,000 × g in the cold room (4 °C) for 10 min. The 





Table 2.2 – List of primers used for real time quantitative PCR 
Gene Sequence (Forward) 5’ → 3’ Sequence (Reverse) 5’ → 3’ 
β-actin CTCTTCCAGCCTTCCTTCCTG GAAGCATTTGCGGTGGACGAT 
HIF-1α GCAAGCCCTGAAAGCG GGCTGTCCGACTTTGA 
HIF-2α GTCTCTCCACCCCATGTCTC GGTTCTTCATCCGTTTCCAC 
CA9 CGGAAGAAAACAGTGCCTATGAG CAGGGCGGTGTAGTCAGAGA 
PHD2 ACCTGATACGCCACTGTAACG CCCGGATAACAAGCAACCAT 
VEGF TACCTCCACCATGCCAAGTG ATGATTCTGCCCTCCTCCTTC 
GLUT1 TTCACTGTCGTGTCGCTGTTT AGCGCGATGGTCATGAGTAT 
CITED2 CCTAATGGGCGAGCACATACA GGGTGATGGTTGAAATACTGGT 
PAG1 GGACAGATGCAGATCACCCT TGAACGGCTGAACATCTCCT 
EPO GCTGAACACTGCAGCTTGAA CAGACTTCTACGGCCTGCTG 
VHL CCTTGGCTCTTCAGAGATG TGACGATGTCCAGTCTCCT 
ABCA1  CCTGTCATCTACTGGCTCTCTA  CAGATTGGTGGAGGACACATAG 
ABCG1 CTCCGCCTCATTGCCTATTT CTCGGCCACAGTGTCTAATC 
DHRS2  GCCCACGTGGTCATCAG  CCCACGTGGCACACAAT 
EFR3B CCTCATGGAGGATGCAGAAAT ACTGAGGGTACTGATGGTAGAG 
LAMC2  CCCTGGGTTGAACAGTGTATATG  CAGTCTCGCTGAATCTCTCTTG 
CNN1 GTGCTACAGGGTCCAACATAG TACCCACTTGTGAGGGAGT 
MICALCL GGAGAGCCAGAAAGATGAGAAG CTCTGATGCGTTGTTCCTCTAA 




DUSP2 AGTATCCCTGTGGAGGACAA ACCCAGTCAATGAAGCCTATG 
TAF9B TCGAGCCATGCTAAGAAACC CTGCCTTGCGATATCCAGTAA 
 
2.1.2. SDS lysis 
Cells were lysed as described in section 2.1.1, but using the SDS lysis buffer (20 mM 
Tris pH 7.6, 1% SDS, 5 mM NaF, 500 mM Na3VO4, and one protease inhibitor cocktail 
tablet [Roche; catalogue number 11873580001] per 10 mL of buffer). SDS lysis buffer 
containing protease inhibitor was stored in fridge (4 °C) and thawed at room 
temperature before usage. Lysis buffer was used for no longer than 3 months. 
2.1.3. RIPA lysis 
Cells were lysed as described in section 2.1.1, but using the RIPA lysis buffer (50 mM 
Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% Sodium deoxycholate, 5 mM 
NaF, 500 mM Na3VO4, and one protease inhibitor cocktail tablet [Roche; catalogue 
number 11873580001] per 10 mL of buffer). Lysis buffer containing protease inhibitor 
was stored in fridge (4 °C) and used for no longer than 3 months. 
2.1.4. MS lysis 
Cells were lysed as described in 2.1.1, but using the MS lysis buffer (50 mM Tris HCl 
pH 8.0, 150 mM NaCl, 0.5% C7BzO (Sigma), 5 mM NaF, 500 mM Na3VO4, and one 
protease inhibitor cocktail tablet [Roche; catalogue number 11873580001] per 10 mL of 
buffer). Tris HCl, NaCl, NaF and Na3VO4 had been sterile-filtered prior to preparing the 
MS lysis buffer. The 0.5% C7BzO was prepared fresh in sterile-filtered MilliQ water. 




2.2.  Protein quantification 
2.2.1. Bradford assay 
Protein concentrations of cells lysed in the whole cell protein lysis buffer or RIPA 
buffer were determined using Bradford (BioRad), following manufacturer’s 
instructions. Briefly, 2 µL of protein lysates was pipetted into a cuvette containing 
798 µL of MilliQ water, followed by the addition of 200 µL Bradford reagent. 2 µL of 
MilliQ water was used as blank. The mixture was mixed by brief vortexing and 
absorbance value was measured at 595 nM. Protein concentration was determined using 
the absorbance value against a previously generated BSA standard curve. 
2.2.2. BCA protein assay 
Protein concentration of cells lysed in SDS lysis buffer were quantified using Pierce™ 
BCA Protein Assay Kit (Thermo Scientific), following manufacturer’s instructions. 
Briefly, 2 µL of protein lysates was added into a microcentrifuge tube containing 1 mL 
of BCA reagent mixture. The mixture was incubated in a water bath at 37 °C for 
30 min, followed by cooling at room temperature for 10 min. The mixture was 
transferred into a cuvette and absorbance value was obtained using a NanoDrop™ 
2000c spectrophotometer (Thermo Scientific) at 562 nm. Protein concentration was 
calculated using the absorbance value against a BSA standard curve. 
2.3.  Western blot 
2.3.1. Western blotting – semi-dry transfer 
Following protein quantification in the previous section, a total of 20 to 30 µg of 
proteins were prepared in 2 × loading buffer (100 mM Tris HCl pH 6.8, 20% (v/v) 
glycerol, 4% (w/v) SDS, 200 mM DTT and bromophenol Blue), and incubated for 




gel) previously prepared (5% stacking and 10% resolving for all proteins, except for 
VHL protein that requires 12% resolving gel), and run at 80-120 volts in running buffer 
(25 mM Tris, 0.195 M glycine, and 0.1% SDS). A total of 3 µL of SeeBlue® Plus2 Pre-
Stained Standard (Thermo Scientific; LC5925) was loaded as protein ladder. The gel 
was then transferred in a semi-dry transfer system (BioRad) into a PVDF membrane 
(Merck/Millipore; 10344661) for 2 h at 15 volts/0.80 mA in transfer buffer (50 mM 
Tris, 40 mM glycine, 0.001% SDS and 10% methanol). The membrane was then 
blocked with 10% milk in TBS-tween buffer (20 mM Tris pH 7.6, 150 mM NaCl, 0.1% 
Tween) for 10 min. After 3 × 5 min washes with TBS-tween buffer, the membranes 
were incubated with primary antibody for 1 h at room temperature or overnight at 4 °C. 
Antibodies manufacturers and dilutions are shown in Table 2.3. The membranes were 
then washed with TBS-tween (3 × 5 min) and incubated with the appropriate secondary 
HRP antibody (anti-mouse from Cell Signalling [7076S] at 1:2000 dilution, anti-rabbit 
from Cell Signalling [7074S] at 1:2000 dilution, or anti-goat from Thermo Fisher 
[A-11020] at 1:10000 dilution). After washes, membranes were developed using ECL 
solution (Pierce). β-actin was used as loading control. 
2.3.1. LI-COR system 
VHL inhibitor was screened for its ability to stabilise HIF-1α and hydroxylated HIF-1α 
using the LI-COR system to detect and quantify protein level. A total of 20 to 30 µg of 
proteins were prepared in 4 × NUPAGE LDS sample buffer (Thermo Fisher; NP0007) 
supplemented with DTT (ForMedium; DTT010, and incubated for 5 min at 95 °C. 
Samples were loaded into a NUPAGE 4-12% Bis-Tris protein gel (Life Technologies; 
NP0323BOX), and run at 200 volts for 50 min (or until the blue front line reached the 
bottom of the gel) in 1 × MOPS SDS running buffer (Thermo Scientific; NP0001). A 




was loaded as protein ladder. Samples from co-immunoprecipitation experiments 
(2.5.1) were also resolved via the LI-COR system. 
Table 2.3 – List of antibodies along with species, manufactures and dilutions used. 
M – mouse; R – rabbit; G – goat; S - sheep 
Antibody Manufacture Species Dilution 
β-actin Cell Signalling, #3700s M 1:5000 
HIF-1α BD Biosciences, 610958 M 1:1000 
HIF-1α-OH (Hyp564) Cell Signalling, #3434 R 1:1000 
HIF-2α R&D, AF2886 G 1:1000 
VHL Cell Signalling, #2738 R 1:1000 
VHL Cell Signalling, #68547 R 1:1000 
CA9 Novus Biologicals, NB100-417 R 1:1000 
PHD2 Bethyl Laboratories, A300-322A R 1:1000 
PHD3 Bethyl Laboratories, A300-327A R 1:1000 
GLUT1 Cell Signalling, #12939 R 1:1000 
BNIP3 Abcam, ab10433 M 1:10000 
HK2 Cell Signalling, #2867S R 1:2000 
 
2.4.  Luciferase assay 
HeLa and U2OS cells stably expressing a luciferase reporter gene (HRE luciferase 
reporter) as described in (222) were used to examine HIF transcriptional activity. 




2.0 × 105 cells per well, respectively, one day prior to treatment with compounds. 
Medium was replaced with fresh pre-warmed medium, followed by treatment of cells 
with indicated compounds for optimised treatment time of 24 h (HeLa) or 32 h (U2OS). 
Following compound treatment, medium was removed, and cells were washed gently 
with 1 × PBS twice. After removing the final wash, cells were lysed in 200 µL of 
1 × passive lysis buffer (Promega). The 12-well plate containing lysed cells was stored 
in freezer at −20 °C to be frozen (at least 1 h) and thawed at room temperature on a 
shaking platform to enhance cell lysis. From here onwards, cell lysates were handled at 
room temperature and stored in −80 °C freezer. Cells were scraped off the well and 
lysates from each well were transferred to a microcentrifuge tube. Cell debris was 
pelleted by centrifugation at 13,200 rpm, and supernatant was transferred to a new 
microcentrifuge tube. Luciferase assays were performed according to the 
manufacturer’s instructions (Promega). Briefly, 5 µL of the supernatant was pipetted 
into a Sarstedt round-bottom polystyrene tube (Thermo Scientific; 50-809-212) that is 
compatible with Berthold Lumat LB 9507 Luminometer. The tube containing 
supernatant was placed in the Luminometer that had been set to add 50 µL of luciferase 
assay reagent (Promega) into the tube. Luciferase activity was measured 10 sec after the 
addition of reagent by the Luminometer. Results were normalised for protein 
concentration (quantified using Bradford assay [Biorad]), with all experiments being 
performed a minimum of three times before calculating means and standard deviations. 
2.5.  Co-immunoprecipitation 
2.5.1. Co-immunoprecipitation for hydroxylated HIF-1α using 
sepharose beads 
HeLa cells were seeded onto 15 cm plate one day prior to treatment with compounds. 




incubator. After treatment, cells were washed with 1 × PBS twice and lysed in 350 µL 
of whole cell lysis buffer as described in section 2.1.1. Protein was quantified using 
Bradford assay as described in 2.2.1. A total of 300 µg of cell lysates were used per 
immunoprecipitation condition. Protein lysates were incubated with 1 µg of HIF-1α-OH 
antibody (Hydroxy-HIF-1α [Pro564], Cell Signalling, rabbit, #3434) or 1 µg of rabbit 
IgG antibody in a rotating platform at 4 °C overnight. Packed protein-G-sepharose 
beads (20 µl, Generon; PC-G5) were used to recover the immuno-complexes, by 
incubation in a rotating platform for 1.5 h at 4 °C. Lysates were collected as flow-
through (FT) prior to 5 washes with 0.1% Tween-20 in 1 × PBS buffer. The complexes 
were eluted from beads with 20 µL of 2 × SDS-loading buffer (0.1 M Tris-HCL pH 6.8, 
20% glycerol, 4% SDS, 0.2 M DTT, and a touch of bromophenol blue) and resolved as 
described above by immunoblotting (2.3.1). 
2.6.  Cellular Thermal Shift Assay 
Cellular thermal shift assay (CETSA) was adapted from the supplementary of (223).  
HeLa cells were seeded on two 15 cm plates and left to incubate for one to two days 
until the cells grew to 85-90% confluent. Media was removed and cells were washed 
once with 1 × PBS. Cells were harvested with trypsin/EDTA and resuspended in 0.8 mL 
of 1 × PBS containing one protease inhibitor cocktail tablet [Roche] per 10 mL of 
buffer. Cells were lysed by four freeze-thaw cycles using liquid nitrogen (thawing at 
room temperature). The soluble fraction (lysate) was separated from the cell debris by 
centrifugation at 13,200 rpm for 20 min at 4 °C. The lysate was divided into two 
aliquots, with one aliquot being treated with 100 µM of VH298, and the other aliquot 
with vehicle (1% DMSO). After 10-30 min incubation at room temperature, the two 
fractions were divided into smaller aliquots (50 µL), and heated individually at different 




3 min followed by cooling for 3 min at room temperature. Note that these temperatures 
can be adjusted according to the PCR machine used. The heated lysates were 
centrifuged at 13,200 rpm for 20 min at 4 °C, pellets were removed and the soluble 
fractions were analysed by SDS-PAGE (refers to 2.3.1), and immunoblotted for VHL 
(Cell Signalling), stripped (0.25 M glycine pH 2, 1% SDS), and washed before being 
immunoblotted for PHD2 (Bethyl Laboratories). Raw images were processed using 
ImageJ. Non-heated cell lysates were established as 100% intensity for each condition, 
and data quantified relative to that condition and plotted with Graphpad. 
2.7.  Flow cytometry analysis of cell cycle profile 
HeLa or U2OS cells were seeded one day prior at the dentisity 2 × 105 to compound 
treatment on 6-well plate. Cells were treated with indicated compounds for 24 h and 
harvested by trypsin/EDTA. Cells were pelleted and washed once in 1 × PBS before 
fixing in 1 mL ice cold 70% ethanol. Fixed cell suspensions can be stored in the freezer 
(-20 °C) until ready for cell cycle profiling. A total of 400 µL fixed HeLa cells or 1 mL 
of fixed U2OS cells were centrifuged at 450 × g for five min to pellet cells. Ethanol was 
removed and cell pellet was washed in 500 µL of 1 × PBS. Following another 
centrifugation at 450 × g for five min, 200 µL of pre-warmed Guava Cell Cycle reagent 
(Millipore) was added to the pelleted cells and mixed gently by pipetting. After 
incubation at room temperature for 30 min in the dark, cells were analysed for their cell 
cycle profile with Guava easyCyte HT software. Red fluorescence was evaluated on a 
linear scale and pulse width analyses were used to determine cell doublets and cellular 
aggregation. Cells with DNA content between 2N and 4N were designated as being in 
G1, S or G2/M phase of the cell cycle. The number of cells in each phase was expressed 




2.8.  Cell viability assay 
2.8.1. CellTiter-Glo luminescent cell viability assay 
Cell viability was analysed using CellTiter-Glo luminescent cell viability assay 
(Promega) according to manufacturer’s instruction. Briefly, the number of cells seeded 
onto the 384-well plate was optimised for each cell line. Note that cells were plated with 
the Matrix WellMate liquid dispenser to ensure uniform plating. Cells were plated in 
384-well plates (1000 RCC4 cells per well and 1500 HFF, HeLa or U2OS cells per 
well) in a total volume of 25 µL media one day prior to treatment with VHL inhibitors 
and respective non-binding cis-analogues. Following 24 h treatment with the 
compounds, cells and CellTiter-Glo reagent were equilibrated at room temperature for 
30 min. Cells were then incubated with 25 µL CellTiter-Glo reagent in the dark on an 
orbital shaker to induce cell lysis, followed by 10 min incubation at room temperature in 
the dark to stabilise luminescent signal. Luminescence was measured using a 
PHERASTAR plate reader (BMG LabTech). 
2.8.2. Proliferation assay 
A total of 1.5×105 cells were seeded in six-well plates one day prior to treatments with 
VHL compounds. At treatment times of 0, 24, 48, and 72 h, cells were detached using 
400 µL of trypsin, followed by the addition of 600 µL of media to stop the 
trypsinisation reaction. Cells were then counted using haemocytometer. 
2.8.3. Colony formation assay 
A total of 500-2000 cells were seeded in a six-well plate one day prior to treatments 
with VHL compounds. After 24 h of treatment, media was changed and cells were 
further incubated for one week. Cells were washed with 1 × PBS twice and stained with 




temperature. The staining was washed off with water and plates were left to dry 
overnight. Numbers of colonies formed were counted with the M-tools suite from 
OMERO on the scanned plates.  
2.9.  RNA Sequencing 
2.9.1. Sample Preparation 
HeLa cells were seeded in 35 mm dishes at 2 × 105 one day prior to treatments with 
1% DMSO, hypoxia (1% O2), 250 µM IOX2, or 250 µM VH032 for 16 h. RNA was 
extracted as described in section 2.4. , and DNAse treatment (RNase free DNase from 
Qiagen; 79254) was included according to manufacturer’s instruction. Experiments 
were performed in six replicates. RNA samples were handed to Andrew Cassidy from 
the Genetic Core Services Unit in Dundee, who performed the quality control test, 
library preparation and running of the samples on the NextSeq 500 platform. RNA 
ERCC ExFold RNA Spike-In Mix (Mix1 and Mix2) was distributed throughout the 
RNA-Seq experiment. 
2.9.2. Data Analysis 
FastQ files containing reads were quality-controlled with fastQC 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). The raw sequence reads from 
each replicate were aligned to the Ensembl human genome GRCh37 and ERCC 
sequence with STAR. The aligned reads were combined and number of read for each 
gene was counted with subread-featureCounts pipeline (224). The files were found to 
contain ribosomal DNA (rDNA) contaminations, majority of which were the following 
two mitochondrial DNA: ENSG00000211459 and ENSG00000210082 – which were 
removed manually. Differential gene expression analysis was then performed by the R-




2.10.  Tandem mass tag labelling mass spectrometry 
2.10.1. Sample preparation 
A total of 1 × 106 HeLa cells were seeded on four 6 cm plate one day prior to cell 
treatment. Cells were treated with 0.05% DMSO, hypoxia, 250 µM IOX2 and 250 µM 
VH032 for 24 h. Cells were lysed as described in section 2.1.1, but in 4% SDS in 
100 mM Tris-HCl, pH 8.5 and one protease inhibitor cocktail tablet [Roche] per 10 mL 
of buffer. Lysates were sonicated for 6 cycles of 30 sec on low power setting with 
Bioruptor™ Twin (Diagenode). Wenzhang Chen from the FingerPrints Proteomic 
group, Dundee, performed protein digestion, TMT-labelling (TMT 10 plex™ Isobaric 
label reagent set from Thermo Scientific; 90110), fractionation of peptides and database 
search against human protein sequences (Sprot) using the Mascot search engine (Matrix 
Science, Version 2.2) through proteome discovery software (version 1.4). 
2.11.  Co-immunoprecipitation mass spectrometry 
2.11.1. Sample preparation 
HeLa cells were seeded on five 15 cm plates one day prior to treatment with 1% DMSO 
(two plates, one for IgG control), 20 µM MG132, 100 µM VH298, or a mix of 20 µM 
MG132 and 100 µM VH298. After 3 h compound treatment, cells were lysed in the 
250 µL of MS lysis buffer as described in section 2.1.4. Protein was quantified by 
Bradford assay as described in section 2.2.1. A total of 750 µg of protein lysate were 
used per immunoprecipitation condition. Prior to immunoprecipitation, 50 µg of 
Dynabeads® Protein G (Thermo Scientific, 10003D) were incubated with 6 µg of VHL 
antibody (BD Biosciences, mouse, 556347) or negative control mouse IgG in a rotating 
platform at 4°C for 10 min. The antibodies-coated beads were then incubated with 




immunoprecipitation, the beads were washed with 300 µL of ice-cold 50 mM 
ammonium bicarbonate thrice. Before removing the last wash, one-third of the total 
complexes (100 µL) was transferred to a fresh Eppendorf tube, supernatant was 
removed and the co-IP complex was eluted from beads with 20 µL SDS-loading buffer 
for immunoblotting. 
The following protocol was mainly carried out by Kelly Hodge from GRE proteomic 
support group, Dundee. The remaining beads (two-third of the total complexes) were 
resuspended in 50 µL of 50 mM ammonium bicarbonate supplemented with 10 mM 
DTT, and incubated at ambient temperature for 1 h on a shaking platform. 20 mM 
iodoacetamide was added to the mixture and incubated on a shaking platform in the 
dark for 15 min at ambient temperature. Immuno-bound proteins were digested on the 
beads with 1 µg trypsin (Roche) at 37°C for 1 h. The supernatant was removed and the 
remaining beads were resuspended in 40 µL of 50 mM ammonium bicarbonate for 
subsequent re-trypinisation (1 µg, 37°C, overnight). All supernatants were pooled. The 
acquired peptide mixture was cleaned using a C18 resin matrix and eluted with 25% 
acetonitrile prior to drying. Resuspended peptides were analysed by on-line 
nanoLC-MS/MS using a LTQ OrbiTrap Velos Pro (Thermo Scientific) coupled to the 
Ultimate 3000 RSLCnano system (Thermo Scientific). Peptides were loaded on a 
PepMap 100 C18 column (100 µM x 2 cm, Dionex) in 0.1% formic acid, and 
subsequently separated on an Easy-Spray PepMap RSLC C18 column (75 µM x 50 cm, 
Dionex), using 80% acetonitrile in 0.08% formic acid buffer. Separation was performed 
with a 2-40% gradient and a 0.3 µL/min flow rate for 156 m. The OrbiTrap Velos Pro 
was operated in data dependent acquisition mode. MS spectra were acquired in the mass 
range of 335-1800 m/z at a resolution of 60,000 full width at half maximum (FWHM). 




3. Characterisation of VHL inhibitors 
3.1.  Introduction 
Hypoxia, which occurs when oxygen demand exceeds supply, is an important 
physiological and pathological stimulus (11). Furthermore, components of the hypoxia 
response pathway are evolutionary conserved in multicellular organisms (226). The 
cellular response to hypoxia is mediated by the action of the Hypoxia-Inducible Factors 
(HIFs), a family of transcription factors activated in hypoxia. 
The hypoxia pathway represents a compelling therapeutic target, given that it plays a 
major role in a wide range of diseases. The pathway has been historically targeted to 
enhance or inhibit the stabilisation of HIFs through the knockdown/knockout of the 
HIFs or PHDs and more recently through pharmacological approaches. HIF stabilisers 
described in 1.4.  have been widely used as in biochemical and biomedical research, 
however they affect multiple pathways and have poor target selectivity, which limit 
their scope as chemical tools for understanding the hypoxia signalling. 
Alternative to the abovementioned targets for activating HIFs, the VHL E3 ubiquitin 
ligase, which is the master regulator of HIFs also represents an attractive target for the 
stabilisation HIFs. Development of a potent inhibitor of the VHL:HIF-α protein–protein 
interaction would allow intervening in the HIF pathway downstream of PHD enzymes 
and potentially in a more selective fashion; this may avoid the HIF-independent off-
target effects observed with PHD inhibitors (211). 
Small molecules disruptors of the VHL:HIF-α interaction had been previously 
developed, but were ineffective in the induction of HIFs in cells because of their limited 
potency (211-213). In order to achieve compound-induced HIF-α activity and a pseudo-




to compete with its high affinity for the endogenous hydroxylated HIF-α substrates 
inside cells (215). 
At the beginning of my PhD project, the Ciulli group had just reported a VHL inhibitor 
series with in vitro nanomolar binding affinities, which included VH032 (also called 
ligand 7 in the published data) (214). VH032 was the most potent VHL inhibitor 
reported in this study, with a dissociation constant (Kd) of 150±30 nM as assessed in 
competitive fluorescence polarisation (FP) assay and 185±6 nM as determined by 
isothermal titration calorimetry (ITC) (Table 3.1). Based on the X-ray crystal structure 
of VH032 bound to VHL:ElonginB:ElonginC (VBC) complex, the Ciulli group 
designed and synthesised a new series of VHL inhibitors. Carles Galdeano and Pedro 
Soares of the Ciulli group performed FP and ITC to measure the binding of these VHL 
inhibitors and identified VH101 to be the first double-digit nanomolar affinity binder to 
VBC, with a measured Kd of 90±10 nM by FP and 44±9 nM by ITC Table 3.1.  
The Ciulli group also generated suitable negative control compounds that do not bind to 
VHL, but maintain as closely as possible the physiochemical properties of the parent 
binder. For VH032 and VH101, the respective inactive epimers are the cis-
hydroxyproline analogues cisVH032 and cisVH101, respectively. This change in 
stereochemistry at the carbon atom bearing the hydroxyl group of the hydroxyproline 
ring results in the loss of binding for VBC as shown by ITC by Pedro Soares (Table 
3.1). This result confirmed that the stereospecific effect that had previously been 
observed in the context of the HIF peptide (227) is retained in the context of VHL 
inhibitors. These inhibitors, however, had not been investigated with regards to their 
effectiveness at stabilising HIF-α in cells. 
Therefore, the aim of the work presented in this chapter was to determine whether VHL 








studying the hypoxia signalling pathway in cells. Here, VHL inhibitors VH032 and 
VH101 were shown to stabilise transcriptionally active HIF-α, but VH101 was 
discovered to be cytotoxic at the concentration used. A new series of VHL inhibitors 
were then screened for their ability to accumulate HIF-α, and VH298 was found to be 
the best and not toxic at the maximum concentration used (250 µM). 
Table 3.1 – Chemical structures, and dissociation constants measured by FP and 
ITC of VH032 and VH101 by Carles Galdeano and Pedro Soares. Figures of 
chemical structures were provided by Pedro Soares 
Inhibitor Chemical Structure Kd FP (nM) Kd ITC (nM) 
VH032 
 
150 ± 30 185 ± 6 
VH101 
 
90 ± 10 44 ± 9 
cisVH032 
 
Not tested No binding 
cisVH101 
 





3.2.  VHL inhibitors VH032 and VH101 stabilise hydroxylated 
HIF-1α 
To determine the ability of VHL inhibitors VH032 and VH101 to stabile HIF-1α protein 
in cells, HeLa cells were treated with VH032 or VH101 at different concentrations for 2 
h; time course experiments showed that the level of accumulated HIF-1α was the 
highest at 2 h (not shown). In the presence of VH032 (Figure 3.1A) or VH101 (Figure 
3.1B), HIF-1α protein levels increased in HeLa cells in a dose-dependent manner, but 
not when the inactive epimers cisVH032 and cisVH101 were used (Figure 3.1A and B). 
The maximum HIF-1α protein level was achieved with 250 µM VH032 inhibitor 
(Figure 3.1A) and 150 µM VH101 (Figure 3.1B). Immunoblots with antibodies specific 
for HIF-1α hydroxylated at Pro564 (HIF-1α-OH) showed increased levels of this 
HIF-1α form only after treatment with the VHL inhibitors VH032 and VH101, and 
proteasome inhibitor MG132, but not with CoCl2 and IOX2 (PHD inhibitors). This 
observation is consistent with notion that disruption of the VHL:HIF-α interaction by 
VHL inhibitors occurs downstream of HIF-α hydroxylation by PHDs.  
Serum proteins may bind to small molecule drug-like compounds and subsequently 
decrease the concentration of free active drugs that can penetrate into cells. In cell 
treatment experiments, 10% fetal bovine serum (FBS) is used in the growth medium. To 
investigate if the presence of serum affects the activity of VHL inhibitors, HeLa cells 
were treated with VH032 and VH101 in the presence of growth medium containing 
0-10% of FBS (Figure 3.1C and D). The presence of FBS did not alter the stabilisation 
profiles of HIF-1α and hydroxylated HIF-1α induced by VH032 (Figure 3.1C) or 
VH101 (Figure 3.1D), indicating that VH032 and VH101 activity is not significantly 




Here, VH032 and VH101 were shown to be the first VHL inhibitors that stabilise 
HIF-1α in mammalian cells, demonstrating the ability of these inhibitors to enter the 
cells, and leading specifically to the accumulation of hydroxylated HIF-1α. This 
indicates that the mode of action of the VHL inhibitors is downstream of hydroxylation 
by PHD enzymes. Moreover, the activity of these small molecules was not affected by 
the presence of serum in the growth medium.  
 
 
Figure 3.1 – VHL inhibitors VH032 and VH101 increase HIF-1α and hydroxylated 
HIF-1α levels independent of the presence of serum in the growth medium. HeLa 
cells were seeded on 6-well plates and treated for 4 h with 1% DMSO only (vehicle 
control), 4 h of 100 µM CoCl2 (hypoxia-mimetic condition), 4 h of 20 µM proteasome 
inhibitor MG132, 6 h of 250 µM PHD inhibitor IOX2, 2 h of 250 µM negative control 
of VHL inhibitor cisVH032 (A) or cisVH101 (B), and VHL inhibitor VH032 (A) or 
VH101 (B) at the concentration indicated. 150 µM VH032 (C) or VH101 (D) was used 
to treat HeLa cells in 6-well plates in the presence of 0, 1, 2, 5, and 10% FBS in fresh 
growth medium for 2 h. HeLa cells were also treated with 20 µM MG132 for 3 h and 
150 µM cisVH032 (C) or cisVH101 (D) for 2 h in the presence of 10% FBS in fresh 
growth medium as positive and negative control, respectively. Protein levels were 
analysed by immunoblotting using antibodies against HIF-1α, HIF1α-OH (Hyp564), 
and β-actin, which acted as a loading control. Precision Plus protein standards (Bio-






























































































































3.3.  VHL inhibitors VH032 and VH101 induce 
transcriptionally active HIF-α 
To investigate the ability of VHL inhibitors to promote HIF activity, a luciferase 
reporter assay was performed. In HRE-luciferase reporter cells, HeLa-HRE and U2OS-
HRE, treatments with VHL inhibitors VH032 and VH101 exhibited marked 
concentration-dependent increase of HIF-dependent luciferase activity, consistent with 
hypoxia and IOX2 treatments, while no activity was observed with high concentration 
of non-binding epimers cisVH032 and cisVH101 (Figure 3.2A and B). Since VH101 is 
more potent than VH032 (Table 3.1), VH101 required a lower concentration (50 µM) 
than VH032 (150 µM) to reach the same level (threefold increase relative to control) of 
HIF activity in U2OS-HRE cells (Figure 3.2A). Consistently, at the concentration of 
150 µM, VH101 induced a higher HIF activity (fourfold increase relative to control) 
than VH032 (threefold increase relative to control) in HeLa-HRE cells (Figure 3.2B). 
HIF activity of VH101 at 150 µM was comparable to hypoxia exposure and inhibition 
of PHDs by IOX2 at the same concentration, while VH032 required a higher dose 
(250 µM) in U2OS-HRE cells (Figure 3.2A). Peculiarly, VH101-induced HIF activity 
profile diminished in HeLa-HRE cells at high dosage of 250 µM (Figure 3.2B). 
Nonetheless, this analysis revealed that VHL inhibitors-induced HIFs are able to bind to 
HRE motifs and be transcriptionally active.   
Increase of HRE-luciferase activity in the presence of VHL inhibitors would suggest 
that HIF-α stabilised by VHL inhibitors forms HIF dimer and binds to the HRE motifs 
of its target genes to drive the transcription process. To further assess HIF 
transcriptional activity induced by VHL inhibitor, mRNA levels of known HIF-target 





Figure 3.2– VHL inhibitors VH032 and VH101 induce HIF-α transcriptional 
activity. U2OS (A) and HeLa (B) cells stably expressing an HRE-luciferase reporter 
plasmid were treated with indicated conditions for 32 h and 24 h, respectively. (C) 
Time-dependent curves of HIF targets (VEGF, GLUT1, CA9 and PHD2) mRNA 
expression in HeLa cells treated with 150 µM cisVH101 or VH101. (D) mRNA 
expression of HIF targets (VEGF, GLUT1, CA9 and PHD2) in HeLa cells treated with 
1% DMSO (normoxia control), 1% O2 (hypoxia), IOX2, cisVH101, VH032 and VH101 
for 16 h. mRNA was collected, reverse transcribed and analysed by qRT-PCR. The 
levels of the indicated mRNAs were normalised to those of β-actin. Graphs depict the 
mean + SD of three independent biological replicates. Two-tailed student’s t-test was 
performed to calculate p values, and levels of significance are denoted as follows: 


















































































































































































































































































































































































quantitative real-time PCR (qRT-PCR). Time-course treatment with VH101 resulted in 
marked upregulation of HIF-target genes, but not with inactive epimer cisVH101 
(Figure 3.2C). mRNA of VEGF reached the maximum levels with the shortest treatment 
time (4 h) amongst the HIF-target genes examined, whereas CA9 required the longest 
presence of VH101 (16 h) (Figure 3.2C). Since 16 h treatment with VH101 induced 
significant increase in mRNA levels of the four genes tested, 16 h treatment time was 
used in the coming experiments assessing mRNA levels of HIF-target genes. VH032 
and VH101 resulted in significant increase in the mRNA levels of the genes monitored, 
but this was not observed when the negative control cisVH101 was added to HeLa cells 
(Figure 3.2D). The more potent cellular activity of VH101, when compared with 
VH032, was further confirmed as VH101 treatment induced higher increase in mRNA 
levels of all the genes analysed than treatment with VH032 at equimolar concentration 
and identical treatment time (Figure 3.2D). Together, the results obtained demonstrate 
that pharmacological inhibition of VHL by small molecules stabilises transcriptionally 
active HIFs and that VH101 is a more potent VHL inhibitor than VH032. 
3.4.  VHL inhibitors VH032 and VH101 do not alter cell cycle 
In addition to its role in oxygen sensing, VHL has been associated with other biological 
processes (140), and one of such is mitosis (228-230). VHL suppresses spindle 
misorientation by protecting microtubules from depolymerisation and thereby 
stabilising the microtubules (228). In addition, VHL plays a role in maintaining normal 
mitotic checkpoint control and resultant chromosomal stability as the inactivation of 
VHL causes reduced level of Mad2 that controls the spindle checkpoint function (229). 
To determine whether the inhibition of VHL at the interface where HIF-α binds might 
affect VHL function on mitosis, cells treated with VHL inhibitors were analysed by 
flow cytometry for their cell cycle profiles. Whereas inhibition of PHD2 by IOX2 and 




U2OS cells (Figure 3.3B), both increase the G1 population of HeLa cells (Figure 3.3A). 
Apart from altering the cell cycle profile of cells, VH101 and its non-binding inactive 
analogue cisVH101 also resulted in an increase of cell death (Figure 3.3A and B), thus 
rendering their effect on cell cycle unreliable. Nonetheless, the increase in G1 
population exhibited in IOX2- and VH032-treated cells may be the effect of the 
stabilised HIF-1α, which has been shown to result in G1 cell cycle arrest due to the 
HIF-1α-dependent upregulation of CDK inhibitors p27 and p21 (231). 
 
Figure 3.3 – VHL inhibitors VH032 and VH101 do not significantly alter cell cycle. 
Cell cycle profile graphs of HeLa (A) and U2OS (B) cells were treated with indicated 
conditions for 24 h. Graphs depict the mean + SD of three independent biological 
replicates. Two-tailed student’s t-test was performed to calculate p values, and levels of 
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3.5.  VH101 is cytotoxic, but not VH032 
VHL inhibitors could serve as a useful tool for the study of the biological functions of 
VHL and may have the potential to be an alternative therapeutic target in the hypoxia 
pathway. Therefore, it is important that VHL inhibitors are not toxic and act selectively 
on-target inside cells. However, analysis of the cell cycle profile of cells (Figure 3.3) 
showed that treatment with VH101 and its non-binding epimer cisVH101 resulted in 
cell death. To further investigate if VHL inhibitors are cytotoxic, several experiments 
assessing cellular viability were performed. 
3.5.1. Cell proliferation and viability assay by trypan blue exclusion 
First, cell proliferation in the presence of VHL inhibitors VH032 and VH101, and their 
respective negative control compounds (cisVH032 and cisVH101) were assessed. The 
number of HeLa and U2OS cells were counted from starting time point of 0 h (cells 
were seeded one day prior) to 72 h in the presence of compounds for every 24 h using 
trypan blue exclusion assay (Figure 3.4). VH032 and PHD inhibitor IOX2 treatments 
resulted in reduced proliferation (Figure 3.4A), which could be due to the 
abovementioned G1 cell cycle arrest observed in the analysis (Figure 3.3). VH101 and 
cisVH101 also resulted in a significant reduction in proliferation, particularly at higher 
concentrations: 50 µM for VH101 in both HeLa and U2OS cells, but 50 µM cisVH101 
in U2OS and 150 µM cisVH101 in HeLa cells (Figure 3.4B). At 50 µM, VH101 
reduced cell proliferation more efficiently than its non-binding analogue in both cell 
lines (Figure 3.4B), suggesting the inhibition of VHL could lead to reduced 
proliferation. Nevertheless, the reduced proliferation in the presence of cisVH101 





Figure 3.4 – VH101 impairs cell proliferation and viability, but not VH032. (A and 
B) Time-dependent proliferation curves of HeLa and U2OS cells treated with indicated 
compounds for 0, 24, 48, and 72 h. At the end of each treatment, cells were trypsinised 
and stained with trypan blue for counting. The levels of significant changes at 72 h 
treatments were determined. Graphs depict the mean + SEM of three independent 
biological replicates. Two-tailed student’s t-test was performed to calculate p values, 
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3.5.2. Clonogenic assay 
To further substantiate the proliferation results, colony formation assay was performed. 
Low density of cells were treated for 16 h with compounds and allowed to grow for 1-2 
weeks. Cells were stained with crystal violet to observe the ability of cells to form 
colonies. After the treatment with IOX2 and VH032, HeLa and U2OS cells were able to 
form colonies (Figure 3.5A) and quantification showed that there were no significant 
decreases in the colony numbers, with the exception of VH032 resulting in a slight drop 
of colony numbers in U2OS cells (Figure 3.5B). In contrast, cells treated with VH101 
exhibited significant decrease of colonies formed and its inactive epimer cisVH101 also 
decreased the number of colonies, particularly in U2OS cells (Figure 3.5A and B). 
 
Figure 3.5 – VH101 impairs colony formation ability of cells, but not VH032. (A 
and B) HeLa and U2OS cells were seeded in 6-well plates at 1000-2000 cells per well 
and treated with 0.05% DMSO, 250 µM IOX2, 150 µM cisVH101, 150 µM VH101 and 
250 µM VH032 for 16 h. After treatment, media were changed and incubated for 1-2 
weeks. Cells were stained with crystal violet (A) and colonies formed were counted (B). 
Graphs depict the mean + SEM of three independent biological replicates. Two-tailed 
student’s t-test was performed to calculate p values, and levels of significance are 










































3.5.3. CellTiter-Glo luminescent cell viability assay 
To further confirm whether the decreased proliferation and colony formation are due to 
the inhibition of VHL by the inhibitors or the nature of the chemical composition of the 
VHL inhibitors, a high-throughput cytotoxicity assay (CellTiter-Glo luminescent cell 
viability assay) was performed for VH032 and VH101, as well as their respective 
inactive analogues (cisVH032 and cisVH101) in six cell lines: HeLa, U2OS, HFF, 
HEK293, and VHL-null RCC4 cells constituted with HA-tag (RCC4-HA) or HA-
tagged VHL (RCC4-HA-VHL). The use of the two RCC4 cell lines would be ideal for 
differentiating cytotoxicity effect of the inhibitors from reduced cell proliferation due to 
VHL inhibition.  
The viability of cells treated with VH032 or cisVH032 did not seem to be affected in 
the cell lines tested, up to the dosage of 250 µM and even a twofold increase to 500 µM 
(Figure 3.6A). However, in the presence of VH101 as well as cisVH101, cell viability 
notably decreased in all cell lines (Figure 3.6B), and crucially in a similar fashion for 
RCC4-HA compared to RCC4-HA-VHL, suggesting that the cytotoxicity of VH101 is 
due to its chemical properties and not the effect of VHL inhibition by VH101. 
Collectively, cell proliferation, colony formation and CellTiter-Glo assay indicate that 
VH101 is cytotoxic, presumably via a mechanism other than due to on-target binding, 





Figure 3.6 – VH101 induces cytotoxicity in cells, but not VH032. The viability of 
HFF, HeLa, U2OS, RCC4-HA and RCC4-HA-VHL cells treated with cisVH032, 
cisVH101, VH032 and VH101 for 24 h was determined using the CellTiter-Glo 
Luminescent Cell Viability Assay kit. Graphs depict the mean + SEM of three 



























































































































































3.6.  VHL inhibitor screen 
At this point, the discovery that the most potent VHL inhibitor VH101 is cytotoxic 
prompted the dropping of this compound from further biological studies. While the less 
potent inhibitor VH032 was not cytotoxic and able to upregulate transcriptionally active 
HIF-1α, it required to be used at relatively high dose to elicit HIF stabilisation in cells  
 
Figure 3.7 – VHL inhibitor screen. HeLa cells were treated with 50 µM VHL 
inhibitors for 2 h. DMSO (2 h) was used as vehicle control and PHD inhibitor IOX2 (2 
h) as positive control for HIF-1α and negative control for HIF-1α-OH. (A) Protein 
levels were analysed by immunoblotting using antibodies against HIF-1α, HIF1α-OH 
(Hyp564), and β-actin, which acted as a loading control. PageRuler Plus Prestained 
protein ladder (Thermo Fisher) was used, ladder size in kb. (B) HIF-1α and HIF1α-OH 
(Hyp564) protein levels were quantified with LI-COR system. Graphs depict the mean 
+ SD of three independent biological replicates. Two-tailed student’s t-test was 
performed to calculate p values, and levels of significance are denoted as follows: 


















































































































































































































































Table 3.2 – Chemical structures, and dissociation constants measured by FP and 
ITC of VH284, VH297, VH298 and cisVH298 by Pedro Soares. Figures of chemical 
structures were provided by Pedro Soares. 
Inhibitor Chemical Structure Kd FP (nM) Kd ITC (nM) 
VH284 
 
245 ± 50 210 ± 12 
VH297 
 
167 ± 30 106 ± 14 
VH298 
 
79 ± 30 90 ± 5 
cisVH298 
 
No binding No binding 
 
(Figure 3.1 and Figure 3.2). This inspired the Ciulli group to design a new series of 
VHL inhibitors by changing the left-hand side of VH032 and VH101 to structure that 
fits better to the VHL pocket with improved chemical property (key compounds tested 
further are listed in Table 3.2 and the rest are in Appendix Table 9.1), with the goal to 
identify a new inhibitor that would be more potent in cells than VH032, and not 
cytotoxic. FP, SAR and ITC were performed by Pedro Soares of the Ciulli group on 
these compounds, and based on the measured binding affinity of the inhibitors to VBC, 
number of them were selected to be screened by Western blotting for their ability to 
accumulate HIF-1α in cells (Figure 3.7). Western blots of lysates from HeLa cells 
treated with 2 h of VHL inhibitors were generated and HIF-1α and its hydroxylated 
form on Pro564 (HIF-1α-OH) were quantified using the LI-COR system. Consistent 




VH101 stabilised a higher level of HIF-1α than VH032 (Figure 3.7). VH298 was the 
most potent of the novel compounds tested and stabilised HIF-1α and HIF-1α-OH, to a 
level similar to that observed using VH101. This was closely followed by VH297 
(Figure 3.7B). The most active compounds VH298 and VH297, as well as VH284 that 
induced similar HIF-1α levels as VH032, were selected to be examined for their 
cytotoxicity effects. 
3.7.  Cytotoxicity screen for VH284, VH297 and VH298 
To select non-toxic VHL inhibitor, the high-throughput screen CellTiter-Glo 
luminescent assay, for the assessment of cell viability was performed using VH284, 
VH297 and VH298 VHL inhibitors (Figure 3.8). The overall cell viability profiles of 
the three VHL inhibitors showed a higher decrease in cell viability at high 
concentrations of 500 µM (Figure 3.8), compared to that of VH032 (Figure 3.6). 
However, their respective inactive epimers (cisVH284, cisVH297 and cisVH298) 
demonstrated different cell viability profiles. In all the cell lines tested, cisVH284 cell 
viability curves were similar to that of VH284, except in HEK293, in which the inactive 
negative control cisVH284 induces a higher decrease in cell viability than its parent 
binder (Figure 3.8A). Treatment with inactive epimers, cisVH297 (Figure 3.8B) and 
cisVH98 (Figure 3.8C), resulted in smaller decreases in cell viability compared to their 
respective parent binders, VH297 and VH298, respectively, indicating the reduced cell 
viability of VH297 and VH298 could be due to the effect of VHL inhibition and not the 
cytotoxic effect of the compound composition. In addition, among the three negative 
control compounds, only cisVH284 exhibited cytotoxicity, suggesting that chemical 





Figure 3.8 –VH298 and VH297 are not cytotoxic, but VH284 is. The viability of 
HFF, HeLa, U2OS, RCC4-HA and RCC4-HA-VHL cells treated with cisVH284, 
cisVH297, cisVH298, VH284, VH297 and VH298 for 24 h was determined using the 
CellTiter-Glo Luminescent Cell Viability Assay kit. Graphs depict the mean + SEM of 





































































































































































































































3.8.  VH298 is not cytotoxic 
VH298 is the most potent VHL inhibitor screened (Figure 3.7) and its cis-
hydroxyproline analogue shows no apparent cytotoxicity effect (Figure 3.8). However, 
to further confirm that levels of VH298 cytotoxicity were limited and tolerable, cell 
proliferation and colony formation assays were carried out in HeLa cells. VH298 and its 
inactive negative control cisVH298 did not alter cell proliferation rate (Figure 3.9A) and 
the ability of HeLa cells to form colonies (Figure 3.9B and C). Altogether, these data 
suggested that VH298 is not cytotoxic at the high micromolar concentrations required to 
be used in cells. 
 
Figure 3.9 – VH298 is not cytotoxic in HeLa cells. (A) Time-dependent proliferation 
curve of HeLa cells treated with indicated compounds for 0, 24, 48, and 72 h. At the end 
of each treatment, cells were trypsinised and stained with trypan blue for counting. The 
levels of significant changes at 72 h treatments were determined. (B) HeLa cells were 
seeded in 6-well plates at 1000-2000 cells per well and treated with 0.05% DMSO, 150 
µM cisVH298 and 150 µM VH298 for 24 h. After treatment, media were changed and 
incubated for 1-2 weeks. Cells were stained with crystal violet (B) and colonies formed 
were counted (C). Graphs depict the mean + SD of three independent biological 
replicates. Two-tailed student’s t-test was performed to calculate p values, and levels of 
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3.9.  Discussion 
Chemical probes that target different components of the hypoxia signalling to activate 
HIFs are useful tools for the study of this signalling pathway. One of the targets is the 
VHL E3 ubiquitin ligase. Previous studies have reported small molecules that bind the 
VHL protein at the interface where hydroxylated HIF-1α would normally bind, 
disrupting the interaction between VHL and HIF-1α (211-214). However, these VHL 
inhibitors were proven to be inactive in cells or had yet to be investigated for their 
activity in cells. The Ciulli group optimised the best inhibitor VH032 [ligand 7 from ref. 
(214)] at the time to improve binding affinities of VHL inhibitors, leading to the 
discovery of a more potent compound, VH101, possessing double-digit nanomolar 
binding affinity. 
Herein, VH032 and VH101 were shown for the first time to stabilise hydroxylated 
HIF-1α that is transcriptionally active in cells. Consistently, the more potent binder 
VH101 induced a higher transcriptional activity than VH032 in HRE-reporter cell lines. 
Moreover, mRNA levels of HIF-target genes were higher in VH101-treated cells than 
following VH032 treatment. Altogether revealing that VH101 is more potent than 
VH032 in cells. 
Unfortunately, VH101 and its non-binding analogue cisVH101 were found to be 
severely cytotoxic at the concentrations needed to be used in cells. Following cell cycle 
analysis, both compounds were found to result in cell death. VH101 and cisVH101 also 
greatly reduced cell proliferation and viability, and prevented HeLa and U2OS cells 
from forming colonies, suggesting that these compounds caused these cells to die. 
Although VH032 was active and non-toxic at concentration required in cells, a 
relatively high dose of up to 250 µM inhibitor was required to induce HIF activity to 




To overcome these problems, the Ciulli lab designed another series of VHL inhibitors 
by optimising the left-hand side of VH032 and VH101, in order to improve the 
permeability of the inhibitor as well as alter the inhibitor to fit better to the VHL pocket; 
the latter was possible by assessing the crystal structure of VHL with the inhibitor. To 
identify the best compound, these compounds were initially screened by western 
blotting for HIF-1α protein levels. VH298 was found to be the best in stabilising HIF-1α 
protein levels, followed by VH297 and VH284. The three compounds were screened for 
cytotoxicity effects, which demonstrated that only VH284 was cytotoxic. VH298 was 
selected for further studies as the most potent VHL inhibitor, and at the same time was 
not cytotoxic at micromolar concentrations required to be used for biological studies in 
cells. 
Potential contribution for the observed mismatch between the micromolar 
concentrations of the inhibitors required to stabilise HIF-1α in cells despite the 
nanomolar-binding affinities were also investigated. Amongst one possible reason 
considered was the presence of serum protein in the growth medium, which could affect 
the activity of VHL inhibitors in case of high serum protein binding. However, this was 
found not to be the case for the inhibitors tested (VH032 and VH101). With the 
discovery of VH298, the goal to improve the inhibitor activity in cells and reduce the 
dose required was ultimately achieved. 
In summary, small molecule disruptors of VHL:HIF-α interaction were shown for the 




4. Characterisation of VH298: a potent and 
selective VHL inhibitor 
4.1.  Introduction 
Small molecules that bind, potently and selectively, to their protein target inside the cell 
can be useful chemical tools to study and perturb the molecular target in biological 
systems. These small molecule modulators are also known as chemical probes. In recent 
years, development of high-quality chemical probes (potent, with known target 
selectivity and proven mechanism of action) has enabled significant progress in both 
basic and translational research, and provided a starting point for the development of 
drugs (208,209). This is achieved through their unique advantages of being 
complementary to genetic approaches such as CRISPR and RNAi, as well as the 
probes’ ability of rapidly and reversibly inhibit a target in any cell types or animals. 
Small molecule disruptors of VHL:HIF-α interaction could therefore serve as useful 
chemical probes to study the biology of the hypoxia signalling pathway. 
In the previous chapter, VH298 was identified to be the best VHL inhibitor in 
accumulating hydroxylated HIF-1α and its cytotoxicity was tolerable in cells. In order 
for VH298 to meet the criteria for use as a potential chemical probe to address biology 
(i.e. potency, selectivity, on-target effect, lack of toxicity, amongst others), it is essential 
to fully characterise its cellular activity. 
Here, the aim of the work presented was to characterise VH298 as chemical probe and 
elucidate further its potency, target engagement and mode of action in disrupting 
VHL:HIF-α interaction inside cells. The ability of VH298 to stabilise transcriptionally 
active hydroxylated HIF-α and consequently HIF-targets were also explored. One 




demonstrating possible therapeutic potential of VHL inhibitor. Overall, the results 





4.2.  Biophysical and structural characterisation of VH298 
As VH298 was the best compound assessed in the cellular activity assay (Figure 3.7) 
amongst the VHL inhibitor screened, VH298 and its inactive cis-hydroxyproline 
analogue cisVH298 were first characterised for their binding affinity to recombinant 
VHL protein by other members of the Ciulli Lab. VH298 and cisVH298 (Figure 4.1A) 
(compounds synthesised by Pedro Soares) both bear a cyanocyclopropyl group in place 
of the terminal methyl group of VH032 (Table 3.1). Pedro Soares assessed the binding 
affinity of VH298 for the VHL:ElonginB:ElonginC (VBC) complex, using isothermal 
titration calorimetry (ITC) and fluorescence polarisation (FP) assays. VH298 showed a 
dissociation constant (Kd) of 90 nM as determined by ITC, while no binding could be 
detected for cisVH298 (Figure 4.1C), confirming that cisVH298 is inactive. In a 
competitive FP assay, VH298 confirmed a higher binding affinity (80 nM) than VH032 
(150 nM) (Figure 4.1D). 
Crystal structure of VH298-bound VBC solved by Dr. Morgan Gadd showed that 
VH298 maintains the same overall binding mode as VH032 (214), binding to the pocket 
on VHL where hydroxylated HIF-1α would normally bind (Figure 4.1B), thus 










Figure 4.1 – Biophysical and structural characterisation of VH298, a new potent 
VHL inhibitor. (A) Chemical structure of VH298 VHL inhibitor and its non-binding 
derivative cisVH298. Figures were from Pedro Soares. (B) Crystal structure of VBC in 
complex with VH298 (orange carbons, PDB code 5LLI) solved by Dr. Morgan Gadd 
(who also provided the figure). VHL is shown as a purple surface and the VHL residues 
forming the binding pocket as grey stick representations. The bound ligand is shown as 
sticks representation with orange carbons, nitrogen atoms in blue, oxygen in red and 
sulfur in dark yellow.  The inset panel shows the Fo-Fc omit map contoured at 3 σ 
around the ligand. (C) ITC titrations of 300 µM VH298 (blue) and 300 µM cisVH298 
(green) into 30 µM VBC protein were performed by Pedro Soares. (D) Competitive 
fluorescence polarisation binding assays of VH298 and VH032 displacing a 20-mer 
FAM-labelled HIF-1α peptide binding to VBC (Kd = 3 nM), confirming the relative 
potency observed by ITC. (C and D) Figures were made by Pedro Soares who 











4.3.  VH298 selectively engages VHL 
To investigate whether VH298 could interact with cellular VHL protein, a cellular 
thermal shift assay (CETSA) (223) was performed. CETSA utilises the thermal 
denaturation temperature of a protein from cell lysates. The binding of a ligand to target 
protein can increase the thermal denaturation temperature of a protein, and thus if 
VH298 binds to VHL protein, melting curve of VHL will shift. 
Protein levels of both the on-target VHL and the primary potential off-target PHD2 
were monitored at different temperatures of incubation in HeLa cell lysates treated with 
VH298 using western blotting. PHD2 enzyme could be an off-target for at least two 
reasons. Firstly, at the biological level, it is essential to ensure that HIF-dependent 
hypoxic response is not due to the inhibition of PHD enzymes. Secondly, at the 
molecular level, products of enzymatic reaction are known to be able to bind to their 
enzyme, resulting in a feedback inhibition. Therefore, it is important to ensure that the 
small molecule VHL inhibitor, which contains hydroxyproline residue found also in 
hydroxylated-HIF-α (the primary product of PHDs), does not bind to PHD enzymes. 
PHD inhibitor FG-4592 was used as a control in the assay for PHD2 stabilisation. In the 
presence of VH298, a significant shift in the VHL melting curve was observed, 
demonstrating compound-induced target stabilisation inside cells (Figure 4.2A). In 
contrast, no thermal stabilisation was observed for PHD2 upon VH298 treatment 
(Figure 4.2B). A shift in the melting curve of PHD2, but not VHL, was observed in the 
presence of FG-4592 (Figure 4.2A and B) confirmed the validity of the assay. 
The initial VHL antibody used for western blotting was purchased from Cell Signalling 
(#2738). This antibody was discontinued and replaced with a latest one (#68547), which 
detects multiple VHL bands (Figure 4.2C). The multiple bands were proven to be VHL 




absence of all VHL bands in VHL-null renal cells 786-O and RCC4-HA (Figure 4.2C). 
The CETSA experiment with VH298 treatment (Figure 4.2A) was repeated and blotted 
with the new VHL antibody (Figure 4.2D). In the presence of VH298, all the VHL 
bands detected were stabilised, suggesting that VH298 binds to all the multiple forms of 
VHL (Figure 4.2D).  
 
Figure 4.2 – VH298 selectively engages VHL. Cellular thermal shift assay (CETSA) 
to monitor cellular target engagement of (A) VHL and (B) PHD2. VH298 and FG-4592 
(100 µM) were incubated in HeLa cell lysates for 15-30 min. Representative western 
blots and quantifications are shown. Data are presented as means ± SEM from three 
independent experiments. (C) HeLa cells were transfected with siRNA non-targeting 
(NT) control and VHL. Represented western blot includes cell lysates from renal cells 
786-O and RCC4-HA that lack VHL. (D) CETSA of (A) was repeated with a newer 
VHL antibody (Cell Signalling; #68547) that detects multiple bands of VHL. 
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4.4.  VH298 leads to HIF-α accumulation inside cells 
VH298 had been shown to stabilise hydroxylated HIF-1α in cells at a concentration of 
50 µM in the VHL inhibitor screen assay (Figure 3.7). To determine the concentration 
of VH298 required to induce the stabilisation of HIF-1α, HeLa cells were treated with 
VH298 in a dose-dependent manner for 2 h (Figure 4.3A). VH298 induced 
concentration-dependent accumulation of HIF-1α levels, with detectable HIF-1α bands 
visible as low as 10 µM and the strongest HIF-1α accumulation at 150 µM (Figure 
4.3A). cisVH298 was inactive even at high concentration (250 µM), demonstrating that 
the inhibitor’s activity is strictly dependent on the binding to VHL. The accumulation of 
HIF-1α was also observed in non-tumoural cell lines, including human foreskin 
fibroblast (HFF) cells (Figure 4.3B) and mouse cytotoxic T lymphocyte (CTL) cells 
(215), demonstrating that the cellular activity of VH298 is not limited to immortalised 
cancer cells, but also active in other mammalian cell types. 
Beside HIF-1α, HIF-2α was also stabilised in the presence of VH298 (Figure 4.3B). The 
extent of VH298-induced HIF-α subunit accumulation after 2 h was comparable to that 
observed on treating cells over the same time with 1% O2 (hypoxia) for 2 h or PHD2 
inhibitors (IOX2 or FG-4592) at identical concentrations (100 µM) for 2 h in all cell 
lines tested (Figure 4.3A and B). Immunoblots with an antibody specific for HIF-1α 
hydroxylated at Pro564 (HIF-1α-OH) showed increased levels of this species only upon 
treatment with VH298 (Figure 4.3A and B) and proteasome inhibitor MG132 (Figure 
4.3A), but not with IOX2 and FG-4592 (Figure 4.3A and B), consistent with disruption 
of the VHL:HIF-α interaction by VH298 downstream of HIF-α hydroxylation. 
To further evaluate the activity of VH298, time-course experiments in HeLa cells 
following treatment with VH298 and hypoxia (1% O2) were performed and levels of 




D). VH298 induced a more rapid and pronounced accumulation of HIF-1α and HIF-2α 
compared to hypoxia (Figure 4.3C), and both HIF-1α and HIF-2α (Figure 4.3D) 
remained accumulated over the treatment time, with protein levels detectable already 
after 5 min and persisting beyond 24 h after treatment. 
To confirm that the increase of HIF-α was indeed due to the inhibition of VHL activity, 
clear cell renal cell carcinoma VHL–⁄– renal cell carcinoma 4 (RCC4) cells were treated 
with VH298. In the complete absence of functional VHL proteins in RCC4 cells 
expressing only the haemagglutinin (HA) tag, the levels of HIF-α subunits did not 
increase further upon VH298 treatment (Figure 4.3B). In contrast, RCC4 cells 
expressing HA-tagged VHL showed accumulation of HIF-α subunits in the presence of 
VH298 (Figure 4.3B), demonstrating the on-target specificity of VH298. 
Taken together, these data show that VH298 is able to induce the stabilisation of HIF-α 
subunits in tumoural and non-tumoural cell lines, resulting from effective and specific 





Figure 4.3 – VH298 induces concentration- and time-dependent on-target specific 
accumulation of hydroxylated HIF-α in human cell lines. (A) Immunoblots of HIF-α 
subunits in HeLa cells treated with increasing concentrations of VH298, 1% DMSO, 
hypoxia, 250 µM cisVH298, 100 µM IOX2, 100 µM FG-4592 for 2 h, and 20 µM 
MG132 for 3 h. (B) Treatment of 1% DMSO, hypoxia (1% O2), and 100 µM of 
indicated compounds in HFF, HeLa, RCC4-HA and RCC4-HA-VHL cells for 2 h. (C 
and D) Time-course immunoblots of lysates from HeLa cells subjected to hypoxia (1% 
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4.5.  VH298 selectively stabilises hydroxylated HIF-1α 
To further interrogate the specificity of the compound’s mode of action, the stabilised 
HIF-1α induced by VH298 was examined for the levels of its hydroxylated form. Since 
the HIF-1α antibody recognises both hydroxylated and non-hydroxylated HIF-1α 
species, while the HIF-1α-OH antibody is specific for the hydroxylated species on 
Pro564, co-immunoprecipitation (co-IP) experiments with the HIF-1α-OH antibody 
were performed. In the presence of VH298, the accumulated HIF-1α was found mainly 
in the IP fraction, and not in the flow-through (FT) (Figure 4.4C), indicating that 
majority of the HIF-1α species stabilised by VH298 were hydroxylated. A similar result 
was observed with the proteasome inhibitor MG132, which blocks the pathway 
downstream of HIF hydroxylation. In contrast, when cells were treated with the PHD 
inhibitor IOX2, that inhibit HIF hydroxylation, HIF-1α was found in the FT and not in 
the IP fractions, demonstrating that the HIF-1α-OH antibody pulled down only the 
hydroxylated HIF-1α (Figure 4.4C). 
 
 
Figure 4.4 – The majority of the VH298-induced HIF-1α is hydroxylated. Co-
immunoprecipitation experiments on lysates from HeLa cells treated with vehicle 
DMSO (1% for 2 h), MG132 (20 µM for 3 h), IOX2 (250 µM for 6 h), or VH298 (100 
µM for 2 h) prior to lysis. 300 µg of protein were used to immunoprecipitate with the 
HIF-1α-OH (Pro564) antibody. Rabbit immunoglobulin G (IgG) was used as a control. 
Inputs represent 10% of the starting material used per immunoprecipitation (IP) and 
flow-through (FT) represents 20% of the flow-through collected after IP. The blots 











































































































Taken together, these results are consistent with the VHL inhibitor VH298 engaging 
potently and selectively the VHL E3 ubiquitin ligase (Figure 4.2A-B and D) as its 
cellular target downstream of HIF hydroxylation, leading to specific intracellular 
accumulation of the hydroxylated HIF-α form. 
4.6.  VH298 induces HIF transcriptional activity 
To assess the ability of VH298 to promote HIF activity, a luciferase reporter assay was 
initially performed. In addition, quantitative real-time PCR (qRT-PCR) analysis for 
endogenous HIF-dependent targets was also conducted to confirm the ability of VH298 
to stabilise transcriptionally active HIF. To further ensure that VH298 is indeed the best 
VHL inhibitor, VH032 and VH297 were included in the qRT-PCR assay. Cytotoxicity 
effects of VH032 and VH297 were previously shown to be limited (Figure 3.8). In 
addition, VH297 was found to be the second best VHL inhibitor in its ability to stabilise 
HIF-1α in the VHL inhibitor screen, followed by VH032 (Figure 3.7). 
4.6.1. Luciferase assay 
In HRE-luciferase reporter cells, U2OS-HRE, treatments with VH298 exhibited marked 
concentration-dependent increase of HIF-dependent luciferase activity, consistent with 
hypoxia and IOX2 treatments, while no activity was observed with high concentration 
of non-binding epimer cisVH298 (Figure 4.5A). 
4.6.1. Quantitative real-time PCR 
The ability of VH298 to induce transcriptionally active HIF was further confirmed in 
qRT-PCR assays monitoring mRNA levels of known HIF-target genes including CA9 
and GLUT1 in different cellular backgrounds. Optimum treatment time with VH298 




expression of GLUT1 mRNA levels of six known HIF-target genes including CA9, 
GLUT1, GLUT3, BNIP3, PHD2 and VEGF (Figure 4.6A). 
Treatments with VH032, VH297 and VH298 showed marked increase of HIF-target 
genes, but not with inactive epimers cisVH032, cisVH297 and cisVH298 (Figure 4.6B). 
Different responses to VHL inhibitor treatment were observed in different cell lines. For 
instance, HFF was the most sensitive to VHL inhibitors among the cell lines used; 
maximum mRNA levels of CA9 and GLUT1 were reached with 100 and 25 µM of 
VH298, respectively, in HFF cells. VH297 showed the weakest induction profiles of 
CA9 and GLUT1 mRNA amongst the three VHL inhibitors (Figure 4.6B). Consistently 
in all cell lines, even when used at 250 µM concentration, VH297 could not achieve the 
maximum increase of CA9 and GLUT1 mRNA levels as seen with VH298, with the  
 
Figure 4.5 – VH298 induces HIF-α transcriptional activity in U2OS-HRE. (A) 
U2OS cells stably expressing an HRE-luciferase reporter plasmid were treated with 
indicated conditions for 32 h. Graphs depict the mean + SD of three independent 
biological replicates. Two-tailed student’s t-test was performed to calculate p values, 



































































































Figure 4.6 – VHL inhibitors induce HIF-α transcriptional activity in various cell 
lines. (A) HFF cells were treated with 150 µM of VH298 for 0, 2, 4, and 24 h. 
Experiment was performed once. (B) Dose-response curves of CA9 and GLUT1 mRNA 
expressions in HFF (24 h), HeLa (16 h) and U2OS (16 h) cells in the presence of 
cisVH032, cisVH297, cisVH298, VH032, VH297 and VH298. Graphs depict the mean 
+ SD of three independent biological replicates. (A and B) mRNA was collected, 
reverse transcribed and analysed by qRT-PCR. The shown levels of the indicated 
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exception of GLUT1 in HFF cells (achieved with 100 µM of VH297). Comparing the 
remaining two VHL inhibitors, VH298 required a lower concentration than VH032 to 
increase mRNA levels of target genes analysed. 
Altogether, these results indicate that VHL inhibitor-induced hydroxylated HIF proteins 
are transcriptionally active and confirm the superiority of VH298 over VH032 and 
VH297 with regards to its cellular potency. 
4.7.  VH298 upregulates HIF-dependent gene products 
To examine whether the observed VH298-dependent increases of HIF target mRNAs 
would be translated into proteins, protein levels of known HIF target gene products 
(CA9, GLUT1, PHD2, PHD3, BNIP3, and HK2) were monitored in mammalian cells 
treated for 24 h with VH298 or PHD inhibitors IOX2 and FG-4592 (each at 
concentration of 100 µM), or hypoxia (1% O2). Accumulation of all the HIF targets 
analysed was detected following prolonged treatment of VH298 in cells, to levels 
consistent to those observed with hypoxia or PHD inhibition treatments (Figure 4.7A-
B). In all cell lines tested, hypoxia induced the highest levels of protein expression for 
the majority of HIF targets screened, with GLUT1 and CA9 being the most prominent 
(Figure 4.7A-C). PHD3 levels were also the highest under hypoxia in most cell lines, 
but not in RCC4-HA-VHL (Figure 4.7B), in which PHD3 levels were not affected by 
any treatments. VH298 proved as effective as hypoxia in increasing PHD2 and HK2 
protein levels (Figure 4.7A-B), however in HFF cells, BNIP3 protein level increased 
more with VH298 treatment than hypoxia treatment. By contrast, VH298 treatment 
resulted in similar levels of induction of the protein analysed when compared with PHD 
inhibition in all cell lines tested. The exception was RCC4-HA-VHL cells, in which 
IOX2 and FG-4592 treatments were the most effective conditions, as observed by 




Of note, a higher concentration (150 µM) of VH298 was required in RCC4-HA-VHL 
cells to detect a good response to VHL inhibition, which was likely due to the high level 
of HA-tagged VHL expressed in these cells, as compared to the VHL level in HFF, 
HeLa or U2OS (Figure 4.7D). 
Time course treatments with 1% O2 (hypoxia) and VH298 in HeLa cells showed that 
most HIF-target genes examined were stabilised at similar time points in both 
 
Figure 4.7 – VH298 elicits a HIF-dependent hypoxic response in various cell lines. 
1% DMSO, hypoxia (1% O2) and indicated compounds at 100 µM were introduced to 
(A) HFF, HeLa, U2OS and (B) RCC4 cells expressing HA-tagged VHL (with the 
exception of cisVH298 and VH298 used at 150 µM) for 24 h. (C) Time-course 
immunoblots of HIF targets from HeLa cells subjected to hypoxia (1% O2) or 100 µM 
VH298. (D) VHL protein levels were analysed by western blotting in HFF, HeLa, 
U2OS, RCC4 expressing HA tag or HA-tagged VHL. Protein levels were analysed by 
immunoblotting using antibodies against the indicated proteins, with β-actin as the 
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conditions, but reaching the maximum levels at different times (Figure 4.7C). PHD3 
was the first to reach the maximum level in hypoxia treatment at 4 h, but not increased 
much in VH298 treatment, while CA9 was the last to be upregulated and reached 
maximum level at 48-72 h of hypoxia or 48 h of VH298 treatment (Figure 4.7C). 
In prolonged treatment of 72 h, all target genes tested had started to decrease in protein 
levels when treated with VH298, but not so much with hypoxia treatment (Figure 4.7C). 
Altogether, the results suggested that all HIF-target genes were upregulated in response 
to HIF stabilisation by the different stimuli used, albeit at different rate. Overall, the 
data presented here supports the application of VH298 as chemical probe to elicit 
effective HIF-dependent hypoxic response inside cells. 
4.8.  VH298 stimulates EPO production in VHL-dependent 
manner 
HIF transcriptional activities are known to stimulate the production of the hormone 
erythropoietin (EPO), which is primarily expressed in the kidney and liver. To 
investigate whether VH298-induced HIF activity is able to stimulate EPO production, 
mRNA levels of EPO in RCC4 cells reconstituted with HA-tag or HA-VHL were 
analysed by qRT-PCR. While VH298 had no effect on the mRNA level of EPO in 
RCC4-HA cells that lack VHL, the VHL inhibitor increased mRNA levels of EPO in 
RCC4-HA-VHL, restoring to a similar level compared to the VHL-null RCC4-HA cells 
(Figure 4.8A). This indicates that pharmacological inhibition of VHL is able to 





Figure 4.8 – VH298 stimulates EPO production in VHL-dependent manner. (A) 
EPO production in RCC4-HA and RCC4-HA-VHL cells subjected to 100 µM VH298. 
Graphs depict the mean + SD of three independent biological replicates. Two-tailed 
student’s t-test was performed to calculate p values, and level of significance is denoted 


































4.9.  Discussion 
Small molecule that selectively binds to VHL on the interface where HIF-α normally 
binds would compete with HIF-α. If the VHL inhibitor binds with sufficient potency 
relative to the natural substrate, it could fully occupy the target-binding site, leading to 
the stabilisation of HIF-α subunits and subsequently induce HIF transcriptional activity. 
Work from the Ciulli lab showed that the best VHL inhibitor in stabilising HIF-1α, 
VH298, was able to compete with 20-mer HIF-1α peptide in the FP assay and bind to 
VBC complex with high potency on the VHL pocket where hydroxylated HIF-1α would 
normally bind. Importantly, the cis-hydroxyproline analogue cisVH298 does not show 
any detectable binding to VHL, and is thus inactive in cells (Figure 4.1) (215). Because 
cisVH298 has a very similar structure to VH298, and consequently similar 
physiochemical properties, it provides ideal negative control. 
To provide a useful chemical tool to study the biology of VHL and HIF, it was 
important to fully characterise VH298 for its ability to stabilise HIF subunits and 
activate HIF transcriptional activity in cells. Here, VH298 was shown to stabilise both 
HIF-α subunits: HIF-1α and HIF-2α in various mammalian cell lines. Importantly, in 
the absence of VHL in renal cell carcinoma cell line RCC4 that stably expresses HA tag, 
VH298 could not stabilise HIF-α subunits. However, when RCC4 cells express 
HA-tagged VHL, VH298 induced HIF-α accumulation (Figure 4.3B). This mode of 
inhibition by binding to VHL was further confirmed by the stabilisation of HIF-1α that 
was in its majority hydroxylated, proving that VH298 acts downstream of HIF-α 
hydroxylation. Furthermore, CETSA analysis that showed that VH298 specifically 
engaged VHL as its target but not PHD2 (Figure 4.2). 
The stabilisation of HIF-α subunits when cells were treated with VH298 led to the 




that monitored two known HIF-target genes (CA9 and GLUT1). Previously published 
VHL inhibitor, VH032 (214), and the second best VHL inhibitor screened by western 
blotting for HIF-1α protein levels, VH297, also upregulated CA9 and GLUT1 mRNA, 
but to lower levels when compared to VH298 (Figure 4.5B), making VH298 the most 
potent VHL inhibitor tested. Gratifyingly, mRNA of these two HIF-target genes, as well 
as others (PHD2, PHD3, BNIP3 and HK2) was translated into protein products in 
multiple mammalian cells (HeLa, U2OS, HFF, and RCC4-HA-VHL) treated with 
VH298, confirming the ability of VH298 to elicit effective HIF-dependent hypoxic 
response inside cells. 
An important observation to consider was the dose of VH298 required in cells. 
Although being more potent and more permeable (215) than VH032, a high 
concentration of up to 100 µM VH298 was still required to stabilise HIF-1α. One reason 
for this could be the amount of VHL present in cells (Figure 4.7D). Cells with more 
VHL such as RCC4-HA-VHL (Figure 4.7D) required a higher dose of 150 µM to 
stabilise detectable HIF-α (Figure 4.7B), while in cells with less VHL such as HFF 
(Figure 4.7D), increased HIF-target mRNAs at lower concentration than HeLa and 
U2OS (Figure 4.6B). These results provide additional evidence for the on-target activity 
of the VHL inhibitors, and suggest that target abundance affects the dose of VH298 
required. Another reason could conceivably be the requirement of the compound to 
occupy fully the VHL binding site, e.g. to 99.9%, in order to effectively block its 
activity – consistent with even a small percentage of unbound VHL being sufficient to 
effectively catalyse HIF polyubiquitination and subsequent degradation. Such a high-
bar to target engagement for effective inhibition means that at least 100-fold higher 
concentration relative to Kd is required for cellular activity (i.e. 10 µM concentration in 
spite of a Kd of ~ 100 nM). This feature, combined with potential limitations to cell 




binding affinities measured. These features are common to many chemical probes used 
for biochemical and biomedical research, which also show huge differences between 
binding affinity measured in vitro to concentration required for cell treatment. One of 
such example is the PHD inhibitor used here, IOX2, which possesses IC50 of 22 nM, but 
is used at micromolar range (203). Nonetheless, despite requiring micromolar range for 
cell treatment, the dose administered to achieve required HIF-α stabilisation and 
transcriptional activity is tolerable for the period of experimentation. Therefore, VH298 
is suitable for use as chemical probe and is now available through the newly established 
Chemical Probes Portal (http:www.chemicalprobes.org/vh298). 
Besides being a potential chemical probe of the hypoxic signalling pathway, VH298 
may have therapeutic potential as a HIF stabiliser. Over the years, a number of 
strategies have been developed to stabilise HIF-α through escaping or blocking its 
degradation by the proteasome, with the most promising being the inhibition of HIF-α 
hydroxylation catalysed by PHDs (232). A number of PHD inhibitors are currently in 
clinical trials for the treatment of anaemia in patients with chronic kidney disease, and 
this is because the transcriptional HIF activity is able to stimulate the production of 
EPO that benefits anaemic patients lacking sufficient EPO synthesis (105). Here, 
VH298 was shown for the first time to have the ability to stimulate the production of 
endogenous EPO (Figure 4.8), indicating that it may have therapeutic potential for the 
anaemic patients. In addition to EPO production, the stabilisation of HIF is known to 
stimulate angiogenesis via HIF-mediated VEGF expression (233). The increase of 
VEGF mRNA expressions in HFF fibroblasts in the presence of VH298 (Figure 4.6A) 
suggests that VH298 may also have the potential in stimulating angiogenesis. 
Although not shown here, we have screened VH298 against > 100 tested cellular 
kinases, ion channels, and GPCRs in vitro at the concentration of 50 µM, and found 




Taken together, the data presented in this chapter identified VH298 as the most potent 
VHL inhibitor tested and a high-quality chemical probe with potential for the study of 
HIF-dependent responses, as it is potent, has known selectivity and a proven mechanism 
of action. The data further provides evidence for the potential of VH298 as therapeutic 





5. Transcriptome and proteome changes induced 
by VHL inhibitors 
5.1.  Introduction 
The HIF transcription factor is known to regulate many genes by binding directly to the 
HRE motif on the promoter of HIF-target genes, resulting in the increase of mRNA 
levels of these genes, and subsequently protein levels. In previous chapters, the 
inhibition of VHL using small molecule that binds to the pocket of hydroxylated 
HIF-1α binding site on VHL, were shown to lead to the stabilisation of transcriptionally 
active hydroxylated HIF-1α. However, the investigation of the VHL inhibitor so far was 
focused on monitoring HIF-α levels and the effects on a selected panel of few 
HIF-target genes. 
As a chemical probe to study the biology of VHL, it is important to fully evaluate the 
effects of the inhibition of VHL by the small molecule in an unbiased manner. Here, the 
aim of the work presented in this chapter is to gain a more complete understanding of 
the effect of VHL inhibitor in cells at a global level. To achieve this, global 
transcriptome and proteome analyses were performed. 
5.1.1. Transcriptomic analysis by RNA-sequencing 
Transcriptome analysis would provide an understanding of the global changes of 
transcripts in the cells in the presence of the VHL inhibitor. Such an analysis would 
allow validating the anticipated effects on the HIF pathway, as well as identifying 
potential new pathways involved and novel regulatory units activated by the inhibition 
of VHL. To analyse the transcriptome, the deep-sequencing approach, RNA-sequencing 
(234), was employed. Briefly, RNA is converted to cDNA fragments, which are then 




Each cDNA fragment is sequenced in a high-throughput fashion to obtain short 
sequences of 30-400 bp, which are called ‘reads’. The resulting reads are aligned to a 
reference genome. This produces a transcriptome profile containing the number of 
aligned reads for each gene, which is used as input for differential expression analysis. 
RNA-sequencing has been shown to be highly sensitive, reproducible, and reliable 
technique to accurately measure transcriptome changes in the cell (234).  
With the use of RNA-sequencing, analysis comparing several conditions is possible. In 
addition to the analysis of changes in gene expression following treatment with the 
VHL inhibitor (in this case, VH032 was used, because VH298 has not yet been 
designed) comparing to vehicle control DMSO; the conditions of hypoxia and PHD 
inhibitor (IOX2) were also included. These additional treatments represent standard 
methods in the field of stabilisation of HIF-α, but each also affects different and 
additional pathways in the cell. 
5.1.2. Proteomic analysis by TMT labelling 
Proteomic analysis was conducted using the 10-plex tandem mass tags (TMTs)-
labelling method. 10-plex TMT labelling approach enables simultaneous identification 
and quantification of protein levels from up to 10 different samples. Each sample is 
labelled separately with one of the TMT isobaric reagents, after which all samples are 
pooled together. Although the mass difference between these reporters is extremely 
small, they can be resolved with the current generation of mass analysers (235,236). 
Like the RNA-sequencing analysis, proteomic analysis of VH032, hypoxia, IOX2 and 
DMSO treatments were performed. 
Overall, through the RNA-sequencing approach, it was found that the VHL inhibitor 




Interestingly, the proteomic approach identified that besides HIF-1α and HIF-target 





5.2.  RNA-sequencing – quality control of samples 
To determine the global transcriptome changes induced by the small molecule-
inhibition of VHL, an unbiased RNA-sequencing approach was used. HeLa cell line 
was selected for this study as most of the characterisation of VHL inhibitor had been 
carried out in this cell line. Importantly, there are transcriptomic data of hypoxia and 
HIF study in HeLa. 
RNA-sequencing experiments and analysis were performed in HeLa cells following 
treatment of 1% DMSO (vehicle/negative control), 1% O2 (hypoxia), PHD inhibitor 
IOX2 or VHL inhibitor VH032 (Figure 5.1). IOX2 and VH032 were used at the 
concentration of 250 µM, which showed good induction of HIF activity. VH032 was  
 
Figure 5.1 – RNA-sequencing workflow. HeLa cells were treated with 1% DMSO, 
1% O2 (hypoxia), 250 µM of IOX2 or VH032 for 16 h prior to harvesting. RNA was 
extracted and converted to cDNA. Library preparation and quality control (QC) were 
performed by Andrew Cassidy from the Genetic Core Services Unit in Dundee. RNA 
samples were submitted for Illumina sequencing. The following data analysis was 
performed with guidance from Christian Cole from the Data Analysis Group in Dundee. 
Raw reads obtained from sequencing was quality-controlled using FastQC software. 
Raw sequence reads were aligned to Ensembl human genome GRCh37 with STAR and 
counts for the reads aligned to each gene were obtained with subread-featureCounts 
pipeline. Differential gene expression analysis was performed using the R package 
edgeR according to edgeR user guide. 
1% DMSO 
N=6 
250 µM VH032 
N=6 
250 µM IOX2 
N=6 
1% O2 (hypoxia) 
N=6 
RNA ! cDNA 
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used in this experiment instead of VH298 because VH298 had yet to be designed and 
synthesised at the time these experiments were performed. Treatment time of 16 h was 
used to ensure that the treatment was long enough to induce optimum transcriptome 
changes, and in hope that it was insufficient to observe secondary transcriptome 
changes stimulated by the initial transcription products. 
For this experiment, six biological replicates for each condition were carried out, as it 
had been shown that six replicates provide sufficient statistical mean to strengthen 
robustness of the result (237). Before submitting samples for sequencing, a portion of 
RNA extracted from each sample was used for qRT-PCR to monitor mRNA levels of 
HIF-target genes since the treatment of hypoxia, IOX2 or VH032 led to the 
transcription of HIF-target genes including VEGF, GLUT1, CA9, and PHD2 (Figure 
3.2D). The three conditions in all six replicates successfully upregulated mRNA of the 
HIF-target genes tested significantly (Figure 5.2A). Samples of these six replicates were 
prepared, quality-controlled, and sequenced in an Illumina sequencer by Andrew 
Cassidy from the Genetic Core Services Unit in Dundee (Figure 5.1). 
The data obtained from the sequencing unit was analysed with the help of Christian 
Cole from the Data Analysis Group of the Centre for Gene and Regulation & 
Expression at the University of Dundee (Figure 5.1). The quality of the six replicates for 
each condition was determined by statistical analysis of the correlation between 
replicates, and the relationship between variance and mean (Figure 5.2B and C and 
Figure 5.3).  
The correlation between replicates measures the similarity between expression values 
for transcripts between the samples. In this case, DMSO samples clustered together and 
showed weak correlation to the other conditions (Figure 5.2B). Replicates of hypoxia, 




heat-map (Figure 5.2B), suggesting that the three conditions may result in similar 
transcriptome changes. 
Nevertheless, replicates of each condition clustered together in the multidimensional 
scaling plot generated according to the 2000 largest leading logFC for genes between 
samples (Figure 5.2C) and heat-maps for each condition showed a strong correlation 
between 0.92 and 1 across replicate of the same condition (Figure 5.3), suggesting that 
replicates of the same condition were similar and statistically close to each other. 
 
Figure 5.2 – RNA-sequencing – quality control of samples. (A) HeLa cells were 
treated with 1% DMSO, 1% O2 (hypoxia), 250 µM of IOX2 or VH032 for 16 h prior to 
harvesting. mRNA was extracted and qRT-PCR was performed for HIF-target genes 
(VEGF, GLUT1, CA9 and PHD2) to confirm the expected effect on those genes. (B) 
Heat-map of Pearson correlations among RNA-sequencing samples that had been 
normalised to their total counts. (C) Multidimensional scaling plot of RNA-sequencing 
data generated by edgeR’s plotMDS. The distance between two samples reflects the 
leading logFC of the corresponding RNA samples. The leading logFC is the average 



























































































































































































































































Figure 5.3 – RNA-sequencing – quality control of replicates. Heat-map of Pearson 
correlations between replicates for DMSO, hypoxia, IOX2 or VH032 treatment. Each 












5.1.  RNA-sequencing – differential expression 
To investigate the differences in gene expression between treatments, volcano plots 
were generated to show the gene expression changes between pairs of conditions 
(Figure 5.4A). In addition, to observe the overall changes of transcriptome induced by 
the treatment of hypoxia, IOX2 or VH032 comparing to DMSO control, Venn diagrams 
were generated  (Figure 5.4B and C). Differentially expressed genes were selected with 
the criteria of a false discovery rate (FDR) under 0.05 (5% of the results was expected 
to be false positive), and logarithm base 2 of the fold change between conditions 
(log2FC) > 1 for upregulated genes and log2FC < –1 for downregulated genes. 
Overall, when compared to DMSO control, hypoxia induced the broadest transcriptional 
changes, followed by IOX2 and VH032 (Figure 5.4A). Hypoxia treatment resulted in 
the largest transcriptome changes: 734 mRNAs upregulated and 508 mRNAs 
downregulated (Figure 5.4B and C). In contrast, IOX2 and VH032 led to changes in a 
smaller set of genes, mainly resulting in increased gene expression (714 increased and 
45 decreased in IOX2; 274 increased and 21 decreased in VH032). In the volcano plot 
comparing VH032 to IOX2 treatment, little difference in differential gene expression 
was observed, with only slightly more genes upregulated in IOX2 than VH032 (Figure 
5.4A). However, when VH032 or IOX2 treatments were individually compared to 
DMSO treatment, more genes were increased in expression in the presence of IOX2 
(714 genes) than VH032 (274 genes) (Figure 5.4B), suggesting that small molecule 
inhibiting PHD2 (IOX2) induced a broader transcriptome change than the small 
molecule inhibiting VHL (VH032). 
Majority of genes upregulated in the presence of VH032 overlapped with hypoxia and 
IOX2 treatments – 232 genes (Figure 5.4B and Appendix Table 9.3). Since the three 




of the 232 genes were presumed to be HIF-targets. To confirm this, the subset of genes 
shared by the three conditions was compared to a number of publicly available datasets 
(Table 5.1). 
A total of 83 genes out of the 232 genes upregulated in hypoxia, IOX2 and VH032 were 
found in at least one of these lists (Figure 5.5) and noted in Appendix Table 9.3, 
suggesting that these overlapped genes consisted of HIF-targets and confirming the 
validity of the experiment and analysis. 
 
Figure 5.4 – RNA-sequencing – volcano plots and Venn diagrams of differential 
gene expression analysis. (A) Each dot represents a differentially expressed gene 
comparing the two conditions stated in the heading legend; comparing the condition on 
the left to the right, i.e., hypoxia to DMSO on the top left figure. Blue dots represent 
genes with increased expression (logFC > 1; to the right) or decreased expression 
(logFC < –1; to the left) at FDR<0.05. Blue triangles (present at –log10 FDR of 30) 
represent genes with logFC > 1 or < –1 and –log10 FDR > 30. (B and C) Venn 
diagrams showing the number of genes (B) upregulated (logFC > 1) or (C) 
downregulated (logFC < –1) with FDR < 0.05 in hypoxia, IOX2 and VH032 treated 




Table 5.1 – Publicly available datasets on validated and known HIF-targets, 
hypoxia-inducible genes, and genes containing HIF-1 or HIF-2 binding sites. 
Reference Description Number of 
genes 
(84) Validated known HIF-targets adapted from the reference 
manuscript and listed in Appendix Table 9.4 
100 
(85) Genes induced in hypoxia across 16 cell lines. Data was 
provided by Prof. Luis del Peso Ovalle, Madrid, Spain. 
Authors performed meta analysis of hypoxia-treated gene 
profiling datasets across 19 experiments and 16 cell lines 
and listed in Appendix Table 9.5 
259 
(238) Genes upregulated in hypoxia in HeLa cells. Data was 
provided by Prof. Luis de Peso Ovalle, Madrid, Spain, 
after re-analysis of reference paper and listed in 
Appendix Table 9.6 
1141 
(239) Genes upregulated in hypoxia in MCF7 cells 356 
(240) Genes containing HIF-1 binding sites identified by ChIP-
sequencing 
301 





Figure 5.5 – RNA-sequencing – comparison of genes upregulated in hypoxia, IOX2 
and VH032 treatments to publicly available datasets. 232 genes upregulated in 
hypoxia, IOX2 and VH032 was compared to publicly available datasets including (1) a 
list of 100 known and validated HIF targets, (2) a list of 259 upregulated genes 
conserved across 16 cell lines, (3) a list of 1141 genes upregulated in hypoxia in HeLa 
cells, (4) a list of HIF-1 (356 genes) or (5) HIF-2 (301 genes) targets identified by 


























5.2.  RNA-sequencing – validation 
From the data analysis, a list of 232 upregulated genes (Appendix Table 9.3), as well as, 
a list of 4 downregulated genes (Appendix Table 9.2), were found overlapped in 
hypoxia, IOX2 and VH032 treatments comparing to DMSO negative control. Five 
genes (CA9, PHD2 (also known as EGLN1), NDRG1, GLUT1 (also known as SLC2A1), 
and BNIP3) from the upregulated list and two genes (DUSP2 and TAF9B) from the 
downregulated list were selected for validation to confirm that the mRNA of these 
genes were increased or decreased, respectively. 
To validate these genes shared by the three conditions, mRNA levels were measured by 
qRT-PCR (Figure 5.6). All the genes chosen for validation with a log2FC > 1 
(upregulated genes) or log2FC < −1 (downregulated genes) presented a significant 
increase or decrease, respectively, in the presence of hypoxia, IOX2, VH032, when 
compared with DMSO control. In addition, the most potent VHL inhibitor VH298 also 
resulted in significant increases for the upregulated genes and decrease for the 
downregulated genes at 100 µM or 250 µM concentration used (with the exception that 
the increase of DUSP2 gene in the presence of 100 µM VH298 was not significant) 
(Figure 5.6). Taken together, the validation for these genes affected by hypoxia, IOX2 
and VH032 was considered as successful. 
A list of 11 genes (Table 5.2) and a list of 12 genes (Table 5.3) were found in the 
category of upregulated genes and downregulated genes, respectively, for VH032 
treatment only, but not hypoxia or IOX2, when compared to DMSO control (Figure 
5.4B). These genes could be potential indirect target of inhibiting VHL, independent of 
HIFs, PHDs or the requirement of oxygen. Four genes (ABCA1, ABCG1, DHRS2, and 
EFR3B) from the upregulated list (described in Table 5.2) and four genes (LAMC2, 




were selected for validation by qRT-PCR to confirm whether the mRNA of these genes 
were increased or decreased, respectively, as observed in RNA-sequencing. These genes 
were selected as they showed increased or decreased expression from DMSO control, in 
 
Figure 5.6 – RNA-sequencing – validation on genes upregulated or downregulated 
in hypoxia, IOX2 and VH032. HeLa cells were treated with 1% DMSO control, 1% 
O2 (hypoxia), 250 µM IOX2 or 250 µM VH032 for 16 h prior to mRNA extraction. The 
graphs show relative mRNA transcripts normalised to actin mRNA levels. Black bars 
represent conditions as those used in RNA-sequencing experiment. Red bars represent 
VH298 VHL inhibitor treatments at 100 or 250 µM concentration (16 h). The mean + 
SEM were determined from three independent experiments. Two-tailed student t-test 
analysis was performed * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and ns: P>0.05. 
 





































































































































































































































































































particular ABCA1 and ABCG1, which showed the largest log2FC of 1.60 and 1.44, 
respectively, in the treatment with VH032. In addition, these selected genes are 
involved in important biological processes (as described in Table 5.2 and Table 5.3) and 
interestingly; ABCA1 and ABCG1 belong to the same family, the ATP-binding cassette 
(ABC) transporters superfamily, that function to transport cholesterol and 
phospholipids, suggesting that VH032 may activate the lipid transport pathway. 
Table 5.2 – List of 11 genes upregulated in the presence of VH032 only, but not 
hypoxia or IOX2, when compared to DMSO control. Genes were selected at FDR < 
0.05 and log2FC > 1. In red: selected for validation by qRT-PCR and description for 
these genes were included. 
Ensembl gene ID Gene name Description 
ENSG00000076641 PAG1  
ENSG00000081665 ZNF506  
ENSG00000084710 EFR3B Part of a complex that localise PI4K to the plasma 
membrane, may act as the membrane-anchoring 
component. 
ENSG00000100867 DHRS2 Attenuates MDM2-mediated p53/TP53 degradation, 
leading to p53/TP53 stabilisation and increased 
transcription activity, resulting in the accumulation 
of MDM2 and CDKN1A/p21 
ENSG00000140986 RPL3L  
ENSG00000149260 CAPN5  
ENSG00000149564 ESAM  
ENSG00000160179 ABCG1 ATP-binding cassette (ABC) transporters 
superfamily member. Involved in macrophage 
cholesterol and phospholipids transport and may 
regulate cellular lipid homeostasis in other cell types 
ENSG00000165029 ABCA1 ATP-binding cassette (ABC) transporters 
superfamily member. Function as a cholesterol efflux 
pump with cholesterol as its substrate, in the cellular 
lipid removal pathway 
ENSG00000212916 MAP10  






Table 5.3 – List of 11 genes downregulated in the presence of VH032 only, but not 
hypoxia or IOX2, when compared to DMSO control. Genes were selected at FDR < 
0.05 and log2FC < –1. In red: selected for validation by qRT-PCR and description for 
these genes were included. 
Ensembl gene ID Gene name Description 
ENSG00000058085 LAMC2 Laminin is a family member of extracellular 
matrix glycoproteins and involved in biological 
processes such as cell adhesion, differentiation, 
migration, signalling, neurite outgrowth and 
metastasis 
ENSG00000122367 LDB3  
ENSG00000130176 CNN1 Calponin 1 is implicated in the regulation and 
modulation of smooth muscle contraction. 
ENSG00000133808 MICALCL May cooperate with MAPK1/ERK2 via an 
intracellular signal transduction pathway in the 
morphogenetic development of round spermatids 
to spermatozoa. 
ENSG00000166923 GREM1 May play a role in regulating organogenesis, body 
patterning and tissue differentiation. May play a 
role during carcinogenesis and metanephric 
kidney organogenesis. 
ENSG00000167994 RAB3IL1  
ENSG00000236947 RP11-98G7.1  
ENSG00000242951 RP11-507E23.1  
ENSG00000254101 RP11-30J20.1  
ENSG00000257588 RP11-469H8.6  
ENSG00000260401 RP11-800A3.4  
ENSG00000261788 RP11-480G7.1  
 
Previously, a small portion of RNA samples was used to synthesise cDNA prior to 
submitting for RNA-sequencing. These cDNA samples were used for validation by 
qRT-PCR (Figure 5.7; black bars). All the genes chosen for validation with a 
log2FC > 1 (upregulated genes) presented an increase in the presence of VH032, when 
compared with DMSO control, particularly, a significant increase for ABCA1 and 
EFR3B. 
On the other hand, out of the four genes selected for validation with a log2FC < –1 
(downregulated genes), only CNN1 presented a significant decrease in mRNA levels 
(Figure 5.7; black bars). However, IOX2 treatment also resulted in a significant 




presence of only VH032. While LAMC2 mRNA level was not downregulated in the 
presence of VH032, mRNA levels of MICALCL and GREM1 decreased, but not 
significantly. 
 
Figure 5.7 – RNA-sequencing – validation on genes upregulated or downregulated 
in VH032 only, but not in hypoxia, and IOX2. HeLa cells were treated with 1% 
DMSO control, 1% O2 (hypoxia), 250 µM IOX2 or 250 µM VH032 for 16 h prior to 
mRNA extraction. The graphs show relative mRNA transcripts normalised to actin 
mRNA levels. Black bars: cDNA used was taken from RNA samples prior to 
submission for RNA-sequencing. Red bars: RNA samples were not submitted for RNA-
sequencing. The mean + SEM were determined from three independent experiments. 
Two-tailed student t-test analysis was performed * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 
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To further validate these genes altered by the presence of VH032 only, qRT-PCR 
experiment was repeated with the same concentration of VH032 (250 µM) and VH298 
(100 and 250 µM) VHL inhibitors. The two VHL inhibitors did not significantly 
decrease mRNA levels of any of the four downregulated genes (Figure 5.7; red bars). 
Strikingly, the four genes that were found upregulated in the presence of VH032 did not 
present significant increase in mRNA levels in the presence of VH032 or VH298. 
ABCA1, ABCG1 an d EFR3B that had approximately 5-fold increase (Figure 5.7; black 
bars) when compared to DMSO control no longer increased when a new batch of 
compound was used (Figure 5.7; red bars). 
Taken together these results, the validation for VH032-specific genes showed that VHL 





5.3.  TMT-labelling – experimental setup 
To gain a more complete understanding of the effects of VHL inhibitor in cells, a 
proteomic study was performed (Figure 5.8).  
HeLa cells were treated with 250 µM VH032 (VH298 had yet to be designed), 
comparing with vehicle control (1% DMSO). Hypoxia (1% O2) and PHD inhibitor 
IOX2 (250 µM) were included in the proteomic analysis controls. A total of four 
conditions were carried out with the treatment time of 24 h to observe the global 
proteome changes. Enabled by the 10-plex tandem mass tags (TMTs)-labelling strategy, 
experiment was performed in duplicate and peptides from each sample were labelled 
according to Figure 5.8 by Wenzhang Chen from the FingerPrints Proteomic group, 
Dundee. By use of the mass spectrometry-based method, more than 8,043 proteins were 
identified with FDR < 0.01 and quantified. 
 
Figure 5.8 – Tandem mass tag (TMT)-labelling – workflow. HeLa cells were treated 
with 1% DMSO, 1% O2 (hypoxia), 250 µM IOX2, 250 µM VH032 for 24 h – in 
biological duplicate. Proteins were obtained by cell lysis, cleaned up, digested by 
trypsinisation, and labelled with 10-plex TMT labelling reagent according to the table 
shown (carried out with the help of Wenzhang Chen from the FingerPrints Proteomic 
group, Dundee, apart from the cell lysis). Labelled peptides were combined, desalted, 
fractionated and analysed by mass spectrometry (MS). Red text indicates steps carried 









































To determine the reproducibility between the two replicates, the relative abundance for 
each protein between replicates to each respective DMSO control replicate was plotted 
(Figure 5.9A). Hypoxia treatment showed high reproducibility in protein quantification 
(Pearson correlation: 0.81). Instead, IOX2 and VH032 treatments were not as 
reproducible (Pearson correlation: 0.43, 0.30, respectively). Nonetheless, the data was 
used to detect possible proteome changes induced by these treatments and validation by 
western blotting would be performed to confirm any changes on target of interest. 
 
Figure 5.9 – TMT-labelling – Impact of hypoxia, IOX2 and VH032 on the cellular 
proteome in HeLa cells. (A) Scatter plot representation of relative protein abundances 
obtained for different treatment conditions compared to respective replicate of vehicle 
(DMSO)-treated cells, for a total of 8,043 proteins quantified. The two axes are relative 
abundance (log2FC) from two different replicates in this experiment. Red dots represent 
upregulated proteins in both replicates (absolute fold change difference to DMSO > 1.3) 
and blue dots represent downregulated proteins in both replicates (absolute fold change 
difference to DMSO < 0.7). Red line is the linear fit to the data. (B) Venn diagrams 
depicting the number of upregulated proteins and downregulated proteins in the two 




5.4.  TMT-labelling – differentially regulated proteins 
To identify changes in protein expression, a cut-off filter of absolute fold change 
difference > 1.3 (a 30% increase for upregulated genes) and < 0.7 (a 30% decrease for 
downregulated genes) to DMSO control (FDR < 0.01) was selected. Comparing to 
vehicle control DMSO, treatments of hypoxia, IOX2 and VH032 altered protein 
expression in cells (Figure 5.9). Among the three treatments, hypoxia induced the 
highest number of protein expression changes; 220 proteins increased in level in 
hypoxia, while 139 proteins decreased. On the other hand, the majority of differentially 
regulated proteins were increased in the presence of IOX2 (39 versus 2 decreased) or 
VH032 (35 versus 3 decreased). 
To investigate overall proteome changes comparing hypoxia, IOX2 and VH032 
treatments, Venn diagrams for increased and decreased protein levels were plotted 
(Figure 5.9B). The majority of proteome changes in the presence of IOX2 and VH032 
were overlapped with hypoxia (Figure 5.9B), sharing 26 upregulated targets (Table 5.4) 
and only one downregulated target (Table 5.5) 
5.4.1. Differentially regulated proteins shared by hypoxia, IOX2 
and VH032 
HIF-1α was found in the list of 26 upregulated proteins in common between hypoxia, 
IOX2 and VH032 treatments (Table 5.4), suggesting that the cell treatments had 
successfully stabilised HIF-1α. Among the 26 shared upregulated proteins (Table 5.4), 
22 proteins (highlighted in blue) were found in at least one of the publicly available 
dataset listed in Table 5.1, which contained hypoxia-inducible genes. In addition, 
transcripts of these 22 genes encoding these proteins (highlighted in blue) and two 
additional genes (PP13G and KAD4, highlighted in green) were found increased in 




these proteins were regulated at transcriptional level. Although KAD4 (also known as 
AK4, adenylate kinase 4) was not found in the lists in Table 5.1, it had been confirmed 
to be HIF-target genes (241). On the other hand, PP13G (also known as PPP1R3G) was 
found to be a hypoxia-inducible gene in the osteoclast microarray, but not known to be 
regulated by HIF (242).  
Table 5.4 – List of 26 upregulated proteins shared between hypoxia, IOX2 and 
VH032 treatment. Proteins were selected at FDR < 0.01 and relative abundance to 
DMSO control > 1.3 for each replicate. Uniprot ID and gene name are listed with 
relative abundance to DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 
and IOX2-2), and VH032 (VH032-1 and VH032-2) in duplicate. In red: known primary 
target (HIF-1α). In blue: transcripts for the respective genes were found to be 
upregulated in hypoxia, IOX2 and VH032 by RNA-sequencing (Appendix Table 9.3) 
and found in at least one of the publicly available dataset (Table 5.1). In green: 
transcripts were found to be upregulated in hypoxia, IOX2 and VH032 by RNA-









Q12983 BNIP3 18.11 3.33 11.59 2.60 8.33 2.03 
P35318 ADML 6.47 4.73 2.05 4.81 1.47 3.44 
O76061 STC2 3.24 1.59 1.58 4.36 1.84 1.31 
P11169 GTR3 7.52 6.58 1.39 2.51 1.63 1.95 
Q16790 CAH9 6.76 6.04 3.31 3.93 3.94 3.26 
P06307 CCKN 1.43 2.46 1.71 1.80 1.35 1.98 
Q16665 HIF1A 4.00 2.31 2.37 3.68 2.19 1.98 
Q15413 RYR3 2.32 1.87 2.20 2.86 1.45 4.30 
P98155 VLDLR 3.51 2.60 2.01 3.45 1.97 1.85 
P05412 JUN 2.89 1.94 1.34 2.03 1.32 1.37 
Q16877 F264 6.29 4.48 1.85 2.97 2.10 2.09 
P11166 GTR1 3.59 2.79 1.35 1.72 1.47 1.42 
Q9Y4K0 LOXL2 3.89 2.96 1.30 2.11 1.46 1.44 
Q9BXL7 CAR11 2.13 1.72 1.85 2.33 1.56 3.23 
Q9NX57 RAB20 2.50 1.93 1.44 2.34 1.58 1.49 
P28300 LYOX 4.81 3.63 1.59 4.38 1.44 1.72 
Q92597 NDRG1 5.06 4.25 1.36 1.58 1.62 1.41 
B7ZBB8 PP13G 4.37 3.65 1.57 1.84 1.73 1.37 
P13674 P4HA1 2.45 2.31 1.48 1.53 1.50 1.58 
Q15118 PDK1 2.07 1.84 1.62 1.63 1.61 1.54 
P09104 ENOG 3.03 2.62 1.39 2.23 1.70 1.74 
Q9Y4C1 KDM3A 2.53 2.23 1.46 1.47 1.56 1.44 
P27144 KAD4 1.42 1.38 1.31 1.38 1.33 1.37 
O00469 PLOD2 2.76 2.53 1.41 1.50 1.55 1.58 
Q9GZT9 EGLN1 1.87 1.61 1.37 1.44 1.39 1.34 






Table 5.5 – A downregulated gene shared by hypoxia, IOX2 and VH032 
treatments. Gene was selected at FDR < 0.01 and relative abundance to DMSO control 
< 0.7. Uniprot ID and gene name are listed with relative abundance to DMSO control 
for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and IOX2-2), and VH032 (VH032-1 
and VH032-2) in duplicate. 
Uniprot 
ID 
Gene name Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
Q9BRL6 SRSF8 0.60 0.58 0.56 0.49 0.62 0.60 
 
The remaining three genes (CCKN, RYR3, and CAR11) (Figure 5.4) were not known to 
be HIF-target genes or hypoxia-inducible genes. In addition, gene expressions of CCKN 
and RYR3 were not detected in the RNA-sequencing analysis, while CAR11 gene 
expression was not significantly increased in the presence of hypoxia (log2FC of 
0.2115), IOX2 (log2FC of -0.2106), or VH032 (log2FC of -0.2688) with FDR < 0.01, 
suggesting that CAR11 could be a direct substrate of VHL or indirectly regulated in a 
post-translational manner by VHL target. On the other hand, CCKN and RYR3 could 
potentially be HIF-targets, or similar to CAR11, VHL substrates or regulated by VHL 
target. 
Overall, the exposure to hypoxia or the treatment of PHD inhibitor IOX2 or VHL 
inhibitor VH032 successfully stabilised HIF-1α and known HIF-target proteins, 
validating the pharmacological intervention in an unbiased –omic level. 
5.4.2. Differentially regulated proteins in VH032 only, and not in 
hypoxia or IOX2 
Proteins upregulated upon VH032-mediated VHL inhibition, but not in hypoxia or PHD 
inhibition by IOX2 could be potential VHL targets that bind to the same pocket as 
HIF-α, but independent of PHD hydroxylation. In the proteomic analysis, two proteins 
were identified to be upregulated in VH032, but not hypoxia or IOX2: VHL and AMY1 




(1.02 for replicate 1 and 0.94 for replicate 2) and decreased slightly in hypoxia (0.87 for 
replicate 1 and 0.89 for replicate 2, thus not meeting the criteria of < 0.7). Interestingly, 
VHL protein abundance increased in VH032 (1.59 for replicate 1 and 1.53 for replicate 
2) relative to DMSO control. This suggests that VHL protein may be altered by the 
small molecule-mediated inhibition of VHL. VH032 treatment also increased AMY1 
protein abundance (4.64 for replicate 1 and 1.42 for replicate 2), but not hypoxia or 
IOX2 (although replicate 1 of hypoxia showed a ratio of 1.25 to DMSO control). AMY1 
encodes for the salivary alpha-amylase, which is involved in catalysing the initial 
digestion of dietary starch and glycogen. This could potentially be a direct VHL target, 
but further validation would be required. 
On the other hand, only one protein significantly decreased in level in the presence of 
VH032, but not in hypoxia or IOX2 (Table 5.7): RGCC. However, protein expression 
of RGCC also decreased in one replicate of hypoxia (0.71 in Hpx-1) and both replicates 
of IOX2 (0.79 in IOX2-1 and 0.45 in IOX2-2). RGCC fell under this category due to the 
selection criteria, which required the relative fold change to be < 0.7 in both replicates. 
RGCC (regulator of cell cycle), also known as RGC32 (response gene to complement 
32), is induced by p53 in response to DNA damage and modulates the kinase activity of 
cell cycle. RGCC has been reported to be a hypoxia-inducible gene (243) and involved 
in high-altitude physiology (244). Yet, here RGCC decreased in protein levels in all 
three conditions. Validation would be required to further confirm the results. 
Among the three genes, protein expression of VHL was consistent between the two 
replicates and significantly distinct from hypoxia or PHD inhibition treatments, and was 






Table 5.6 – List of two proteins with increased levels in the presence of VH032, but 
not hypoxia or IOX2. Genes were selected at FDR < 0.01 and relative abundance to 
DMSO control > 1.3. Uniprot ID and gene name are listed with relative abundance to 
DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and IOX2-2), and 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
P40337 VHL 0.87 0.89 1.02 0.94 1.59 1.53 
P04745 AMY1 1.25 0.86 1.01 0.90 4.64 1.42 
 
 
Table 5.7 – List of one protein with increased level in the presence of VH032, but 
not hypoxia or IOX2. Genes were selected at FDR < 0.01 and relative abundance to 
DMSO control < 0.7. Uniprot ID and gene name are listed with relative abundance to 
DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and IOX2-2), and 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
Q9H4X1 RGCC 0.71 0.97 0.79 0.45 0.54 0.58 
 
5.4.3. Differentially regulated proteins in other categories 
Four proteins were found to significantly change in abundance in IOX2 treatment only 
and not overlapped with hypoxia or VH032 (Table 5.8). These four proteins could be 
target of PHD enzymes, but not recognised by VHL and independent of oxygen level. 
However, the fold changes in protein abundance for all four genes were > 1.3 in 
hypoxia replicate 1 only, and two genes (KCT2 [keratinocyte-associated transmembrane 
protein 2] and H2A1B [histone H2A, core component of nucleosome]) were > 1.3 in 
VH032 replicate 1 (Table 5.8), suggesting that they could be induced in hypoxia or 
upon VH032 treatment, respectively. Similar observation were seen in category of 
proteins shared by two of the three treatments (Table 5.9, Table 5.10, Table 5.11), 
where these proteins could potentially be induced in all three conditions and validation 




• ANKZ1 protein falls into the category of proteins induced in hypoxia and IOX2, 
but not VH032 (Table 5.9). However, ANKZ1 (ankyrin repeat and zinc finger 
domain containing 1; involved in endoplasmic reticulum-associated degradation 
pathway) is one of the gene containing HIF-1 binding site identified by ChIP-
sequencing (240) and RNA-sequencing analysis identified ANKZ1 (ANKZF1 in 
the RNA-sequencing list) to be common target of hypoxia, IOX2 and VH032 
(Appendix Table 9.3). 
• HXK2 (hexokinase 2, also known as HK2) from Table 5.10 was increased in 
gene expression in hypoxia and VH032, but not IOX2 as analysed by RNA-
sequencing (Appendix Table 9.3). However, HK2 is a known HIF-target gene 
and was shown in the previous chapter to be upregulated in all three conditions 
by western-blotting (Figure 4.7A-B). 
• TXNIP was found in the category induced by IOX2 and VH032, but not 
upregulated by hypoxia (Table 5.11) was identified in hypoxia treatment in 
MCF7 cells (239). TXNIP (thioredoxin interacting protein, also termed VDUP1 
for vitamin D upregulated protein) is a major regulator of cellular redox 
homeostasis. Interestingly, TXNIP mRNA was reported to increase in hypoxic 
perinecrotic areas of conventional renal cell carcinoma and glioblastoma (245). 
However, TXNIP was also reported to decrease in mRNA and protein levels in 
hypoxia in a HIF-independent manner, but in different cell culture backgrounds 
(HeLa and HEK293), and decrease in mRNA in the VHL-null 786-O cells 
(246). Furthermore, TXNIP was found to enhance VHL:HIF-1α interaction to 
promote nuclear export of the complex and subsequently HIF-1α degradation 
(247). Unfortunately, its gene expression was not detected in the RNA-




data suggest that TXNIP plays a role in the hypoxia signalling, and it would 
therefore be very interesting to validate TXNIP. 
Altogether, results suggest that proteins found to increase or decrease in abundance may 
not all be exactly correct and validation would need to be performed to confirm all these 
changes. In addition, there were more proteins not mentioned above that would be 
interesting for further pursuing, such as K1C16 and ALPK3 that seemed to increased in 
both hypoxia and IOX2, but not VH032, and P2RX2 and CJ011 that were increased in 
hypoxia and IOX2, but not VH032. 
Table 5.8 – List of four proteins with increased abundance in the presence of 
IOX2, but not hypoxia or VH032. Genes were selected at FDR < 0.01 and relative 
abundance to DMSO control > 1.3. Uniprot ID and gene name are listed with relative 
abundance to DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
P08779 K1C16 2.80 1.21 1.34 1.49 0.98 1.11 
Q8NC54 KCT2 1.44 1.05 1.34 1.35 1.44 1.12 
P04908 H2A1B 1.72 1.16 1.39 1.58 1.74 1.07 
Q96L96 ALPK3 2.62 0.80 1.35 1.63 1.18 0.96 
 
 
Table 5.9 – List of six proteins with increased abundance that are shared by 
hypoxia and IOX2, but not VH032. Genes were selected at FDR < 0.01 and relative 
abundance to DMSO control > 1.3. Uniprot ID and gene name are listed with relative 
abundance to DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and 
IOX2-2), and VH032 (VH032-1 and VH032-2) in duplicate. In green: upregulated in 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
Q86SJ2 AMGO2 2.06 1.63 1.61 1.81 1.48 1.27 
Q9H7J1 PPR3E 4.73 6.23 2.33 3.06 3.20 1.25 
Q9UBL9 P2RX2 2.97 1.45 1.41 1.50 1.30 1.09 
Q9H8Y5 ANKZ1 1.82 1.52 1.43 1.43 1.40 1.26 
O14556 G3PT 2.12 1.75 1.51 1.99 1.55 1.27 





Table 5.10 – List of four proteins with increased abundance that are shared by 
hypoxia and VH032, but not IOX2. Genes were selected at FDR < 0.01 and relative 
abundance to DMSO control > 1.3. Uniprot ID and gene name are listed with relative 
abundance to DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
Q58FG1 HS904 1.78 1.46 1.22 1.74 1.35 5.63 
P52789 HXK2 1.55 1.42 1.26 1.24 1.35 1.38 
P07205 PGK2 2.06 1.96 1.26 1.40 1.33 1.51 
Q6ZMT1 STAC2 1.37 1.46 1.45 1.07 1.43 1.34 
 
Table 5.11 – List of three proteins with increased abundance that are shared by 
IOX2 and VH032, but not hypoxia. Genes were selected at FDR < 0.01 and relative 
abundance to DMSO control > 1.3. Uniprot ID and gene name are listed with relative 
abundance to DMSO control for hypoxia (Hpx-1 and Hpx-2), IOX2 (IOX2-1 and 
IOX2-2), and VH032 (VH032-1 and VH032-2) in duplicate. In blue: upregulated in 





Hpx-1 Hpx-2 IOX2-1 IOX2-2 VH032-1 VH032-
2 
Q6ZMR3 LDH6A 2.42 0.50 6.90 3.14 3.89 2.14 
Q9H6K1 CF106 1.62 1.20 1.48 1.86 1.40 2.78 




5.5.  Discussion 
A chemical probe is a small molecule modulator useful for addressing questions about 
its target in biochemical, cell-based and animal studies. In previous chapters, VHL 
inhibitors were characterised as potential chemical probes for the study of hypoxia 
signalling. VHL inhibitors can rapidly and selectively inhibit their target protein VHL, 
leading to the stabilisation and subsequently transcriptional activity of HIF-α subunits. 
Here, it was decided to extensively characterise the cellular effects induced by VHL 
inhibitor in an unbiased manner by assessing its global effect on transcriptome and 
proteome, using the HeLa cell-based system, which has been broadly used to assess the 
hypoxic response. In addition, hypoxia and the PHD inhibitor IOX2 were included in 
the studies. These three conditions trigger a hypoxic response – leading to the 
stabilisation of HIF-1α – but each affects different components involved in the hypoxia 
signalling pathway. The inclusion of hypoxia and PHD inhibitor treatments was 
postulated to allow distinguishing HIF-dependent target genes to HIF-independent 
target genes mediated by VHL. In addition, the proteomic analysis would also allow 
distinguishing HIF-target proteins from potential VHL targets independent of PHD 
hydroxylation. 
 Briefly, below are the key findings of the work presented here. 
1. RNA-sequencing analysis. Hypoxia induced the largest transcriptome changes 
amongst the three conditions that inhibited different components of the hypoxia 
signalling pathway. Comparing the two inhibitors, VHL inhibitor VH032 was 
found to induce a less broad transcriptome alteration compared to the PHD 
inhibitor IOX2. Known HIF-target genes including CA9, GLUT1, PHD2, 




activating the HIF transcription activity. On the other hand, several genes was 
identified to specifically be altered by VH032 only and not hypoxia or IOX2 
(ABCA1, ABCG1, DHRS2, and EFR3B that increased in gene expression and 
LAMC1, CNN1, MICALCL, and GREM1 that decreased in gene expression); 
however the analysis of mRNA levels using a fresh batch of VH032 or in the 
more potent inhibitor VH298 mostly showed no significant changes, 
inconsistent with the RNA-sequencing results. 
2. TMT-labelling analysis. Similar to the transcriptome changes, hypoxia condition 
resulted in the highest number of increased and decreased protein expression, 
while IOX2 and VH032 treatments led to mainly increased expression with 
similar number of proteins (39 and 35, respectively). Most interesting finding 
was the increase of VHL in the present of the VHL inhibitor VH032, which was 
not observed in hypoxia or IOX2 treatment. 
Oxygen is key for survival and the deprivation of oxygen, or hypoxia, causes significant 
stress in living cells. To adapt to hypoxic stress, cells activate a number of cellular 
pathways including mTOR signalling, the unfolded protein response (UPR), and gene 
regulation by HIFs (44). In a HIF-dependent manner, expression of hundreds of genes is 
induced in hypoxia (239). Comparison of hypoxia and the two small molecule HIF 
stabilisers (IOX2 and VH032) showed an overlapped group of genes (Appendix Table 
9.3) and proteins (Table 5.4) in the transcriptomic and proteomic data, respectively. 
Majority of these were HIF-target genes/proteins, which is as expected because the 
three conditions induce HIF activity. On the other hand, some of these hits could be 
novel HIF-targets, and therefore would be worth validating. 
Hypoxia was also found to alter gene and protein expressions of many genes not found 
in IOX2 or VH032 – likely regulated in a HIF-independent manner. Many other 




(68,248,249), PGC-1α (250), ATF-4, Egr-1 (249), dERR in Drosophila melanogaster 
(251) and BLMP in Caenorhabditis elegans (252), could play a role in regulating 
HIF-independent genes, which are subsequently translated into proteins. In addition, 
hypoxia adaptations through mTOR signalling and the UPR are known to influence 
mRNA translation and consequently gene expression (44,86). Altogether, these factors 
could be responsible for the IOX2- or VH032-independent changes in transcriptome and 
proteome. 
PHDs are known to have other substrates beyond HIF, including IKKβ, Cep198, the 
β-adrenergic receptor, and RNA polymerase (63,64). In addition, the inhibition of PHDs 
via genetic or pharmacologic approaches has been shown to induce mTORC1 and 
autophagy activation in response to amino acids, independent of HIFs (253). These 
signify that PHDs could potentially mediate HIF-independent responses to hypoxia and 
oxygen-independent responses to other stimuli such as amino acids. This may explain 
the induction of large number of genes in the presence of the PHD inhibitor IOX2 – 189 
genes upregulated shared by IOX2 and hypoxia but not VH032 and 269 genes 
upregulated in IOX2 only and not hypoxia/VH032. Interestingly, these 189 genes may 
represent genes transcriptionally regulated by target proteins of PHD hydroxylation, 
independent of VHL recognition, at least by the pocket that binds to hydroxylated 
HIF-1α. Potential transcription binding sites present in these 189 genes were computed 
through the Gene Set Enrichment Analysis (GSEA) website at FDR < 0.05 (top 10 gene 
sets in Appendix Table 9.7, list of overlapped genes in Appendix Table 9.8). These data 
may be useful in identifying potential novel transcription factor induced by PHD 
hydroxylation, independent of VHL. In addition, the transcriptomic data combined with 
the proteomic data would allow the revelation of possible novel PHD-targets. On the 
other hand, proteins shared between IOX2 and VH032 (not in hypoxia) might be 




One flaw of the proteome analysis was the reproducibility of the replicates and 
detection of proteins. Only two biological replicates were performed and the 
reproducibility between the replicates for IOX2 and VH032 was poor. Data obtained 
would not be completely reliable and validation would be required to confirm any hits 
of interest. Furthermore, mass spectrometry detection of peptides is known to be “hit 
and miss” and detection of peptides from the same protein is not always consistent 
between replicates. Therefore, increasing the number of replicates would greatly 
strengthen the reliability of data obtained. The amount of protein lysates used for co-IP 
should be increased to ensure the pullldown of sufficient VHL protein. In addition, 
repeat with VH298, the most potent VHL inhibitor identified so far, would be ideal as 
VH298 is now available for purchase via commercial suppliers 
(https://www.tocris.com/products/vh-298_6156), and extensive study with VH298 
would be useful for the community in hypoxia field. 
Nonetheless, the analysis was sufficient as an initial screen for identifying potential 
targets of interest, as demonstrated by the presence of HIF-1α and HIF-targets in 
hypoxia, IOX2 and VH032. The proteomic analysis would be useful for distinguishing 
HIF-target proteins to potential VHL targets independent of PHD hydroxylation. 
Interestingly, VHL was identified to increase in protein expression in the present of 
VH032, but not hypoxia or IOX2, and this result led to the decision to validate and 
further investigate this observation, which will be discussed in the next chapter. 
Although not pursued in this thesis due to time constraints, in future, it would also be 
interesting to further validate and investigate hits of RNA-sequencing and proteomic 
mentioned, and especially discussed in this chapter that may be potential novel 
HIF-targets, PHD-targets independent of VHL or PHD-targets recognised by VHL. 




and western-blotting to confirm the changes in protein levels would be warranted, 
especially if good antibodies are available for the identified hits. 
Most important to highlight was the overall effect of VHL inhibitor on the global 
transcriptome and proteome. Data showed that the VHL inhibitor was very specific – 
majority of gene and protein expression changes are common with hypoxia and IOX2, 
indicating that the VHL inhibitor may be specifically influencing primarily HIF 
activation. As the small molecule inhibitor was designed to possess a hydroxyproline 
residue, thus mimicking the hydroxylated proline residue of HIF-1α in order to compete 
with and stabilise hydroxylated HIF-1α, it is an important and reassuring discovery of 
the work presented in this chapter that the VHL inhibitor was not found to affect 
putative HIF-independent VHL functions. It is rare for chemical probes to be 
characterised so extensively at the transcriptome and proteome level. The thorough 
study of VHL inhibitors presented herein would therefore be useful for scientists using 
this compound as chemical probe. For instance, if there were a specific gene of interest 
that may be regulated by VHL, glimpse at transcriptomic and proteomic levels would be 
available. 
In summary, analyses of VHL inhibitor VH032 at the transcriptome and proteome level 
in an unbiased fashion revealed for the first time that the VHL inhibitor was very 
selective and on-target – affecting primarily, if not, exclusively the canonical VHL:HIF 
interaction. Furthermore, the inclusion of IOX2 and hypoxia conditions in these 
analyses have uncovered potential novel hits, such as HIF-targets and HIF-independent 
PHD-targets, which provide a direction for further exploration on the functions of PHDs 
and VHL. These datasets would be useful for scientists using the chemical probe and 





6. VHL inhibitors increase VHL protein levels 
6.1.  Introduction 
In hypoxia, HIF-α proteins are known to be readily upregulated, but this is not sustained 
in prolonged hypoxia as HIF-α proteins are eventually degraded by mainly the 
proteasome (Figure 4.3C and D). This feedback effect is known to be due to the 
increase of HIF-targets, PHD enzymes, PHD2 and PHD3 (Figure 4.7C) (254). The 
downregulation of the stabilised HIF-α was also observed in cells treated with VHL 
inhibitor for prolonged periods (Figure 4.3D); however, unlike following hypoxia 
treatment, PHD3 was not greatly upregulated under VHL inhibition (Figure 4.7C). In 
addition, proteomic analysis (shown in the previous chapter) in the presence of VHL 
inhibitor VH032 revealed an increase in VHL protein levels. Interestingly, this increase 
was not observed when cells were treated with the PHD inhibitor IOX2 or hypoxia (1% 
O2). 
The aim of the work presented in this chapter was to investigate the significance of the 
increase of VHL proteins in the presence of VHL inhibitor. 
Here, in agreement with the proteomic data, VH032 treatment led to increased VHL 
protein levels in HeLa cells and also in HFF cells. In addition, the most potent VHL 
inhibitor, VH298, also induced this upregulation. Treatment with VHL inhibitors did 
not result in changes in VHL at the transcriptional level. Importantly, increased levels of 
VHL protein, observed in the presence of VHL inhibitor, were responsible for the 
downregulation of HIF-1α occurring following prolonged treatment. Furthermore, this 
occurred primarily via the proteasomal degradation. Using a variety of approaches, 
results revealed that the upregulation of VHL levels was mediated by an increase in 
VHL half-life in the presence of VH298. Co-immunoprecipitation of VHL coupled with 




6.2.  VHL inhibitors increase VHL protein levels in cells 
TMT-labelling proteomic analysis indicated that VHL was increased at the protein level 
following a 24 h of treatment with the VHL inhibitor VH032, but not following 
treatment with hypoxia (1% O2) or PHD inhibitor IOX2 (Table 5.6 and Figure 6.1). To 
validate this observation, VHL protein levels in HeLa cells treated with VH032 were 
monitored by western blot. VHL protein levels did not increase after a short treatment 
of 2 h, but showed marked upregulation in response to the longer treatment of 24 h with 
 
Figure 6.1 – VHL protein levels increase in the presence of VHL inhibitors. (A) 
Graph depicting relative VHL protein abundance to DMSO control for hypoxia, IOX2 
and VH032 treatments after 24 h. Data are presented as means + SD from proteomic 
analysis (TMT-labelling) of two independent biological experiments. Two-tailed 
student’s t-test was performed to calculate p values, and levels of significance are 
denoted as follows: **0.001<P<0.01 and, ns: P>0.05. HeLa cells were treated with (A) 
250 µM VH032 or (C) 100 µM VH298 for indicated time. (D) HeLa or (E) HFF cells 
were treated with 1% DMSO, hypoxia (1% O2), and 100 µM of indicated compounds 
for 24 h. 786-O cell lysate was loaded in (E) as negative control for VHL bands. Protein 
levels were analysed by immunoblotting using antibodies against HIF-1α, VHL, VHL* 
(older VHL antibody #2738; Cell Signalling), and β-actin which acted as a loading 
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VH032 (Figure 6.1B). The increase in VHL protein levels was also observed with the 
more potent VHL inhibitor, VH298 (Figure 6.1C-E), also in a time-dependent manner 
(Figure 6.1C), confirming that this increase is due to the inhibition of VHL by the small 
molecules. Additionally, the increase in VHL protein levels was not observed with the 
non-binding epimer cisVH298 (Figure 6.1D-E), further demonstrating that the 
inhibition of VHL by small molecules results in the accumulation of VHL. 
In HeLa and HFF cells, the treatment of hypoxia or PHD inhibitor IOX2 did not 
increase VHL protein levels (Figure 6.1D-E), in agreement with the TMT-proteomic 
results (Figure 6.1A). In addition, treatment with FG-4592, which is also a PHD 
inhibitor, showed similar results to those obtained with IOX2 – no alteration in VHL 
protein levels. 
Altogether, VHL protein was confirmed to be upregulated by the small molecule VHL 
inhibitors, not only in HeLa cells, in which the proteomic analysis was performed, but 
also in HFF fibroblasts, and this increase was not observed following hypoxia or in the 
presence of PHD inhibitors. 
6.3.  Ligand-bound VHL increased protein stability 
To examine whether the increase in VHL protein levels in the presence of VHL 
inhibitor was due to an increase in mRNA levels, qRT-PCR assays monitoring mRNA 
levels of VHL were performed. mRNA levels of VHL were not altered in the presence of 
VH032 or VH298 in HeLa (Figure 6.2A) or VH298 in HFF cells (Figure 6.2B). Similar 
to the unaltered VHL protein levels, hypoxia and IOX2 did not induce changes in VHL 





Figure 6.2 – VHL inhibitor stabilises VHL proteins. VHL mRNA expressions in (A) 
HeLa cells treated with 1% DMSO, hypoxia (1% O2), and 250 µM IOX2, 250 µM 
VH032 or 100 µM VH298 for 16 h or in (B) HFF cells treated with 1% DMSO or 
100 µM VH298 for 24 h. mRNA was collected, reverse transcribed and analysed by 
qRT-PCR. The shown levels of the indicated mRNAs were normalised to those of 
β-actin. Graphs depict the mean + SEM of three independent biological replicates. Two-
tailed student’s t-test was performed to calculate p values, and levels of significance are 
denoted as follows: ns is P>0.05. (C) HeLa cells treated with 20 µM MG132 for 3 h. 
786-O cell lysate was loaded as negative control for VHL and HIF-1α. (D) Half-life of 
VHL proteins of HeLa cells treated with DMSO negative control or VH298 VHL 
inhibitor was measured by treating cells with cycloheximide (CHX) for indicated times. 
(E) VHL protein levels (divided into largest, middle and smallest bands) were 
quantified from multiple blots of different exposure time by ImageJ and plotted. Protein 
levels were analysed by immunoblotting using antibodies against HIF-1α, VHL, and β-
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Another possible cause of the increase of VHL proteins in the presence of VHL 
inhibitor was thought to be that VHL might be auto-regulating itself to be degraded by 
the proteasome, similar to how VHL regulates the proteasomal degradation of HIF-1α. 
To investigate whether VHL targets itself for proteasomal degradation, HeLa cells were 
treated with the proteasome inhibitor MG132 (Figure 6.2C). This analysis showed that 
VHL proteins were not uregulated in the presence of MG132. In fact, the largest band of 
VHL detected (just below 36 kDa) showed a decrease in protein level following 
treatment with the proteasome inhibitor. 
Another possibility of the increased VHL proteins is that the ligand-bound VHL may be 
more stable than the unbound form. To determine if the half-life of VHL increases in 
the presence of VHL inhibitor, a cycloheximide chase experiment, which inhibits de 
novo protein synthesis, was performed on the endogenous VHL in cells. Multiple bands 
of VHL were present and divided into three categories according to their observed sizes: 
VHL-largest, VHL-middle and VHL-smallest. Analysis revealed a shorter half-life of 
around 1.5 h for the largest VHL protein and similar half-life of 4 h for VHL-middle 
and VHL-smallest (Figure 6.2D-E). VHL inhibitor VH298 did not alter protein stability 
of VHL-largest, but increased the half-life of the middle and smallest VHL proteins. 
Half-life of VHL-middle increased from 4 h to 6 h in the presence of VH298, while the 
half-life of VH298-bound VHL-smallest was beyond the 6 h cycloheximide treatment. 
This result correlates to the increased protein levels for VHL-middle and VHL-smallest 
seen in the presence of VHL inhibitors (Figure 6.1B-E). 
Taken together this data indicates that the binding of VHL inhibitor leads to increased 





6.4.  HIF-1α protein levels decreased in prolonged VH298 
treatment 
In hypoxia, HIF-α proteins are known to be readily upregulated, but this is not sustained 
in prolonged hypoxia as HIF-α proteins are eventually degraded by the proteasome, due 
to the increase of HIF-targets, PHD2 and PHD3 (254). The downregulation of HIF-1α 
was also observed when cells were treated with VHL inhibitor (Figure 6.3A). Although 
PHD2 levels increased significantly under VHL inhibitor, PHD3 was not upregulated to 
the same extent as under hypoxia (Figure 4.3D). 
One possible cause for the decrease in HIF-1α in prolonged VH298 treatment is that 
VHL inhibitor was exhausted after long treatment, and therefore was not enough to 
inhibit VHL. To investigate this hypothesis, cells were first treated with 100 µM VH298 
for 24 h, where HIF-1α levels decreased, followed by additional treatment with VH298 
for 2 h at optimum concentration (concentration at which maximum HIF-1α level is 
induced). At 2 h treatment, the optimum doses of VH298 required to treat HeLa and 
HFF cells were 400 µM and 100 µM, respectively (Figure 6.3B). Using the optimum 
concentration of VH298 determined, after the initial 24 h treatment with 100 µM 
VH298, 400 µM and 100 µM VH298 was added to HeLa and HFF cells, respectively. 
The addition of more VH298 increased HIF-1α slightly, but did not rescue the degraded 
HIF-1α to the same level as the initially stabilised HIF-1α at 2 h in both HeLa and HFF 
(Figure 6.3C). 
Results indicate that the decrease of HIF-1α levels in prolonged VH298 treatment was 
not due to insufficient VH298 to inhibit VHL. However, it is possible that the extra-
added inhibitor may still be insufficient to fully saturate the target, given the 





Figure 6.3 – HIF-1α protein levels decreased in prolonged VH298 treatment and 
could not be rescued with the re-addition of VH298. (A) Time-course immunoblots 
of HIF-1α and its targets (PHD2 and PHD3) in hypoxia (1% O2) or 100 µM VH298. (B) 
Dose-dependent immunoblots of HIF-1α in HeLa (left panel) and HFF (right panel) 
cells treated with VH298 for 2 h. (C) HeLa and HFF cells were treated with 100 µM 
VH298 for 2 and 24 h. After 24 h treatment of 100 µM VH298, 400 µM VH298 was 
introduced to HeLa cells for 2 h and 100 µM VH298 to HFF cells for 2 h. A 2 h 
treatment with 400 µM VH298 was also included in HeLa cells. Protein levels were 
analysed by immunoblotting using antibodies against indicated proteins, and β-actin, 
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6.5.  The decrease in HIF-1α levels in prolonged VHL inhibitor 
treatment was due to increased VHL protein levels 
HIF-1α is known to be degraded via the proteasomal (255) as well as lysosomal (256) 
pathways. To investigate if the VHL inhibitor-induced HIF-1α was degraded in 
prolonged treatment by either of the pathways, cells were first treated with VH298 for 
24 h, followed by proteasome inhibitor (MG132) or lysosome inhibitors (chloroquine or 
bafilomycin A1) for the last 3 h. As expected, all three inhibitors stabilised HIF-1α, 
where MG132 accumulate post-translational modified HIF-1α (present as a smear) and, 
both chloroquine and bafilomycin A1 treatments resulted in a single band of HIF-1α 
(Figure 6.4A). 
After 24 h VH298 treatment, MG132 rescued the degraded HIF-1α to similar protein 
levels as 3 h treatment of VH298 (Figure 6.4A). On the other hand, lysosomal inhibitors 
were not as efficient; both chloroquine and bafilomycin A1 increased HIF-1α to a much 
lower extent. These data indicate that the accumulated HIF-1α proteins in the presence 
of VHL inhibitor VH298 were degraded, in the long-term VH298 treatment, via mainly 
the proteasomal pathway. The lysosomal pathway also contributes to HIF-1α 
degradation in the presence of the VHL inhibitor, but to a lower extent. 
Similar to the previous data (Figure 6.2C), the middle and smallest VHL proteins 
remained unaltered in the presence of MG132, while the largest VHL band seen was 
depleted (Figure 6.4A). The combination of VH298 and MG132 treatment resulted in 
the same observed depletion of VHL-largest in MG132, as well as increases in 
VHL-middle and VHL-smallest protein levels. Instead, the treatment of chloroquine or 
bafilomycin A1 alone did not seem to alter VHL protein levels, and the addition of 
either of the lysosome inhibitor to cells that had been treated with VH298 for 24 h also 





Figure 6.4 – The decrease of HIF-1α protein levels in prolonged VH298 treatment 
is mediated by proteasomal degradation in a VHL-dependent manner. (A) HeLa 
cells were treated with 3 and 24 h of 100 µM VH298. After 24 h treatments of 1% 
DMSO or 100 µM VH298, cells were treated with proteasome inhibitor MG132 
(20 µM), autophagy inhibitors chloroquine (CQ; 50 µM) or bafilomycin A1 (Baf A1; 
50 nM) for 3 h. (B and C) HeLa cells were transfected with non-targeting siRNA 
control (siNT) or VHL siRNA (siVHL). (B) After 24 h, media was changed and 
transfected cells were treated with 100 µM VH298 for indicated times. (C) After 46 h, 
media was changed and transfected cells were treated with indicated concentrations of 
VH298 for 2 h. Cell lysate of 786-O was included as negative control for VHL. Protein 
levels were analysed by immunoblotting using antibodies against HIF-1α, VHL, and β-
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The results so far show that in the long treatment of VH298, the initially induced 
HIF-1α levels decreased and VHL increased. To investigate whether the VH298-
induced HIF-1α is degraded in VHL-dependent manner, siRNA-mediated knockdown 
of VHL was performed in HeLa cells. In control siRNA-treated cells, VH298 treatment 
over time resulted in HIF-1α degradation, whereas under VHL knockdown by siRNA, 
HIF-1α remained stabilised over the entire course of the 24 h compound treatment 
(Figure 6.4B). This result suggests that the degradation of VH298-induced HIF-1α was 
mediated by VHL. 
Interestingly, the knockdown of VHL only led to slight stabilisation of HIF-1α. siRNA 
approach might not be able to completely remove all endogenous VHL, and even very 
low amount of the remaining VHL appears to be enough to efficiently polyubiquitinate 
HIF-1α for proteasomal degradation. The high activity and catalytic efficiency of VHL 
might explain the requirement of relatively high concentration of VHL inhibitor in order 
to observe detectable levels of HIF-1α. To examine this hypothesis, a dose-dependent 
VH298 treatment was performed with and without siRNA-mediated VHL knockdown. 
In the knockdown of VHL, HIF-1α levels could be detected already at 1 µM 
concentration of VH298, and 10 µM inhibitor treatment under VHL knockdown could 
achieve similar HIF-1α stabilisation as 100 µM VH298 in the negative control siRNA 
background. The combination of VH298 and the knockdown of VHL clearly showed 
additive effect on accumulating HIF-1α. 
Together, these results indicate that following treatment with VHL inhibitor VH298, 
HIF-1α that is initially stabilised, is eventually degraded via the proteasome pathway, 






6.6.  Analysis of VHL interactome in the presence of VH298 
The results above demonstrate that VHL is upregulated in the present of VHL 
inhibitors. In an attempt to dissect the mechanism behind VHL upregulation in the 
present of VHL inhibitor, a proteomic analysis of VHL interactome was performed 
through co-immunoprecipitation (co-IP) coupled with mass spectrometry (MS) analysis. 
For this study, VHL antibody was used to isolate endogenous VHL in order to observe 
native interactors. Co-IP using VHL antibody was optimised as described below. 
First, a VHL antibody obtained from BD Biosciences was confirmed to be able to 
immunoprecipitate VHL from HeLa cell lysates treated with MG132 (Figure 6.5). 
Furthermore, as MG132 blocks the proteasome, it was possible to demonstrate that, 
under these conditions, HIF-1α was in complex with VHL. Although sepharose protein 
G beads immunoprecipitated more VHL than the magnetic dynabeads protein G, 
sepharose beads were incubated with lysates:antibodies complex longer (overnight), 
compared to 1 h incubation with of lysates with antibody-coated dynabeads (Figure 
6.5A). As both beads seemed to work equally well, it was decided to use dynabeads to 
minimise loss of sample through the use of magnetic separation rather than the 
centrifugation approach of using sepharose beads.  
Next, since 10 min incubation of antibodies with dynabeads immunoprecipated 
comparable amount of VHL to overnight incubation, using 10 min incubation time, 
lysates were incubated with the antibodies-coated dynabeads for 1 h or overnight 
(Figure 6.5B). The antibodies:beads complex formed overnight immunoprecipitated 
much more VHL than the 1 h incubation. Therefore for this interactome study, 6 µg of 
antibody was first coated on the magnetic beads for 10 min, followed by overnight 





Figure 6.5 – Optimisation for co-immunoprecipitation of VHL. HeLa cells treated 
with MG132 (20 µM for 3 h) prior to cell lysis. 500 µg of protein lysates were used to 
immunoprecipitate VHL with the 4 µg VHL antibody (BD Biosciences). 4 µg Rabbit 
immunoglobulin G (IgG) was used as a control. Inputs represent 10% of the starting 
material used per immunoprecipitation (IP) and flow-through (FT) represents 10% of 
the flow-through collected after IP. (A) co-IP using sepharose beads was compared to 
dynabeads. Protein lysates were incubated with VHL antibodies at 4°C for overnight, 
followed by incubation with sepharose protein G beads for 1.5 h at 4°C on a rotating 
platform. On the other hand, dynabeads were first coated with antibodies for 10 min 
incubation at room temperature or overnight at 4°C, followed by incubation with 
protein lysates for 1 h at 4°C. (B) Dynabeads were first coated with antibodies for 
10 min incubation at room temperature, followed by incubation with protein lysates for 
1 or overnight at 4°C. * denotes IgG light chain at approximately 30 kDa and ** 
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Co-IP experiments were performed on lysates of HeLa cells exposed to 3 h of DMSO 
(negative control), MG132, VH298, and a mix of MG132 with VH298 to block both the 
proteasome and the VHL:HIF-1α interaction (Figure 6.6). The rationale for combining 
MG132 and VH298 was because as VH298 binds to the VHL pocket, a new surface 
could be formed and may lead to interaction with new binder. Thus, blocking the 
proteasome may stabilise VHL:VH298:newbinder interaction, if the new binder were to 
be degraded via the proteasome system. While, the treatment of only MG132 was used 
to exclude protein complexes formed in the presence of the proteasome inhibitor, such 
as HIF-1α and proteins involved in HIF-1α degradation. Analysis was performed in four 
replicates. 
Protein response to treatment was estimated by label-free quantification. Although the 
same amount of VHL antibodies and beads used, peptide intensity for VHL may differ 
between samples in the same replicate due to technical issues such as pipetting and  
 
Figure 6.6 – Co-immunoprecipitation coupled mass spectrometry workflow. HeLa 
cells were treated with 1% DMSO, 20 µM MG132, 100 µM VH298, or a mix of 20 µM 
MG132 and 100 µM VH298 for 3 h prior to harvesting. 6 µg VHL antibody (BD 
Biosciences) was coated on 50 µL dynabeads protein G by shaking at room temperature 
of 24°C for 1 h. 6 µg Mouse immunoglobulin G (IgG) was used as a control. 750 µg 
cell lysates were then incubated with VHL-antibody-coated dynabeads protein G on a 
rotating platform at 4°C overnight. Two-third of samples were used for mass 
spectrometry (MS) analysis and the remaining was kept for validation. For MS analysis, 
proteins were digested by trypsinisation on beads, followed by desalting to clean up 
peptides, and analysed by MS. 
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washing of beads. 
Therefore, within the same replicate, peptide intensities were normalised to the VHL 
intensity of DMSO control in order to set an equal intensity of VHL. Unfortunately, 
protein intensity for VHL was not present in two out of the four replicates (replicate 2 
and replicate 3) for most conditions, as it was not detected in the MS analysis. Therefore 
the normalisation was only performed in replicate 1 and replicate 4. To ensure that 
co-IP experiments were successful, co-IP samples that were set aside previously were 
analysed by western-blotting for VHL protein and gratifyingly, VHL was present in all 
the co-immunoprecipitates of VHL (Figure 6.7A). 
By analysing the protein abundance ratios between immunoprecipitate of treatments and 
immunoprecipitate of IgG control, specific interactors and contaminants can be 
distinguished. With the selection criterion that across all replicates, the peptide intensity 
of each protein in at least one condition has to be more than the intensity in IgG for the 
same protein, 231 out of 1,641 proteins fell under this selection and were analysed 
further. In order for the protein to fall into the “enriched” category, protein intensity has 
to be > 1.5 log two-fold change (log2FC) in the treated samples compared to the DMSO 
control. In addition, these proteins have to be enriched in at least two of the four 
replicates. 
Unfortunately, Cullin2, a component of the VHL ubiquitin ligase complex, did not pass 
the selection criteria, because its intensity in the IgG control in one of the replicates was 
larger than that in any of the treated samples. Gratifyingly, the other components 
including Elongin B and Elongin C were co-immunoprecipitated with VHL. 
Furthermore, HIF 1α was detected in the MG132 treatment of all four replicates (Table 




disrupted VHL:HIF-1α interaction. Amongst proteins that were enriched in any 
conditions, HIF-1α was the only protein that consistently enriched in all four replicates. 
To distinguish proteins of interest affected by each treatment, Venn diagrams for 
enriched and depleted proteins were plotted (Figure 6.7B). Enrichment criteria was set 
at log2FC > 1.5 compared to DMSO and depletion at log2FC < –1.5 to DMSO. The 
combination of VH298 and MG132 co-immunoprecipitated the most number of  
 
Figure 6.7 – Comparison amongst treatments. (A) HeLa cells treated with 1% 
DMSO, 20 µM MG132, 100 µM VH298 or a mix of 20 µM MG132 and 100 µM 
VH298 for 3 h prior to cell lysis. One-third of co-IP samples for MS analysis (described 
in Figure 6.6) were used here for western-blotting. Inputs represent 10% of the starting 
material used per IP (25 µg). (B) Venn diagrams depicting the number of enriched 
proteins (log2FC > 1.5) and depleted proteins (log2FC < –1.5) comparing the presence 
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proteins (42) and enriched 29 proteins not found in individual treatment of VH298 or 
MG132 (Table 6.7), which might be potential interactors of VH298-bound VHL, and 
stabilised by the blocking of proteasome. Indeed, six out of the 29 proteins are known 
interacting proteins of VHL (highlighted in blue), while the rest of the proteins seemed 
to be known ubiquitous contaminants, including keratins, cytoskeletal proteins such as 
actin and tubulins, and high abundance proteins including histones and translation 
elongation factors (257). These contaminants were also found throughout in other 
treatments. 
Interestingly, TCEB1 (Elongin C) was depleted in VH298 and MG132+VH298 
treatments (Table 6.8), and TCEB2 (Elongin B) was depleted in MG132+VH298 
treatment (Table 6.10). The inhibition of VHL by VH298 seemed to induce the 
depletion the two components of VHL E3 ubiquitin complex. One possibility could be 
that as VHL levels increase in response to VH298 treatment, there is a greater relative 
population of VHL that is not bound to Elongin proteins, as those proteins 
stoichiometrically cannot cope with the increase in VHL level – leading to an apparent 
“depletion” of EloB/C from VHL. Another explanation may be that VH298 may 
interfere with the formation of the complex, or that bound HIF-1α promotes the 
formation of the E3 ubiquitin complex, and this effect becomes less pronounced when 
HIF α binding is competed by VH298. 
As mentioned, the aim of this analysis was to dissect the mechanism of VHL regulation 
in the presence of VHL inhibitor. Therefore, the most interesting genes would be those 
enriched or depleted in the presence of VH298 alone (Table 6.6 and Table 6.9), as well 
as MG132+VH298 only (Table 6.7 and Table 6.10) as MG132 stabilised the complex 
formed. However, most of the proteins identified were contaminants, and only one that 
might be a regulatory protein: HERC6, which was depleted in cells treated with both 




ligase that contains a C-terminal HECT domain (258). The HECT domain is predicted 
to form a thioester with ubiquitin before transferring it to a substrate, but this ability has 
not been demonstrated for HERC6. If an E3 ligase were enriched in the treatment of 
both VH298 and MG132, it might be involved in regulating the VH298-bound VHL. 
However, from the results, HERC6 was depleted. The depletion of HERC6 could 
indicate that HERC6 might play a role in regulating VHL. The binding of a ligand, in 
this case VH298, might prevent HERC6 from polyubiquitinating VHL and targeting it 
for degradation. Nonetheless, the proteomic analysis is not sufficient to identify 
confident VHL regulator. Validation on HERC6 would be interesting for future 
investigation. 
Overall, results indicate that co-IP for all four replicates had worked as HIF-1α was 
enriched in all replicates. However, data obtained was not enough to uncover novel 
regulator or interactor of VHL. 
Table 6.1 – List of five proteins enriched in MG132, VH298 and MG132+VH298 
treatments. Proteins were selected with log2FC > 1.5 compared to DMSO control. 
Ensembl ID, uniprot ID, gene name and protein name are listed. 





ENSG00000106636 O15498 YKT6 Synaptobrevin homolog YKT6 
ENSG00000119689 P36957 DLST Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial 
ENSG00000159352 P55036 PSMD4 26S proteasome non-ATPase regulatory subunit 4 
ENSG00000181019 P15559 NQO1 NAD(P)H dehydrogenase [quinone] 1 
ENSG00000188219 Q6S8J3 POTEE POTE ankyrin domain family member E;POTE 
ankyrin domain family member I;Putative beta-
actin-like protein 3;Putative beta-actin-like protein 
3, N-terminally processed;POTE ankyrin domain 






Table 6.2 – List of six proteins enriched in MG132 only, but not VH298 or 
MG132+VH298 treatments. Proteins were selected with log2FC > 1.5 compared to 
DMSO control. Ensembl ID, uniprot ID, gene name and protein name are listed. In 
blue: proteins found to be interacting proteins of VHL when searched in the 
‘GeneCards’ human gene database website (http://www.genecards.org/). 





ENSG00000100644 Q16665 HIF1A Hypoxia-inducible factor 1-alpha 
ENSG00000089597 Q14697 GANAB Neutral alpha-glucosidase AB 
ENSG00000101150 O43399 TPD52L2 Tumor protein D54 
ENSG00000114573 P38606 ATP6V1A V-type proton ATPase catalytic subunit A 
ENSG00000126067 P49721 PSMB2 Proteasome subunit beta type-2;Proteasome 
subunit beta type 







Table 6.3 – List of three proteins enriched in MG132 and VH298, but not the 
combination of MG132+VH298 treatment. Proteins were selected with log2FC > 1.5 
compared to DMSO control. Ensembl ID, uniprot ID, gene name and protein name are 
listed. In blue: proteins found to be interacting proteins of VHL when searched in the 
‘GeneCards’ human gene database website (http://www.genecards.org/). 





ENSG00000102144 P00558 PGK1 Phosphoglycerate kinase;Phosphoglycerate 
kinase 1 
ENSG00000106263 P55884 EIF3B Eukaryotic translation initiation factor 3 
subunit B 
ENSG00000137073 Q5T6F2 UBAP2 Ubiquitin-associated protein 2 
 
Table 6.4 – List of four proteins enriched in MG132 and MG132+VH298, but not 
VH298 treatment. Proteins were selected with log2FC > 1.5 compared to DMSO 
control. Ensembl ID, uniprot ID, gene name and protein name are listed. In blue: 
proteins found to be interacting proteins of VHL when searched in the ‘GeneCards’ 
human gene database website (http://www.genecards.org/). 





ENSG00000100764 P62191 PSMC1 26S protease regulatory subunit 4 
ENSG00000143870 Q15084 PDIA6 Protein disulfide-isomerase A6 
ENSG00000143947 P62979 RPS27A Ubiquitin-40S ribosomal protein 
S27a;Ubiquitin;40S ribosomal protein 
S27a;Ubiquitin-60S ribosomal protein 
L40;Ubiquitin;60S ribosomal protein 
L40;Polyubiquitin-B;Ubiquitin;Polyubiquitin-
C;Ubiquitin 




Table 6.5 – List of four proteins enriched in VH298 and MG132+VH298, but not 
MG132 treatment. Proteins were selected with log2FC > 1.5 compared to DMSO 
control. Ensembl ID, uniprot ID, gene name and protein name are listed. 





ENSG00000105323 Q9BUJ2 HNRNPUL1 Heterogeneous nuclear ribonucleoprotein U-
like protein 1 
ENSG00000124207 P55060 CSE1L Exportin-2 
ENSG00000177425 Q96IZ0 PAWR PRKC apoptosis WT1 regulator protein 
ENSG00000197956 P06703 S100A6 Protein S100-A6;Protein S100 
 
Table 6.6 – List of four proteins enriched in VH298, but not MG132 or 
MG132+VH298. Proteins were selected with log2FC > 1.5 compared to DMSO control. 
Ensembl ID, uniprot ID, gene name and protein name are listed. 





ENSG00000105974 Q03135 CAV1 Caveolin;Caveolin-1 
ENSG00000129116 Q8WX93 PALLD Palladin 
ENSG00000167767 Q6KB66 KRT80 Keratin, type II cytoskeletal 80 
ENSG00000178209 Q15149 PLEC Plectin 
 
Table 6.7 – List of 29 proteins enriched in MG132+VH298 treatment only, but not 
MG132 or VH298. Proteins were selected with log2FC > 1.5 compared to DMSO 
control. Ensembl ID, uniprot ID, gene name and protein name are listed. In blue: 
proteins found to be interacting proteins of VHL when searched in the ‘GeneCards’ 
human gene database website (http://www.genecards.org/). 





ENSG00000039560 Q9P0K7 RAI14 Ankycorbin 
ENSG00000077549 P47756 CAPZB F-actin-capping protein subunit beta 
ENSG00000085733 Q14247 CTTN Src substrate cortactin 
ENSG00000087365 Q13435 SF3B2 Splicing factor 3B subunit 2 
ENSG00000099901 P43487 RANBP1 Ran-specific GTPase-activating protein 
ENSG00000101608 P19105 MYL12A Myosin regulatory light chain 12A;Myosin 
regulatory light chain 12B ENSG00000118680 O14950 MYL12B 
ENSG00000108298 P84098 RPL19 Ribosomal protein L19;60S ribosomal 
protein L19 
ENSG00000115091 P61158 ACTR3 Actin-related protein 3 
ENSG00000128595 O43852 CALU Calumenin 
ENSG00000132341 P62826 RAN GTP-binding nuclear protein Ran 
ENSG00000133030 Q6WCQ1 MPRIP Myosin phosphatase Rho-interacting 
protein;Tyrosine-protein kinase receptor 
ENSG00000136810 P10599 TXN Thioredoxin 
ENSG00000140416 P09493 TPM1 Tropomyosin alpha-1 chain 
ENSG00000140740 P22695 UQCRC2 Cytochrome b-c1 complex subunit 2, 
mitochondrial 
ENSG00000143549 P06753 TPM3 Tropomyosin alpha-3 chain 
ENSG00000148396 O15027 SEC16A Protein transport protein Sec16A 
ENSG00000151914 Q03001 DST Dystonin 
ENSG00000162614 Q0ZGT2 NEXN Nexilin 




ENSG00000169813 P52597 HNRNPF Heterogeneous nuclear ribonucleoprotein 
F;Heterogeneous nuclear ribonucleoprotein 
F, N-terminally processed 
ENSG00000172867 P35908 KRT2 Keratin, type II cytoskeletal 2 epidermal 
ENSG00000180879 P51571 SSR4 Translocon-associated protein subunit delta 
ENSG00000182944 Q01844 EWSR1 RNA-binding protein EWS 
ENSG00000184009 P63261 ACTG1 Actin, cytoplasmic 2;Actin, cytoplasmic 2, 
N-terminally processed 
ENSG00000186395 P13645 KRT10 Keratin, type I cytoskeletal 10 
ENSG00000197321 O95425 SVIL Supervillin 
ENSG00000197728 P62854 RPS26 40S ribosomal protein S26;Putative 40S 
ribosomal protein S26-like 1 
ENSG00000254772 P26641 EEF1G Elongation factor 1-gamma 
 
 
Table 6.8 – List of a protein depleted in VH298 and MG132+VH298 treatments, 
but not MG132. Proteins were selected with log2FC < −1.5 compared to DMSO 
control. Ensembl ID, uniprot ID, gene name and protein name are listed. In blue: 
proteins found to be interacting proteins of VHL when searched in the ‘GeneCards’ 
human gene database website (http://www.genecards.org/). 





ENSG00000154582 Q15369 TCEB1 Transcription elongation factor B polypeptide 1 
 
Table 6.9 – List of two proteins depleted in VH298, but not MG132 or 
MG132+VH298. Proteins were selected with log2FC < −1.5 compared to DMSO 
control. Ensembl ID, uniprot ID, gene name and protein name are listed. 
Ensembl ID Uniprot ID Gene name Protein name 
ENSG00000138594 Q9NYL9 TMOD3 Tropomodulin-3 
ENSG00000198467 P07951 HEL-S-273 Tropomyosin beta chain 
 
Table 6.10 – List of five proteins depleted in MG132+VH298, but not MG132 or 
VH298. Proteins were selected with log2FC < −1.5 compared to DMSO control. 
Ensembl ID, uniprot ID, gene name and protein name are listed. In blue: proteins found 
to be interacting proteins of VHL when searched in the ‘GeneCards’ human gene 
database website (http://www.genecards.org/). 





ENSG00000277443 P29966 MARCKS Myristoylated alanine-rich C-kinase substrate 
ENSG00000103363 Q15370 TCEB2 Transcription elongation factor B polypeptide 
2 
ENSG00000138642 Q8IVU3 HERC6 Probable E3 ubiquitin-protein ligase HERC6 
ENSG00000136824 O95347 SMC2 Structural maintenance of chromosomes 
protein;Structural maintenance of 
chromosomes protein 2 





6.7.  Discussion 
In the previous chapter, proteomic analysis of VHL inhibitor-treated HeLa cells 
identified VHL to be upregulated. Validation by Western-blotting confirmed that VHL 
protein levels indeed increased in the presence of VHL inhibitor VH032. In addition, 
this effect was also observed following treatment with the more potent VHL inhibitor, 
VH298. Furthermore, the non-binding cis-hydroxyproline analogue of VH298, 
cis-VH298, could not upregulate VHL. This demonstrated that the upregulation of VHL 
was not an off-target effect of the inhibitors and it required the binding of the VHL 
inhibitor. This upregulation was not only observed in HeLa cells, but also in fibroblast 
cells, HFF. Importantly, this effect is not dependent on oxygen availability or PHD 
enzymes as the treatment of hypoxia or PHD inhibitors (IOX2 and FG-4592) did not 
lead to an increase in VHL levels.  
The increase of VHL protein levels in the presence of its inhibitor could be due to 
several reasons: VHL inhibitor could induce the transcription or translation of VHL; 
VHL could be autoregulating itself for degradation, an activity which would be blocked 
by the compound; or the ligand-bound VHL might be stabilised and less degradable 
inside the cell. Results showed that VHL inhibitor did not alter mRNA level of VHL 
and VHL does not autoregulate itself for the degradation by the proteasome. In contrast, 
the inhibitor-bound VHL showed a longer half-life, demonstrating that in the ligand-
bound form, VHL might be less degradable. The antibody used for Western-blotting 
detected three bands of VHL, which are designated as VHL-smallest, VHL-middle and 
VHL-largest in this study. VHL encodes for two isoforms from the same transcripts: a 
24-kDa longest isoform of 213-amino acid, and a 19-kDa isoform of 160-amino acid. 
The shorter isoform is initiated from an internal alternative start codon in frame that is 
159 bp downstream the first start codon (145-147). The three bands detected by the 




sufficient evidence from the literature to suggest that the band designated as 
”VHL-smallest” (which runs as an approximate ~19 kDa protein) corresponds to the 
short isoform [also named pVHL19] (145-147). All three bands could potentially be 
from the short isoform that is post-translationally modified; alternatively the 
VHL-middle and VHL-largest bands could be detecting different forms of the long 
isoform of VHL (pVHL30). 
Nonetheless, this increase in VHL levels in the presence of VHL inhibitor was found to 
be responsible for the downregulation of HIF-1α that was rapidly accumulated due to 
the treatment. Interestingly, the siRNA-mediated knockdown of VHL in normoxia 
accumulated very little HIF-1α compared to VHL inhibitor. As mentioned previously, 
VHL inhibitor VH298 has a binding affinity in the nanomolar range as measured by 
ITC, but was used at micromolar range in cells. Considering that even the knockdown 
of VHL mediated by siRNA approach could not stabilise much HIF-1α, it is likely that 
all cellular VHL has to be completely engaged with the compound and inhibited to 
prevent the interaction between VHL and HIF-1α, which would lead to the stabilisation 
of HIF-1α. This was further demonstrated by the combination of siRNA-mediated 
knockdown of VHL and VH298 treatment – VH298 stabilised comparable amounts of 
HIF-1α at a 10-fold lower dose when combined with VHL knockdown. 
VHL inhibitors are being widely used as part of the proteolysis targeting chimeric 
molecules (PROTACs) to induce degradation of a specific target-protein by recruiting 
the target-protein to the VHL E3 ubiquitin ligase complex for ubiquitination. Optimum 
degradation of protein-of-interest is typically achieved at sub-µM concentrations of 
PROTACs, and at these low doses, such compounds have been shown not to induce 
HIF-1α stabilisation in cells (217,220). This could explain the observation mentioned 
above. At low dose of PROTACs usage, low but sufficient VHL E3 ubiquitin ligase 




interest. Likewise, only low amount of VHL is required to polyubiquitinate 
hydroxylated HIF-1α for proteasomal degradation. 
To understand the mechanism of VHL regulation in the presence of VHL inhibitor, 
co-immunoprecipitation (co-IP) coupled mass spectrometry (MS) analysis was 
performed. In the VHL inhibitor-bound form, a new surface is formed on VHL, which 
was hypothesised might lead to the interaction with proteins that are not VHL-binding 
proteins as neo-substrates. This hypothesis is based on the knowledge that other ligands 
for Cullin RING ligase, such as auxin (259) and immunomodulatory drug (260) 
compounds, induce such mechanism of action. If these proteins are regulated by the 
proteosomal degradation pathway, MG132 treatment would be expected to stabilise 
them in a bound complex with VHL. Co-IP was performed using antibody against 
VHL. By isolating endogenous VHL, VHL expression would be controlled by the 
endogenous promoter and its function would not be altered by addition of a tag.  
Analysis showed that HIF-1α was found in the VHL co-immunoprecipitate of MG132 
treatment in all four replicates performed, demonstrating that the co-IP was successful. 
However, there were a few caveats with this approach. 
First, MS detection is rather random and not all resulting peptides can be confidently 
detected across replicates. Indeed, peptides (hence proteins) detected from this analysis 
were inconsistent across replicates. For instance, VHL was not detected in the second 
and third replicates of the analysis, but western blotting of the samples set aside before 
processing for MS showed successful isolation of VHL. Next, the current MS 
approaches are able to detect a large number of proteins, including non-specific 
interactors (contaminants). This poses a challenge for discriminating between 
contaminants and relevant interactors. Here, despite the inclusion of IgG negative 
control, it was not sufficient to filter out contaminants. As a result, these contaminants 




not confidently identify potential VHL regulators. All proteins listed as enriched or 
depleted were not consistent in all four replicates, with the exception of only HIF-1α. It 
would be ideal to carefully re-evaluate data obtained in the future. In addition, a change 
of approach to confidently identify possible VHL interactors may be worthwhile. Using 
data independent acquisition (DIA) analysis (261) would solve this problem and 
potentially identify low abundance interactors responsible for the increase in VHL 
protein levels following treatment with VH298. 
Nonetheless, the analysis identified HERC6, a probable E3 ubiquitin ligase, as being 
depleted in cells treated with both VH298 and MG132. This suggests that HERC6 
might play a role in regulating VHL. The adaptors of VHL E3 ubiquitin ligase complex, 
EloB and EloC (TCEB2 and TCEB1, respectively), were also depleted in 
MG132+VH298 treatment (Elongin B) and MG132+VH298 as well as VH298 alone 
(EloC), respectively. This suggesting that there might be insufficient EloB/C due to the 
increase of VHL level, or VH298 may disrupt the formation of the E3 complex, or that 
HIF-1α is required for the formation of the E3 ubiquitin complex. It would be 
interesting to validate these hits, first by repeating the co-IP experiment for 
immunoblotting and detecting changes in protein levels using antibodies. Size-exclusion 
chromatography on lysates of cells treated with DMSO vehicle control or VHL inhibitor 
may also reveal whether HERC6 and Elongin B/C are in complex with VHL and if they 
dissociate from VHL in the presence of inhibitor. As HERC6 may play a role in 
regulating VHL, knockdown of HERC6 using approach such as siRNA, may uncover if 
VHL protein level changes in response to HERC6 depletion. Ultimate proof of the role 
of HERC6 as an E3 ubiquitin ligase would be to perform in vitro ubiquitination assay. 
Overall, the data presented in this Chapter together showed that VHL levels increased in 
the presence of VHL inhibitor, which in turn induced the degradation of the 




VHL levels was due to the increase in its half-life when bound by the VHL inhibitor, 
presumably as a result of mere ligand-bound stabilisation. However, the mechanism that 
regulates the inhibitor-bound VHL remains to be fully understood. Results also indicate 
that VHL may be a very active E3 ubiquitin ligase and only little VHL is required to 
polyubiquitinate hydroxylated HIF-1α for proteasomal degradation – thus explaining 





7. Discussion and conclusion remarks 
VHL is the E3 ubiquitin ligase regulating HIF-1α for proteasomal degradation; its 
crucial function in response to hypoxia and cellular oxygen sensing are well established 
owing to the use of genetic tools. Genetic knockout and knockdown to inactivate VHL 
have been widely used in biochemical studies. Although mice with homozygous 
VHL − ⁄ − are embryonically lethal (152), heterozygous and conditional tissue-specific 
knockouts of VHL (262), as well as the use of siRNA targeting VHL (263), have proved 
to be useful tools providing important insights into the biological consequences of VHL 
inactivation and its critical role in HIF regulation. However, the functional 
consequences of specifically disrupting the interaction between VHL and HIF-α remain 
to be elucidated. The development of a chemical probe that unambiguously blocks the 
VHL:HIF-α interaction would allow addressing biological questions about VHL 
molecular target, and functional consequences of disrupting the interaction in a manner 
complementary and potentially synergistic with genetic tools. 
In 2012, a collaboration work between the Ciulli group and a group at Yale University 
produced the first series of small molecule inhibitors of VHL E3 ubiquitin ligase 
(211,213), achieving what was previously thought unfeasible, as the development of E3 
ligase inhibitors had been unprecedented and unsuccessful via previous approaches. The 
inhibitors were designed rationally to contain a hydroxyproline group as a starting 
point, since hydroxyproline of HIF-1α is key for interaction with VHL. The first 
generation of VHL inhibitors was able to bind to VHL:ElonginB:Elongin C (VBC) in 
vitro with single-digit micromolar potency, but inactive in cells. The Ciulli group 
further optimised the inhibitors and generated more potent VHL inhibitors with 
nanomolar binding affinities in 2014 (214). However, these small molecules were yet to 




mere inhibitors of the VHL:HIF-α interaction in vitro using recombinant proteins, but 
not characterised and qualified as chemical probes. 
Therefore, this project began with the aim of characterising VHL inhibitors in cells. 
Here, VHL inhibitors were shown for the first time to be active in cells – able to 
stabilise hydroxylated HIF-α and activate HIF transcriptional activity. However, 
challenges were faced when some of the VHL inhibitors induced cytotoxicity at the 
concentration used, independent of its mode-of-action. As it is important for a 
compound to not cause cytotoxicity aside from its inhibition effect, the Ciulli group 
continued to optimise the inhibitors to increase their potency and improve their 
physicochemical properties, with the aim of finding inhibitors, which are not just 
potent, but also highly selective, and not cytotoxic. Through cellular activity and 
cytotoxicity screens, the most potent VHL inhibitor, VH298, was identified. This work 
has characterised VH298 as a VHL inhibitor that is: potent with double-digit nanomolar 
in vitro binding affinity, cell-permeable, active in cells, selectively inhibits VHL, and 
importantly, does not induce toxicity at the concentration required for HIF-α 
stabilisation (215). With the cellular studies, the initial aim of characterising VHL 
inhibitors in cells was achieved. In addition, the work validates VHL inhibitors as 
chemical probes with potential to investigate specific roles of VHL, which could help to 
distinguish between HIF-dependent and independent VHL functions. 
Once VHL inhibitors were characterised as chemical probes, it was decided to take the 
validation of VHL inhibitors a step further by investigating global transcriptome and 
proteome changes induced by the inhibitor. Through the use of RNA-sequencing and 
TMT-labelling, VHL inhibitor was revealed to induce primarily HIF-dependent changes 
in global gene and protein expression. This was reassuring and provided confidence that 




its binding pocket for hydroxylated HIF-α, and thus should not affect HIF-independent 
VHL functions. 
Interestingly, VHL was found upregulated in the proteomic analysis in the presence of 
VHL inhibitor. This was unexpected at the time, however in hindsight, it is known that 
it is not uncommon for inhibitors to induce an increase in protein level of their targets 
inside cells [for examples in the case of inhibitors of the BET proteins (264)]. Indeed, it 
can be envisaged that ligand-bound protein could be more stable, or evade degradation 
as interaction with negative regulators of the target may be disrupted. Cellular work 
validated that the inhibition of VHL by the small molecule indeed increases protein 
levels of VHL, which in turn promotes HIF-α degradation in prolonged treatment. As 
VHL inhibitor was found to increase the half-life of VHL in cells, the binding of 
inhibitor may result in increased VHL stability, thus protecting VHL from cellular 
degradation. To this end, VHL is a tumour suppressor protein living “on the edge” of 
thermal stability. The melting temperature of VHL recombinant protein bound to 
EloB/C is just above 37°C (212), and many mutations are known to inactivate VHL by 
significantly destabilising the protein (58). However, the exact mechanism underlying 
the upregulation of VHL in the presence of its inhibitor remains elusive. Inhibitor-
bound VHL may interrupt its native binding with interactors that mediate the VHL 
stability. Therefore, another aim arose, to dissect the interactome of VHL in the absence 
and presence VHL inhibitor, with the goal to identify the mechanism behind VHL 
upregulation and if possible, to find novel regulators of VHL. Co-IP of VHL coupled 
with mass spectrometry was performed, but data from analysis was insufficient to make 
any conclusive remark and more work is required to validate hits identified. 
Overall, the main objective of this project was achieved through characterisation of 
VHL inhibitors and this enables the introduction of potent VHL inhibitor as chemical 




impact outcome of this work is that the compound is now available to any researcher to 
purchase via the commercial vendor Tocris (https://www.tocris.com/products/vh-
298_6156). This chemical probe would be useful to address biological questions that 
were previously not possible due to the lack of a tool blocking VHL:HIF-α interaction. 
In addition, this work also demonstrates that it is possible to inhibit an E3 ubiquitin 
ligase, which has been deemed challenging, and also possible to interrupt protein–
protein interaction using small molecules to trigger downstream cellular signalling.  
The characterisation of VHL inhibitors demonstrates the suitability of utilising VHL 
inhibitor as part of PROTAC compounds to recruit the VHL E3 complex as degradation 
machinery for a specific target protein. It is important for these PROTACs to not induce 
HIF-dependent response, which would be an undesired effect and may interfere with the 
degradation of the target protein. Indeed, this study shows that at the optimum 
concentration for PROTACs using VHL inhibitor (217,220), the inhibitor is unable to 
stabilise HIF in cells, thereby making VHL ligands suitable as part of PROTAC. An 
exploitable concentration window between the activities of PROTAC and VHL 
inhibitor was also revealed and would be useful information for researchers working on 
PROTACs. In addition, the work in this thesis and PROTAC data demonstrate the 
strong catalytic efficiency of VHL – low amount VHL is sufficient to mediate the 
ubiquitination and subsequent degradation of its target protein. This raises the question 
of why the cellular level of VHL is much higher than the amount required for adequate 
degradation of its target. However, considering the roles of HIF and the importance of 
regulating it, the presence of ubiquitous VHL would ensure tight regulation of HIF-α 
level. VHL appears to be additionally required for HIF-independent roles and regulation 
of other VHL targets. 
Although the crucial role of VHL in the regulation of HIF is well established, many 




mechanistically different from VHL genetic knockout or knockdown, combination and 
comparison of the inhibitor and VHL knockdown would be able to distinguish effects of 
HIF-dependent functions from scaffolding of VHL complex, and in this way, may 
uncover novel HIF-independent roles of VHL. In addition to VHL 
inhibition/knockout/knockdown, comparison with PHD inhibitor that targets upstream 
of VHL:HIF-α may reveal temporal features of target inhibition. It would also be 
interesting to examine whether other known VHL targets (discussed in 1.3.3.2), aside 
from HIF-α, are affected by VHL inhibitor, and in this way, could further validate the 
specificity of VHL inhibitor. 
Recent studies have identified protective role of VHL knockout during mitochondrial 
dysfunction (265). However, there was no cell-penetrant VHL inhibitor available at that 
time. Instead, PHD inhibitor FG-4592 was used as a replacement to mimic VHL 
knockout to trigger hypoxia response, and shown to display the same protective effect 
(265). With the availability of a cell-penetrant and well-characterised VHL inhibitor, 
that is VH298, the direct rescue mechanism of VHL during mitochondrial dysfunction 
can now be investigated. In addition, comparison of VHL inhibition with VHL 
knockdown may determine whether the protective effect is dependent on HIF or due to 
a hypoxic response. Likewise, the use of VHL inhibitor may also be applicable to 
diseases that benefit from increased HIF response. 
PHD inhibitors display protective roles in many diseases, primarily mediated by their 
HIF stabilisation responses. It would be interesting to investigate whether VHL 
inhibitor could achieve the same protective effects, and if pharmacological intervention 
at the VHL:HIF-α interaction might provide an alternative, complementary, and 
potentially more specific approach to PHD inhibition. For instance, PHD inhibitors 
have been shown to greatly improve inflammation-driven diseases, such as 




protective effect is exclusively dependent on HIF, since VHL inhibitor modulates only 
HIF-dependent responses. Moreover, VHL inhibitor is also able to induce EPO 
production required for anaemia treatment. Therefore, VHL:HIF-α inhibition should be 
considered and validated as a potential therapeutic target in diseases that benefit from 
HIF response, including chronic anaemia, inflammation-driven diseases, ischaemia, 
and, conditions such as wound healing and organ transplantation. 
One fact to consider at the beginning of validating the therapeutic potential of 
VHL:HIF-α inhibition, and likely of potential concern to researchers interesting in 
developing such drug leads, is that the small molecule is inhibiting VHL, a tumour 
suppressor. Inactivation of VHL has been implicated with VHL disease-associated 
hemangioblastomas and clear cell renal carcinomas, in which HIF is constitutively 
active (139). However, it is also known that not all tissues are susceptible to tumour 
formation after VHL loss (139), and that VHL loss is required but not sufficient to cause 
tumour growth, i.e. mutations or loss of other genes are required beside that of VHL 
(266,267). Furthermore, HIF-1α and HIF-2α play opposing roles in renal cancer 
progression (97), whereas VHL inhibitor stabilises both isoforms. Besides, the 
inhibition by small molecule is acute and reversible, and very different from complete 
removal of the entire protein, and therefore should not contribute to the long-term 
progression of cancer. Nonetheless, it would be important and interesting to examine 
the phenotype outcomes of the inhibitor in a cell-based and animal models. Not only 
would this validate the potential of using VHL inhibitor in animal-based research, but it 
would also provide greater insights into the functional roles of VHL:HIF-α interaction. 
Overall, this project characterises VHL inhibitor as a chemical probe of the VHL:HIF 
pathway with great potential to address biological questions regarding the roles and 
regulation of VHL. VHL inhibitor is a unique tool due to its on-target selectivity and 
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Table 9.1 – Chemical structures, and dissociation constants measured by FP and 
ITC of a new series of VHL inhibitors by Pedro Soares. Figures of chemical 
structures were made by Pedro Soares. 
Inhibitor Chemical Structure Kd FP (nM) Kd ITC (nM) 
VH058 
 
6500 ± 300 - 
VH070 
 
270 ± 50 - 
VH071 
 
170 ± 30 130 ± 10 
VH079 
 
450 ± 90 - 
VH080 
 
200 ± 30 - 
VH089 
 
770 ± 30 - 
VH100 
 
195 ± 30 105 ± 11 
VH110 
 
345 ± 90 - 
VH185 
 














760 ± 20 - 
VH235 
 
1670 ± 90 - 
VH271 
 
365 ± 40 - 
VH285 
 
320 ± 20 232 ± 20 
VH286 
 
500 ± 30 - 
VH302 
 
4895 ± 200 232 ± 20 
VH311 
 
300 ± 40 140 ± 20 
VH365 
 






Table 9.2 – List of 4 genes downregulated in hypoxia, IOX2 and VH032 treatments 
compared to DMSO control. Genes were selected at FDR < 0.05 and logFC < –1. In 
red: selected for validation by qRT-PCR. 






Table 9.3 – List of 232 genes upregulated in hypoxia, IOX2 and VH032 treatments 
compared to DMSO control. Genes were selected at FDR < 0.05 and logFC > 1. 
Under ‘Comparison’ column, genes were reported in publicly available datasets. 1: list 
of 100 HIF targets. 2: list of 259 genes upregulated in several cell lines. 3: list of 1141 
genes upregulated in hypoxia in HeLa cells. 4: list of 356 genes identified by ChIP-
sequencing for HIF-1. 5: list of 301 genes identified by ChIP-sequencing for HIF-2. 6: 
list of 246 genes upregulated in hypoxia in MCF7 cells. In red: selected for validation 
by qRT-PCR. 
Ensembl gene ID Gene name Comparison 
ENSG00000007516 BAIAP3  
ENSG00000018280 SLC11A1  
ENSG00000025039 RRAGD 2, 6 
ENSG00000044524 EPHA3 3 
ENSG00000047457 CP 1, 3 
ENSG00000048740 CELF2  
ENSG00000054356 PTPRN 4 
ENSG00000059804 SLC2A3 2, 3, 4, 5 
ENSG00000061656 SPAG4 4, 6 
ENSG00000064225 ST3GAL6  
ENSG00000067057 PFKP 2, 4, 6 
ENSG00000067992 PDK3 2, 3 
ENSG00000068971 PPP2R5B 3 
ENSG00000069667 RORA 2 
ENSG00000072682 P4HA2 2, 3, 4, 6 
ENSG00000079739 PGM1 6 
ENSG00000087266 SH3BP2  
ENSG00000088340 FER1L4  
ENSG00000092421 SEMA6A  
ENSG00000095303 PTGS1 2, 3 
ENSG00000099840 IZUMO4  
ENSG00000100290 BIK  
ENSG00000100593 ISM2  
ENSG00000102144 PGK1 1, 2, 3, 6 
ENSG00000103184 SEC14L5  
ENSG00000104419 NDRG1 2, 3, 4, 5, 6 
ENSG00000104765 BNIP3L 1, 2, 6 
ENSG00000104812 GYS1 1, 2, 6 
ENSG00000105220 GPI 1, 4, 5 
ENSG00000105650 PDE4C  
ENSG00000105877 DNAH11  




ENSG00000109107 ALDOC 3, 4, 6 
ENSG00000111669 TPI1 1 
ENSG00000111674 ENO2 2, 3, 6 
ENSG00000112379 KIAA1244  
ENSG00000112715 VEGFA 1, 2 
ENSG00000113083 LOX 1, 2, 3, 6 
ENSG00000113739 STC2 2, 3, 4, 5, 6 
ENSG00000114023 FAM162A  
ENSG00000114268 PFKFB4 2, 3, 4, 5 
ENSG00000114480 GBE1 2, 3, 4, 5, 6 
ENSG00000114646 CSPG5  
ENSG00000115548 KDM3A 1 
ENSG00000116883 RP11-268J15.5  
ENSG00000116977 LGALS8 2 
ENSG00000117266 CDK18  
ENSG00000117394 SLC2A1 1, 2, 3, 4, 6 
ENSG00000119630 PGF  
ENSG00000119950 MXI1  
ENSG00000122884 P4HA1 2, 4, 5, 6 
ENSG00000123095 BHLHE41  
ENSG00000124116 WFDC3  
ENSG00000125629 INSIG2 2, 4, 6 
ENSG00000125895 TMEM74B  
ENSG00000127329 PTPRB 4 
ENSG00000127578 WFIKKN1 3 
ENSG00000127663 KDM4B 1 
ENSG00000129521 EGLN3 1, 2, 4, 5 
ENSG00000130821 SLC6A8 2 
ENSG00000131094 C1QL1  
ENSG00000131668 BARX1  
ENSG00000132139 GAS2L2  
ENSG00000133138 TBC1D8B 3 
ENSG00000133488 SEC14L4  
ENSG00000133874 RNF122  
ENSG00000134013 LOXL2 3, 4, 5, 6 
ENSG00000134107 BHLHE40 3 
ENSG00000134333 LDHA 1, 2, 4, 5 
ENSG00000135245 HILPDA  
ENSG00000135766 EGLN1 1, 2 
ENSG00000136352 NKX2-1  
ENSG00000137285 TUBB2B  
ENSG00000139832 RAB20 2 
ENSG00000141526 SLC16A3  
ENSG00000141959 PFKL 1, 2, 4 
ENSG00000143590 EFNA3 6 
ENSG00000143847 PPFIA4 6 
ENSG00000144063 MALL  
ENSG00000144320 KIAA1715 2 
ENSG00000145491 ROPN1L  
ENSG00000145901 TNIP1 2 
ENSG00000146094 DOK3  
ENSG00000146205 ANO7  
ENSG00000146674 IGFBP3 1, 4, 5, 6 
ENSG00000147036 LANCL3  
ENSG00000147852 VLDLR 6 
ENSG00000148926 ADM 1, 2, 3, 4, 6 




ENSG00000151882 CCL28  
ENSG00000152256 PDK1 1, 2, 4, 5, 6 
ENSG00000152952 PLOD2 2, 3, 4, 5 
ENSG00000153233 PTPRR 2 
ENSG00000154493 C10orf90  
ENSG00000159167 STC1 2, 3, 6 
ENSG00000159208 C1orf51 4 
ENSG00000159399 HK2 1, 3, 4, 6 
ENSG00000160999 SH2B2  
ENSG00000161544 CYGB  
ENSG00000161638 ITGA5 3, 4, 5 
ENSG00000161921 CXCL16  
ENSG00000161958 FGF11  
ENSG00000162433 AK4  
ENSG00000163516 ANKZF1 4 
ENSG00000163689 C3orf67  
ENSG00000164056 SPRY1 4 
ENSG00000164078 MST1R  
ENSG00000164096 C4orf3  
ENSG00000164638 SLC29A4  
ENSG00000164849 GPR146  
ENSG00000166046 TCP11L2 3 
ENSG00000167619 TMEM145  
ENSG00000167695 FAM57A  
ENSG00000167771 RCOR2 1 
ENSG00000167772 ANGPTL4 4, 6 
ENSG00000167971 CASKIN1  
ENSG00000168333 C8orf22  
ENSG00000168350 DEGS2  
ENSG00000170075 GPR37L1 4, 5 
ENSG00000170379 FAM115C  
ENSG00000170525 PFKFB3 1, 2, 3, 4, 5, 6 
ENSG00000171314 PGAM1 4 
ENSG00000171388 APLN  
ENSG00000172081 MOB3A  
ENSG00000173281 PPP1R3B 3 
ENSG00000173376 NDNF  
ENSG00000173566 NUDT18  
ENSG00000173727 AP000769.1  
ENSG00000173890 GPR160  
ENSG00000175414 ARL10  
ENSG00000175874 CREG2  
ENSG00000175938 ORAI3  
ENSG00000176171 BNIP3 1, 2, 3, 6 
ENSG00000176383 B3GNT4 6 
ENSG00000176428 VPS37D  
ENSG00000177181 RIMKLA  
ENSG00000177453 NIM1K  
ENSG00000177606 JUN 2, 3, 6 
ENSG00000178802 MPI 2, 4 
ENSG00000179148 ALOXE3 4 
ENSG00000179344 HLA-DQB1  
ENSG00000179403 VWA1  
ENSG00000180448 HMHA1  
ENSG00000180815 MAP3K15  
ENSG00000181350 FAM211A  




ENSG00000181577 C6orf223  
ENSG00000181652 ATG9B  
ENSG00000182580 EPHB3  
ENSG00000182896 TMEM95  
ENSG00000183111 ARHGEF37  
ENSG00000183775 KCTD16  
ENSG00000184441 AP001062.7  
ENSG00000184731 FAM110C 4 
ENSG00000185022 MAFF 2, 3 
ENSG00000185100 ADSSL1  
ENSG00000186314 PRELID2  
ENSG00000186352 ANKRD37 1, 4, 5 
ENSG00000186765 FSCN2  
ENSG00000186918 ZNF395 2, 4, 5 
ENSG00000187479 C11orf96  
ENSG00000187642 C1orf170  
ENSG00000187667 WHAMMP3  
ENSG00000188820 FAM26F  
ENSG00000196968 FUT11 5, 6 
ENSG00000197358 BNIP3P1  
ENSG00000197557 TTC30A  
ENSG00000197635 DPP4  
ENSG00000197930 ERO1L 2, 5, 6 
ENSG00000199038 MIR210  
ENSG00000203780 FANK1  
ENSG00000204128 C2orf72  
ENSG00000205129 C4orf47  
ENSG00000212864 RNF208  
ENSG00000213290 PGK1P2  
ENSG00000213700 RPL17P50  
ENSG00000213859 KCTD11 5 
ENSG00000214110 LDHAP4  
ENSG00000214193 SH3D21  
ENSG00000214274 ANG 3 
ENSG00000216285 RP11-490H24.5  
ENSG00000219607 PPP1R3G  
ENSG00000223573 TINCR  
ENSG00000225205 AC093818.1  
ENSG00000226415 TPI1P1  
ENSG00000226510 UPK1A-AS1  
ENSG00000227036 LINC00511  
ENSG00000227533 SLC2A1-AS1  
ENSG00000228288 PCAT6  
ENSG00000228328 RP11-516A11.1  
ENSG00000228451 SDAD1P1  
ENSG00000230432 AC114803.3  
ENSG00000230479 AP000695.6  
ENSG00000230581 RP11-390F4.8  
ENSG00000231881 RP5-1120P11.3  
ENSG00000231890 AC093391.2  
ENSG00000232788 AC078883.3  
ENSG00000233818 AP000695.4  
ENSG00000235601 RP11-231K24.2  
ENSG00000235847 LDHAP7  
ENSG00000236064 RP6-191P20.4  
ENSG00000236090 LDHAP3  




ENSG00000237686 RP5-1120P11.1  
ENSG00000240032 RP11-274H2.3  
ENSG00000241129 RPL22P19  
ENSG00000242114 MTFP1  
ENSG00000247095 MIR210HG  
ENSG00000251259 AC004069.2  
ENSG00000251359 WWC2-AS2  
ENSG00000253882 RP11-61L23.2  
ENSG00000254414 RP11-182J1.1  
ENSG00000254554 RP11-351I24.1  
ENSG00000255966 RP5-940J5.3  
ENSG00000256006 AC084117.3  
ENSG00000257913 RP11-386G11.5  
ENSG00000260822 GS1-358P8.4  
ENSG00000260919 CTD-3154N5.1  
ENSG00000261051 RP11-274H2.5  
ENSG00000263535 AK4P1  
ENSG00000263893 CTD-3010D24.3  
ENSG00000266677 RP11-258F1.1  
ENSG00000267424 CTD-2265O21.3  
ENSG00000267964 AC022400.2  
ENSG00000267976 AP000695.1  
ENSG00000268485 AC104841.2  
ENSG00000268603 RP11-316O14.1  
ENSG00000268852 AC132872.2  
ENSG00000268856 AP001579.1  
ENSG00000269968 RP5-940J5.9  
ENSG00000272114 RP1-261G23.7  






Table 9.4 – List of 100 HIF targets. Data adapted from (84) 












































































































Table 9.5 – List of 259 genes upregulated in hypoxia in 16 cell lines. Data was 
provided by Prof. Luis del Peso Ovalle, Madrid, Spain, after meta-analysis of hypoxia-treated 
gene profiling datasets across 19 experiments and 16 cell lines (85). 



















































































































































































































































































Table 9.6 – List of 1141 genes upregulated in hypoxia in HeLa cells. Data provided 
by Prof. Luis del Peso Ovalle, Madrid, Spain. Authors re-analysed microarray data 
taken from (238) and re-analysis was described in (85). 
Ensembl gene ID Gene name  Ensembl gene ID Gene name 
ENSG00000139193 CD27  ENSG00000176809 LRRC37A3 
ENSG00000171060 C8orf74  ENSG00000165029 ABCA1 
ENSG00000170262 MRAP  ENSG00000147613 PSKH2 
ENSG00000159788 RGS12  ENSG00000068366 ACSL4 
ENSG00000278468 MUC4  ENSG00000163636 PSMD6 
ENSG00000133703 KRAS  ENSG00000158825 CDA 
ENSG00000231479 SLC44A4  ENSG00000095303 PTGS1 
ENSG00000141639 MAPK4  ENSG00000173612 GPRC6A 
ENSG00000170264 FAM161A  ENSG00000243902 ELFN2 
ENSG00000248874 C5orf17  ENSG00000166897 ELFN2 
ENSG00000197776 KLHDC1  ENSG00000113070 HBEGF 
ENSG00000100612 DHRS7  ENSG00000147655 RSPO2 
ENSG00000118454 ANKRD13C  ENSG00000174944 P2RY14 
ENSG00000177606 JUN  ENSG00000156976 EIF4A2 
ENSG00000196839 ADA  ENSG00000242852 ZNF709 
ENSG00000131791 PRKAB2  ENSG00000178573 MAF 
ENSG00000273587 SNORA78  ENSG00000149948 HMGA2 
ENSG00000227720 PPP1R11  ENSG00000182168 UNC5C 
ENSG00000164266 SPINK1  ENSG00000242247 ARFGAP3 
ENSG00000145012 LPP  ENSG00000070495 JMJD6 
ENSG00000277209 RPPH1  ENSG00000234058 PPP1R11 
ENSG00000234444 ZNF736  ENSG00000046889 PREX2 
ENSG00000279386 GAFA3  ENSG00000115828 QPCT 
ENSG00000145692 BHMT  ENSG00000134046 MBD2 
ENSG00000117139 KDM5B  ENSG00000182752 PAPPA 
ENSG00000273608 SRCIN1  ENSG00000173852 DPY19L1 
ENSG00000225091 SNORA71A  ENSG00000182866 LCK 
ENSG00000200959 SNORA74A  ENSG00000173480 ZNF417 
ENSG00000109046 WSB1  ENSG00000197928 ZNF677 
ENSG00000273562 NAP1L4  ENSG00000182827 ACBD3 
ENSG00000145623 OSMR  ENSG00000188641 DPYD 
ENSG00000110203 FOLR3  ENSG00000136603 SKIL 
ENSG00000005381 MPO  ENSG00000166046 TCP11L2 
ENSG00000167978 SRRM2  ENSG00000006607 FARP2 
ENSG00000275099 GGNBP2  ENSG00000186818 LILRB4 
ENSG00000075151 EIF4G3  ENSG00000181374 CCL13 
ENSG00000213654 GPSM3  ENSG00000230128 IER3 
ENSG00000117595 IRF6  ENSG00000150627 WDR17 
ENSG00000170688 OR5E1P  ENSG00000159023 EPB41 
ENSG00000215301 DDX3X  ENSG00000011600 TYROBP 
ENSG00000154556 SORBS2  ENSG00000180219 FAM71C 
ENSG00000205592 MUC19  ENSG00000136868 SLC31A1 
ENSG00000162999 DUSP19  ENSG00000275498 PDXDC1 
ENSG00000164418 GRIK2  ENSG00000196267 ZNF836 
ENSG00000124508 BTN2A2  ENSG00000128739 SNRPN 
ENSG00000196826 ZNF709  ENSG00000173482 PTPRM 
ENSG00000112365 ZBTB24  ENSG00000147130 ZMYM3 
ENSG00000276709 PDXDC1  ENSG00000169314 C22orf15 
ENSG00000183303 OR5P2  ENSG00000117036 ETV3 




ENSG00000110841 PPFIBP1  ENSG00000149557 FEZ1 
ENSG00000115970 THADA  ENSG00000198851 CD3E 
ENSG00000149084 HSD17B12  ENSG00000273822 MUC4 
ENSG00000259581 TYRO3P  ENSG00000138641 HERC3 
ENSG00000172367 PDZD3  ENSG00000189376 C8orf76 
ENSG00000166896 XRCC6BP1  ENSG00000163867 ZMYM6 
ENSG00000155754 ALS2CR11  ENSG00000142515 KLK3 
ENSG00000197261 C6orf141  ENSG00000183814 LIN9 
ENSG00000179094 PER1  ENSG00000138767 CNOT6L 
ENSG00000169442 CD52  ENSG00000128590 DNAJB9 
ENSG00000179242 CDH4  ENSG00000077279 DCX 
ENSG00000119138 KLF9  ENSG00000127074 RGS13 
ENSG00000277956 MAPT  ENSG00000186529 CYP4F3 
ENSG00000186231 KLHL32  ENSG00000105426 PTPRS 
ENSG00000141543 EIF4A3  ENSG00000122644 ARL4A 
ENSG00000164751 PEX2  ENSG00000227231 IER3 
ENSG00000143768 LEFTY2  ENSG00000205358 MT1H 
ENSG00000229972 IQCF3  ENSG00000144130 NT5DC4 
ENSG00000260873 SNTB2  ENSG00000156273 BACH1 
ENSG00000064989 CALCRL  ENSG00000160584 SIK3 
ENSG00000115966 ATF2  ENSG00000080822 CLDND1 
ENSG00000132703 APCS  ENSG00000070614 NDST1 
ENSG00000138495 COX17  ENSG00000248098 BCKDHA 
ENSG00000196569 LAMA2  ENSG00000145819 ARHGAP26 
ENSG00000060237 WNK1  ENSG00000197548 ATG7 
ENSG00000151746 BICD1  ENSG00000203879 GDI1 
ENSG00000184619 KRBA2  ENSG00000162714 ZNF496 
ENSG00000148795 CYP17A1  ENSG00000091656 ZFHX4 
ENSG00000096088 PGC  ENSG00000081277 PKP1 
ENSG00000136250 AOAH  ENSG00000014914 MTMR11 
ENSG00000121741 ZMYM2  ENSG00000170122 FOXD4 
ENSG00000116685 KIAA2013  ENSG00000150540 HNMT 
ENSG00000136872 ALDOB  ENSG00000102144 PGK1 
ENSG00000162735 PEX19  ENSG00000145191 EIF2B5 
ENSG00000187210 GCNT1  ENSG00000137975 CLCA2 
ENSG00000143839 REN  ENSG00000146809 ASB15 
ENSG00000237155 IER3  ENSG00000206372 C2 
ENSG00000166171 DPCD  ENSG00000196131 VN1R2 
ENSG00000174177 CTU2  ENSG00000175582 RAB6A 
ENSG00000113739 STC2  ENSG00000111728 ST8SIA1 
ENSG00000215595 C20orf202  ENSG00000128881 TTBK2 
ENSG00000165383 LRRC18  ENSG00000142512 SIGLEC10 
ENSG00000179195 ZNF664  ENSG00000162571 TTLL10 
ENSG00000179889 PDXDC1  ENSG00000186001 LRCH3 
ENSG00000179869 ABCA13  ENSG00000179774 ATOH7 
ENSG00000233490 GPSM3  ENSG00000235336 SLC44A4 
ENSG00000233931 TRIM40  ENSG00000164142 FAM160A1 
ENSG00000102172 SMS  ENSG00000277585 MUC4 
ENSG00000141977 CIB3  ENSG00000169967 MAP3K2 
ENSG00000090020 SLC9A1  ENSG00000156515 HK1 
ENSG00000198844 ARHGEF15  ENSG00000163913 IFT122 
ENSG00000170683 OR10A3  ENSG00000136235 GPNMB 
ENSG00000144724 PTPRG  ENSG00000255794 RMST 
ENSG00000149633 KIAA1755  ENSG00000178974 FBXO34 
ENSG00000175262 C1orf127  ENSG00000065923 SLC9A7 
ENSG00000140521 POLG  ENSG00000163660 CCNL1 




ENSG00000144824 PHLDB2  ENSG00000106089 STX1A 
ENSG00000155816 FMN2  ENSG00000176731 C8orf59 
ENSG00000278555 LILRB4  ENSG00000237621 OR9A1P 
ENSG00000114316 USP4  ENSG00000163349 HIPK1 
ENSG00000104419 NDRG1  ENSG00000013503 POLR3B 
ENSG00000134668 SPOCD1  ENSG00000147894 C9orf72 
ENSG00000011405 PIK3C2A  ENSG00000018625 ATP1A2 
ENSG00000158427 TMSB15B  ENSG00000136750 GAD2 
ENSG00000006530 AGK  ENSG00000231543 C2 
ENSG00000198898 CAPZA2  ENSG00000111011 RSRC2 
ENSG00000127603 MACF1  ENSG00000169764 UGP2 
ENSG00000087074 PPP1R15A  ENSG00000116874 WARS2 
ENSG00000186094 AGBL4  ENSG00000047315 POLR2B 
ENSG00000160226 C21orf2  ENSG00000113532 ST8SIA4 
ENSG00000206501 PPP1R11  ENSG00000143257 NR1I3 
ENSG00000169495 HTRA4  ENSG00000215580 BCORP1 
ENSG00000099942 CRKL  ENSG00000198839 ZNF277 
ENSG00000081181 ARG2  ENSG00000171487 NLRP5 
ENSG00000163749 CCDC158  ENSG00000092200 RPGRIP1 
ENSG00000183696 UPP1  ENSG00000206314 GPSM3 
ENSG00000128683 GAD1  ENSG00000142409 ZNF787 
ENSG00000064012 CASP8  ENSG00000034239 EFCAB1 
ENSG00000100084 HIRA  ENSG00000169035 KLK7 
ENSG00000198650 TAT  ENSG00000137868 STRA6 
ENSG00000185477 GPRIN3  ENSG00000162761 LMX1A 
ENSG00000105737 GRIK5  ENSG00000235017 C2 
ENSG00000126785 RHOJ  ENSG00000136160 EDNRB 
ENSG00000112293 GPLD1  ENSG00000047457 CP 
ENSG00000109061 MYH1  ENSG00000153774 CFDP1 
ENSG00000168615 ADAM9  ENSG00000132530 XAF1 
ENSG00000125144 MT1G  ENSG00000203668 CHML 
ENSG00000184647 PRSS55  ENSG00000104953 TLE6 
ENSG00000205856 C22orf42  ENSG00000157152 SYN2 
ENSG00000129595 EPB41L4A  ENSG00000164123 C4orf45 
ENSG00000142621 FHAD1  ENSG00000120029 C10orf76 
ENSG00000110436 SLC1A2  ENSG00000229252 HLA-E 
ENSG00000278828 HIST1H3H  ENSG00000196071 OR2L13 
ENSG00000160588 MPZL3  ENSG00000224227 OR2L1P 
ENSG00000119688 ABCD4  ENSG00000281530 DGCR12 
ENSG00000139436 GIT2  ENSG00000136381 IREB2 
ENSG00000280641 CDH4  ENSG00000171180 OR2M4 
ENSG00000153094 BCL2L11  ENSG00000179059 ZFP42 
ENSG00000224196 OR5AK4P  ENSG00000262327 AGK 
ENSG00000196932 TMEM26  ENSG00000006128 TAC1 
ENSG00000125414 MYH2  ENSG00000127578 WFIKKN1 
ENSG00000159348 CYB5R1  ENSG00000152952 PLOD2 
ENSG00000075239 ACAT1  ENSG00000154277 UCHL1 
ENSG00000188559 RALGAPA2  ENSG00000186350 RXRA 
ENSG00000079841 RIMS1  ENSG00000183023 SLC8A1 
ENSG00000105649 RAB3A  ENSG00000168806 LCMT2 
ENSG00000079263 SP140  ENSG00000273953 OR10A3 
ENSG00000118263 KLF7  ENSG00000114127 XRN1 
ENSG00000165704 HPRT1  ENSG00000184012 TMPRSS2 
ENSG00000144668 ITGA9  ENSG00000103966 EHD4 
ENSG00000137331 IER3  ENSG00000160401 C9orf117 
ENSG00000154316 TDH  ENSG00000100433 KCNK10 




ENSG00000112941 PAPD7  ENSG00000228001 TRIM40 
ENSG00000102796 DHRS12  ENSG00000259905 PWRN1 
ENSG00000253313 C1orf210  ENSG00000225201 HLA-E 
ENSG00000152760 TCTEX1D1  ENSG00000010404 IDS 
ENSG00000100490 CDKL1  ENSG00000104343 UBE2W 
ENSG00000184203 PPP1R2  ENSG00000180777 ANKRD30B 
ENSG00000228567 VN1R4  ENSG00000072682 P4HA2 
ENSG00000067992 PDK3  ENSG00000183255 PTTG1IP 
ENSG00000130066 SAT1  ENSG00000114480 GBE1 
ENSG00000213203 GIMAP1  ENSG00000237403 PPP1R11 
ENSG00000280497 OR5E1P  ENSG00000185013 NT5C1B 
ENSG00000278466 MUC2  ENSG00000276429 PLCH2 
ENSG00000133138 TBC1D8B  ENSG00000131778 CHD1L 
ENSG00000116748 AMPD1  ENSG00000269226 TMSB15B 
ENSG00000156076 WIF1  ENSG00000165030 NFIL3 
ENSG00000118689 FOXO3  ENSG00000174473 GALNTL6 
ENSG00000078142 PIK3C3  ENSG00000152684 PELO 
ENSG00000039068 CDH1  ENSG00000170310 STX8 
ENSG00000239305 RNF103  ENSG00000130414 NDUFA10 
ENSG00000106511 MEOX2  ENSG00000168421 RHOH 
ENSG00000120693 SMAD9  ENSG00000116151 MORN1 
ENSG00000118046 STK11  ENSG00000078043 PIAS2 
ENSG00000136488 CSH1  ENSG00000159167 STC1 
ENSG00000241697 TMEFF1  ENSG00000141279 NPEPPS 
ENSG00000186868 MAPT  ENSG00000135253 KCP 
ENSG00000161638 ITGA5  ENSG00000153707 PTPRD 
ENSG00000078304 PPP2R5C  ENSG00000172890 NADSYN1 
ENSG00000146143 PRIM2  ENSG00000186952 TMEM232 
ENSG00000133835 HSD17B4  ENSG00000119950 MXI1 
ENSG00000171044 XKR6  ENSG00000059804 SLC2A3 
ENSG00000164761 TNFRSF11B  ENSG00000120738 EGR1 
ENSG00000119771 KLHL29  ENSG00000130592 LSP1 
ENSG00000166747 AP1G1  ENSG00000177842 ZNF620 
ENSG00000144285 SCN1A  ENSG00000013588 GPRC5A 
ENSG00000107518 ATRNL1  ENSG00000185070 FLRT2 
ENSG00000103275 UBE2I  ENSG00000049167 ERCC8 
ENSG00000213901 SLC23A3  ENSG00000112964 GHR 
ENSG00000078114 NEBL  ENSG00000198908 BHLHB9 
ENSG00000075539 FRYL  ENSG00000129226 CD68 
ENSG00000232641 MOG  ENSG00000111674 ENO2 
ENSG00000147753 TTTY7  ENSG00000243335 KCTD7 
ENSG00000082126 MPP4  ENSG00000006740 ARHGAP44 
ENSG00000164287 CDC20B  ENSG00000145794 MEGF10 
ENSG00000166278 C2  ENSG00000116717 GADD45A 
ENSG00000134757 DSG3  ENSG00000121064 SCPEP1 
ENSG00000152348 ATG10  ENSG00000172243 CLEC7A 
ENSG00000229077 SLC44A4  ENSG00000117394 SLC2A1 
ENSG00000164161 HHIP  ENSG00000163602 RYBP 
ENSG00000168386 FILIP1L  ENSG00000179335 CLK3 
ENSG00000170788 DYDC1  ENSG00000172578 KLHL6 
ENSG00000018408 WWTR1  ENSG00000115457 IGFBP2 
ENSG00000145321 GC  ENSG00000214274 ANG 
ENSG00000044524 EPHA3  ENSG00000100292 HMOX1 
ENSG00000127831 VIL1  ENSG00000147571 CRH 
ENSG00000143384 MCL1  ENSG00000108239 TBC1D12 
ENSG00000153933 DGKE  ENSG00000060069 CTDP1 




ENSG00000203837 PNLIPRP3  ENSG00000162105 SHANK2 
ENSG00000169403 PTAFR  ENSG00000155093 PTPRN2 
ENSG00000277363 SRCIN1  ENSG00000146926 ASB10 
ENSG00000184678 HIST2H2BE  ENSG00000203463 SLC44A4 
ENSG00000082153 BZW1  ENSG00000166183 ASPG 
ENSG00000197343 ZNF655  ENSG00000276042 LILRB4 
ENSG00000173575 CHD2  ENSG00000241489 IDS 
ENSG00000188277 C15orf62  ENSG00000171759 PAH 
ENSG00000124151 NCOA3  ENSG00000206478 IER3 
ENSG00000175315 CST6  ENSG00000265241 RBM8A 
ENSG00000186452 TMPRSS12  ENSG00000186866 POFUT2 
ENSG00000137968 SLC44A5  ENSG00000187987 ZSCAN23 
ENSG00000105855 ITGB8  ENSG00000278311 GGNBP2 
ENSG00000173258 ZNF483  ENSG00000173848 NET1 
ENSG00000262145 XRCC6BP1  ENSG00000101236 RNF24 
ENSG00000138670 RASGEF1B  ENSG00000171223 JUNB 
ENSG00000178538 CA8  ENSG00000151729 SLC25A4 
ENSG00000163661 PTX3  ENSG00000156873 PHKG2 
ENSG00000204592 HLA-E  ENSG00000140538 NTRK3 
ENSG00000183643 C15orf32  ENSG00000138722 MMRN1 
ENSG00000110315 RNF141  ENSG00000159399 HK2 
ENSG00000148357 HMCN2  ENSG00000176177 ENTHD1 
ENSG00000179387 ELMOD2  ENSG00000150961 SEC24D 
ENSG00000111880 RNGTT  ENSG00000117519 CNN3 
ENSG00000230254 HLA-E  ENSG00000237046 TRIM40 
ENSG00000198408 MGEA5  ENSG00000186051 TAL2 
ENSG00000187193 MT1X  ENSG00000187144 SPATA21 
ENSG00000221818 EBF2  ENSG00000149573 MPZL2 
ENSG00000186260 MKL2  ENSG00000139496 NUPL1 
ENSG00000150593 PDCD4  ENSG00000152578 GRIA4 
ENSG00000115310 RTN4  ENSG00000175602 CCDC85B 
ENSG00000103227 LMF1  ENSG00000115461 IGFBP5 
ENSG00000147647 DPYS  ENSG00000121691 CAT 
ENSG00000168918 INPP5D  ENSG00000187608 ISG15 
ENSG00000147488 ST18  ENSG00000118245 TNP1 
ENSG00000112576 CCND3  ENSG00000155876 RRAGA 
ENSG00000137672 TRPC6  ENSG00000204161 C10orf128 
ENSG00000102218 RP2  ENSG00000065609 SNAP91 
ENSG00000113971 NPHP3  ENSG00000175592 FOSL1 
ENSG00000075292 ZNF638  ENSG00000213231 TCL1B 
ENSG00000112077 RHAG  ENSG00000152104 PTPN14 
ENSG00000204381 LAYN  ENSG00000100368 CSF2RB 
ENSG00000150275 PCDH15  ENSG00000169026 MFSD7 
ENSG00000145850 TIMD4  ENSG00000176171 BNIP3 
ENSG00000277276 OTUB2  ENSG00000163995 ABLIM2 
ENSG00000185022 MAFF  ENSG00000168297 PXK 
ENSG00000120519 SLC10A7  ENSG00000189152 GRAPL 
ENSG00000171617 ENC1  ENSG00000140945 CDH13 
ENSG00000166592 RRAD  ENSG00000080371 RAB21 
ENSG00000186575 NF2  ENSG00000236399 TRIM40 
ENSG00000142627 EPHA2  ENSG00000163406 SLC15A2 
ENSG00000185920 PTCH1  ENSG00000040341 STAU2 
ENSG00000002016 RAD52  ENSG00000134013 LOXL2 
ENSG00000126581 BECN1  ENSG00000251493 FOXD1 
ENSG00000142867 BCL10  ENSG00000160321 ZNF208 
ENSG00000089199 CHGB  ENSG00000236561 MOG 




ENSG00000275730 LILRB4  ENSG00000100842 EFS 
ENSG00000198125 MB  ENSG00000010610 CD4 
ENSG00000089723 OTUB2  ENSG00000236560 PPP1R11 
ENSG00000172575 RASGRP1  ENSG00000175445 LPL 
ENSG00000048540 LMO3  ENSG00000041982 TNC 
ENSG00000139793 MBNL2  ENSG00000169242 EFNA1 
ENSG00000112299 VNN1  ENSG00000175155 YPEL2 
ENSG00000113734 BNIP1  ENSG00000137857 DUOX1 
ENSG00000235696 C2  ENSG00000160013 PTGIR 
ENSG00000177694 NAALADL2  ENSG00000107819 SFXN3 
ENSG00000281486 SNTG2  ENSG00000120254 MTHFD1L 
ENSG00000138735 PDE5A  ENSG00000177570 SAMD12 
ENSG00000140332 TLE3  ENSG00000138792 ENPEP 
ENSG00000091317 CMTM6  ENSG00000126091 ST3GAL3 
ENSG00000136169 SETDB2  ENSG00000214456 PLIN5 
ENSG00000159958 TNFRSF13C  ENSG00000185915 KLHL34 
ENSG00000145687 SSBP2  ENSG00000113083 LOX 
ENSG00000162882 HAAO  ENSG00000164684 ZNF704 
ENSG00000074695 LMAN1  ENSG00000080224 EPHA6 
ENSG00000129535 NRL  ENSG00000112096 SOD2 
ENSG00000124762 CDKN1A  ENSG00000072364 AFF4 
ENSG00000135929 CYP27A1  ENSG00000138083 SIX3 
ENSG00000224496 TRIM40  ENSG00000088926 F11 
ENSG00000104714 ERICH1  ENSG00000178694 NSUN3 
ENSG00000164483 SAMD3  ENSG00000163646 CLRN1 
ENSG00000161649 CD300LG  ENSG00000217128 FNIP1 
ENSG00000172236 TPSAB1  ENSG00000075420 FNDC3B 
ENSG00000170423 KRT78  ENSG00000132681 ATP1A4 
ENSG00000198133 TMEM229B  ENSG00000178243 C9orf62 
ENSG00000170579 DLGAP1  ENSG00000206378 SLC44A4 
ENSG00000121361 KCNJ8  ENSG00000183114 FAM43B 
ENSG00000125810 CD93  ENSG00000185742 C11orf87 
ENSG00000142484 TM4SF5  ENSG00000118407 FILIP1 
ENSG00000153071 DAB2  ENSG00000204385 SLC44A4 
ENSG00000179420 OR6W1P  ENSG00000101782 RIOK3 
ENSG00000184194 GPR173  ENSG00000164304 CAGE1 
ENSG00000147570 DNAJC5B  ENSG00000104371 DKK4 
ENSG00000113448 PDE4D  ENSG00000123384 LRP1 
ENSG00000175229 GAL3ST3  ENSG00000116675 DNAJC6 
ENSG00000117500 TMED5  ENSG00000130164 LDLR 
ENSG00000033178 UBA6  ENSG00000196104 SPOCK3 
ENSG00000233314 PPP1R11  ENSG00000050438 SLC4A8 
ENSG00000259001 RPPH1  ENSG00000177879 AP3S1 
ENSG00000102096 PIM2  ENSG00000168447 SCNN1B 
ENSG00000168243 GNG4  ENSG00000227458 TRIM40 
ENSG00000138738 PRDM5  ENSG00000163141 BNIPL 
ENSG00000181982 CCDC149  ENSG00000183963 SMTN 
ENSG00000189195 BTBD8  ENSG00000156218 ADAMTSL3 
ENSG00000161944 ASGR2  ENSG00000204614 TRIM40 
ENSG00000104549 SQLE  ENSG00000134107 BHLHE40 
ENSG00000123610 TNFAIP6  ENSG00000145782 ATG12 
ENSG00000204655 MOG  ENSG00000111700 SLCO1B3 
ENSG00000138764 CCNG2  ENSG00000176566 DCAF4L2 
ENSG00000198574 SH2D1B  ENSG00000138642 HERC6 
ENSG00000196177 ACADSB  ENSG00000237834 MOG 
ENSG00000012504 NR1H4  ENSG00000197465 GYPE 




ENSG00000182035 ADIG  ENSG00000149527 PLCH2 
ENSG00000143727 ACP1  ENSG00000135423 GLS2 
ENSG00000116260 QSOX1  ENSG00000114098 ARMC8 
ENSG00000122420 PTGFR  ENSG00000115808 STRN 
ENSG00000184650 ODF4  ENSG00000137766 UNC13C 
ENSG00000127377 CRYGN  ENSG00000163424 C3orf30 
ENSG00000151229 SLC2A13  ENSG00000155380 SLC16A1 
ENSG00000127481 UBR4  ENSG00000100934 SEC23A 
ENSG00000146282 RARS2  ENSG00000169032 MAP2K1 
ENSG00000153046 CDYL  ENSG00000141194 OR4D1 
ENSG00000135740 SLC9A5  ENSG00000078596 ITM2A 
ENSG00000184786 TCTE3  ENSG00000164385 C6orf195 
ENSG00000140416 TPM1  ENSG00000121904 CSMD2 
ENSG00000206493 HLA-E  ENSG00000267206 LCN6 
ENSG00000155508 CNOT8  ENSG00000109103 UNC119 
ENSG00000120149 MSX2  ENSG00000198453 ZNF568 
ENSG00000234508 GPSM3  ENSG00000168032 ENTPD3 
ENSG00000186340 THBS2  ENSG00000171133 OR2K2 
ENSG00000125398 SOX9  ENSG00000104722 NEFM 
ENSG00000137770 CTDSPL2  ENSG00000122335 SERAC1 
ENSG00000125675 GRIA3  ENSG00000255713 OR4D2 
ENSG00000198467 TPM2  ENSG00000164879 CA3 
ENSG00000100285 NEFH  ENSG00000226560 C2 
ENSG00000148926 ADM  ENSG00000102032 RENBP 
ENSG00000076944 STXBP2  ENSG00000110218 PANX1 
ENSG00000141985 SH3GL1  ENSG00000276613 MUC4 
ENSG00000206190 ATP10A  ENSG00000155313 USP25 
ENSG00000101311 FERMT1  ENSG00000143774 GUK1 
ENSG00000169469 SPRR1B  ENSG00000237829 PPP1R11 
ENSG00000162645 GBP2  ENSG00000114388 NPRL2 
ENSG00000168556 ING2  ENSG00000099783 HNRNPM 
ENSG00000162391 FAM151A  ENSG00000140479 PCSK6 
ENSG00000139990 DCAF5  ENSG00000161594 KLHL10 
ENSG00000173281 PPP1R3B  ENSG00000198961 PJA2 
ENSG00000163492 CCDC141  ENSG00000142599 RERE 
ENSG00000183347 GBP6  ENSG00000221866 PLXNA4 
ENSG00000067798 NAV3  ENSG00000141519 CCDC40 
ENSG00000160305 DIP2A  ENSG00000138395 CDK15 
ENSG00000162772 ATF3  ENSG00000111335 OAS2 
ENSG00000168807 SNTB2  ENSG00000156500 FAM122C 
ENSG00000113712 CSNK1A1  ENSG00000173421 CCDC36 
ENSG00000234623 MOG  ENSG00000138435 CHRNA1 
ENSG00000155545 MIER3  ENSG00000182230 FAM153B 
ENSG00000141314 RHBDL3  ENSG00000067066 SP100 
ENSG00000168658 VWA3B  ENSG00000069966 GNB5 
ENSG00000141469 SLC14A1  ENSG00000139973 SYT16 
ENSG00000213639 PPP1CB  ENSG00000130270 ATP8B3 
ENSG00000162928 PEX13  ENSG00000135365 PHF21A 
ENSG00000070756 PABPC1  ENSG00000137345 MOG 
ENSG00000241484 ARHGAP8  ENSG00000164691 TAGAP 
ENSG00000004846 ABCB5  ENSG00000123500 COL10A1 
ENSG00000197779 ZNF81  ENSG00000259207 ITGB3 
ENSG00000084112 SSH1  ENSG00000103507 BCKDK 
ENSG00000171843 MLLT3  ENSG00000033122 LRRC7 
ENSG00000276644 DACH1  ENSG00000135924 DNAJB2 
ENSG00000276025 OR5P2  ENSG00000107447 DNTT 




ENSG00000120708 TGFBI  ENSG00000133742 CA1 
ENSG00000063854 HAGH  ENSG00000057663 ATG5 
ENSG00000151692 RNF144A  ENSG00000170525 PFKFB3 
ENSG00000137809 ITGA11  ENSG00000161542 PRPSAP1 
ENSG00000095370 SH2D3C  ENSG00000109107 ALDOC 
ENSG00000280055 TMEM75  ENSG00000163803 PLB1 
ENSG00000237052 GPSM3  ENSG00000002587 HS3ST1 
ENSG00000198788 MUC2  ENSG00000180008 SOCS4 
ENSG00000010327 STAB1  ENSG00000154485 MMP21 
ENSG00000221995 TIAF1  ENSG00000163131 CTSS 
ENSG00000015171 ZMYND11  ENSG00000006576 PHTF2 
ENSG00000089847 ANKRD24  ENSG00000176293 ZNF135 
ENSG00000142233 NTN5  ENSG00000002079 MYH16 
ENSG00000172594 SMPDL3A  ENSG00000204619 PPP1R11 
ENSG00000176659 C20orf197  ENSG00000137962 ARHGAP29 
ENSG00000115414 FN1  ENSG00000104888 SLC17A7 
ENSG00000085274 MYNN  ENSG00000148848 ADAM12 
ENSG00000102678 FGF9  ENSG00000273984 MUC4 
ENSG00000197976 AKAP17A  ENSG00000152049 KCNE4 
ENSG00000164124 TMEM144  ENSG00000273579 C22orf15 
ENSG00000173545 ZNF622  ENSG00000144426 NBEAL1 
ENSG00000100116 GCAT  ENSG00000011347 SYT7 
ENSG00000177947 ODF3  ENSG00000221914 PPP2R2A 
ENSG00000126217 MCF2L  ENSG00000174953 DHX36 
ENSG00000137802 MAPKBP1  ENSG00000233904 HLA-E 
ENSG00000198743 SLC5A3  ENSG00000152056 AP1S3 
ENSG00000167995 BEST1  ENSG00000275368 TCTE3 
ENSG00000155066 PROM2  ENSG00000068971 PPP2R5B 
ENSG00000183826 BTBD9  ENSG00000243064 ABCC13 
ENSG00000164327 RICTOR  ENSG00000077157 PPP1R12B 
ENSG00000204120 GIGYF2  ENSG00000074410 CA12 
ENSG00000165338 HECTD2  ENSG00000236697 GPSM3 
ENSG00000180532 ZSCAN4  ENSG00000167797 CDK2AP2 
ENSG00000204403 CASP12  ENSG00000281020 SNTG2 
ENSG00000234096 MOG  ENSG00000176597 B3GNT5 
ENSG00000115956 PLEK  ENSG00000228263 SLC44A4 
ENSG00000151014 CCRN4L  ENSG00000143632 ACTA1 
ENSG00000232180 SLC44A4  ENSG00000114315 HES1 
ENSG00000145113 MUC4  ENSG00000162992 NEUROD1 
ENSG00000131389 SLC6A6  ENSG00000113645 WWC1 
ENSG00000177324 BEND2  ENSG00000168542 COL3A1 
ENSG00000179133 C10orf67  ENSG00000076067 RBMS2 
ENSG00000180336 C17orf104  ENSG00000184863 RBM33 
ENSG00000130021 HDHD1  ENSG00000163879 DNALI1 
ENSG00000122121 XPNPEP2  ENSG00000122641 INHBA 
ENSG00000172554 SNTG2  ENSG00000185087 FAM169B 
ENSG00000205277 MUC12  ENSG00000115232 ITGA4 
ENSG00000100504 PYGL  ENSG00000009790 TRAF3IP3 
ENSG00000115020 PIKFYVE  ENSG00000162852 CNST 
ENSG00000077585 GPR137B  ENSG00000184292 TACSTD2 
ENSG00000196876 SCN8A  ENSG00000150907 FOXO1 
ENSG00000144218 AFF3  ENSG00000111676 ATN1 
ENSG00000236632 HLA-E  ENSG00000055483 USP36 
ENSG00000114857 NKTR  ENSG00000216937 CCDC7 
ENSG00000280278 FLJ30679  ENSG00000100784 RPS6KA5 
ENSG00000166819 PLIN1  ENSG00000162692 VCAM1 




ENSG00000136110 LECT1  ENSG00000076554 TPD52 
ENSG00000168268 NT5DC2  ENSG00000278303 MUC4 
ENSG00000152910 CNTNAP4  ENSG00000158113 LRRC43 
ENSG00000180061 TMEM150B  ENSG00000175077 RTP1 
ENSG00000170180 GYPA  ENSG00000007933 FMO3 
ENSG00000230885 MOG  ENSG00000065135 GNAI3 
ENSG00000085265 FCN1  ENSG00000155890 TRIM42 
ENSG00000103316 CRYM  ENSG00000146192 FGD2 
ENSG00000145016 KIAA0226  ENSG00000146592 CREB5 
ENSG00000058063 ATP11B  ENSG00000275052 SMEK2 
ENSG00000048828 FAM120A  ENSG00000161040 FBXL13 
ENSG00000183117 CSMD1  ENSG00000150076 CCDC7 
ENSG00000170743 SYT9  ENSG00000170417 TMEM182 
ENSG00000163975 MFI2  ENSG00000135679 MDM2 
ENSG00000114841 DNAH1  ENSG00000129990 SYT5 
ENSG00000137825 ITPKA  ENSG00000159527 PGLYRP3 
ENSG00000205531 NAP1L4  ENSG00000135801 TAF5L 
ENSG00000110852 CLEC2B  ENSG00000052749 RRP12 
ENSG00000147316 MCPH1  ENSG00000222047 C10orf55 
ENSG00000120645 IQSEC3  ENSG00000187783 TMEM72 
ENSG00000126216 TUBGCP3  ENSG00000048052 HDAC9 
ENSG00000172179 PRL  ENSG00000163814 CDCP1 
ENSG00000160471 COX6B2  ENSG00000196123 KIAA0895L 
ENSG00000180043 FAM71E2  ENSG00000111790 FGFR1OP2 
ENSG00000163081 CCDC140  ENSG00000185112 FAM43A 
ENSG00000272602 ZNF595  ENSG00000127249 ATP13A4 
ENSG00000181355 OFCC1  ENSG00000001084 GCLC 
ENSG00000112655 PTK7  ENSG00000043462 LCP2 
ENSG00000170166 HOXD4  ENSG00000115657 ABCB6 
ENSG00000185684 EP400NL  ENSG00000173273 TNKS 
ENSG00000128652 HOXD3  ENSG00000138036 DYNC2LI1 
ENSG00000102984 ZNF821  ENSG00000092295 TGM1 
ENSG00000239827 SUGT1P3  ENSG00000128563 PRKRIP1 
ENSG00000103642 LACTB  ENSG00000113361 CDH6 
ENSG00000130182 ZSCAN10  ENSG00000143514 TP53BP2 
ENSG00000116117 PARD3B  ENSG00000138640 FAM13A 
ENSG00000198155 ZNF876P  ENSG00000121594 CD80 
ENSG00000133858 ZFC3H1  ENSG00000172995 ARPP21 
ENSG00000164588 HCN1  ENSG00000164494 PDSS2 
ENSG00000281763 DHX36  ENSG00000204364 C2 
ENSG00000013725 CD6  ENSG00000124249 KCNK15 
ENSG00000062038 CDH3  ENSG00000160678 S100A1 
ENSG00000155097 ATP6V1C1  ENSG00000064205 WISP2 
ENSG00000077420 APBB1IP  ENSG00000180263 FGD6 
ENSG00000156413 FUT6  ENSG00000083444 PLOD1 
ENSG00000119979 FAM45A  ENSG00000158473 CD1D 
ENSG00000126391 FRMD8  ENSG00000184635 ZNF93 
ENSG00000234243 GPSM3  ENSG00000160683 CXCR5 
ENSG00000128585 MKLN1  ENSG00000161640 SIGLEC11 
ENSG00000189144 ZNF573  ENSG00000148136 OR13C4 
ENSG00000070019 GUCY2C  ENSG00000131477 RAMP2 
ENSG00000089472 HEPH  ENSG00000166342 NETO1 
ENSG00000140749 IGSF6  ENSG00000176641 RNF152 
ENSG00000173221 GLRX  ENSG00000101443 WFDC2 
ENSG00000196361 ELAVL3  ENSG00000197471 SPN 
ENSG00000048707 VPS13D  ENSG00000264943 SH3GL1P2 




ENSG00000147459 DOCK5  ENSG00000138777 PPA2 
ENSG00000185942 NKAIN3  ENSG00000172183 ISG20 
ENSG00000109684 CLNK  ENSG00000164934 DCAF13 
ENSG00000221869 CEBPD  ENSG00000126218 F10 
ENSG00000163961 RNF168  ENSG00000242441 GTF2A1L 
ENSG00000166598 HSP90B1  ENSG00000165527 ARF6 
ENSG00000131969 ABHD12B  ENSG00000128016 ZFP36 
ENSG00000163568 AIM2  ENSG00000106366 SERPINE1 
ENSG00000143520 FLG2  ENSG00000148175 STOM 
ENSG00000122545 SEPT7  ENSG00000164591 MYOZ3 
ENSG00000072041 SLC6A15  ENSG00000166507 NDST2 
ENSG00000172524 TRIM40  ENSG00000136827 TOR1A 
ENSG00000104332 SFRP1  ENSG00000278279 LILRB4 
ENSG00000143226 FCGR2A  ENSG00000125910 S1PR4 
ENSG00000114120 SLC25A36  ENSG00000276155 MAPT 
ENSG00000071991 CDH19  ENSG00000049246 PER3 
ENSG00000262607 IQSEC3  ENSG00000235030 IER3 
ENSG00000173404 INSM1  ENSG00000103723 AP3B2 
ENSG00000126457 PRMT1  ENSG00000056050 C4orf27 
ENSG00000107798 LIPA  ENSG00000095777 MYO3A 
ENSG00000155052 CNTNAP5  ENSG00000128242 GAL3ST1 
ENSG00000124145 SDC4  ENSG00000164543 STK17A 
ENSG00000114268 PFKFB4  ENSG00000281614 INPP5D 
ENSG00000186480 INSIG1  ENSG00000281434 NDUFA10 
ENSG00000156966 B3GNT7  ENSG00000281917 SLC16A1 
ENSG00000077522 ACTN2  ENSG00000280931 OR5P2 
ENSG00000127241 MASP1  ENSG00000281056 OR5E1P 
ENSG00000026297 RNASET2  ENSG00000281680 OR10A3 
ENSG00000140285 FGF7  LRG_16 ADA 
ENSG00000075340 ADD2  LRG_165 STXBP2 
ENSG00000101928 MOSPD1  LRG_179 CLEC7A 
ENSG00000113916 BCL6  LRG_184 TNFRSF13C 
ENSG00000135749 PCNXL2  LRG_185 RNF168 
ENSG00000204397 CARD16  LRG_236 CTDP1 
ENSG00000174611 KY  LRG_258 NDRG1 
ENSG00000164746 C7orf57  LRG_26 C2 
ENSG00000185811 IKZF1  LRG_274 LDLR 
ENSG00000100055 CYTH4  LRG_3 COL3A1 
ENSG00000164616 FBXL21  LRG_301 CDH1 
ENSG00000143842 SOX13  LRG_319 STK11 
ENSG00000196381 ZNF781  LRG_326 ZBTB24 
ENSG00000092871 RFFL  LRG_34 CASP8 
ENSG00000105398 SULT2A1  LRG_341 UNC119 
ENSG00000005156 LIG3  LRG_349 MASP1 
ENSG00000087510 TFAP2C  LRG_357 CD27 
ENSG00000105835 NAMPT  LRG_365 HK1 
ENSG00000154478 GPR26  LRG_38 CD3E 
ENSG00000185250 PPIL6  LRG_409 LAMA2 
ENSG00000171345 KRT19  LRG_411 NEBL 
ENSG00000143061 IGSF3  LRG_451 ACADSB 
ENSG00000100519 PSMC6  LRG_452 FOXD4 
ENSG00000115590 IL1R2  LRG_466 ERCC8 
ENSG00000119938 PPP1R3C  LRG_511 NF2 
ENSG00000056487 PHF21B  LRG_515 PTCH1 
ENSG00000141527 CARD14  LRG_6 ATP1A2 
ENSG00000118520 ARG1  LRG_607 TYROBP 




ENSG00000169905 TOR1AIP2  LRG_653 ANG 
ENSG00000221937 TAS2R40  LRG_700 CLRN1 
ENSG00000197753 LHFPL5  LRG_722 DPYD 
ENSG00000120129 DUSP1  LRG_725 MAP2K1 
ENSG00000248144 ADH1C  LRG_8 SCN1A 
ENSG00000169057 MECP2  LRG_84 MPO 






Table 9.7 – List of top ten conserved motifs in genes found overlapped between 

























2274 Genes having at least one 
occurrence of the highly 
conserved motif M169 
TTTNNANAGCYR in the 
region spanning up to 4 kb 
around their transcription start 
sites. The motif does not match 









766 Genes having at least one 
occurrence of the highly 
conserved motif M24 
GGGAGGRR in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif matches transcription 
factor binding site V$MAZ_Q6 









2940 Genes having at least one 
occurrence of the highly 
conserved motif M115 
YRTCANNRCGC in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif does not match any 









2485 Genes having at least one 
occurrence of the highly 
conserved motif M7 
TGANTCA in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif matches transcription 









1524 Genes having at least one 
occurrence of the highly 
conserved motif M41 
TGACAGNY in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif matches transcription 
factor binding site 














occurrence of the highly 
conserved motif M114 
YTCCCRNNAGGY in the 
region spanning up to 4 kb 
around their transcription start 
sites. The motif does not match 





265 Genes having at least one 
occurrence of the transcription 
factor binding site 
V$GATA6_01 (v7.4 
TRANSFAC) in the regions 
spanning up to 4 kb around their 









2061 Genes having at least one 
occurrence of the highly 
conserved motif M55 
TGGAAA in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif matches transcription 
factor binding site 








230 Genes having at least one 
occurrence of the transcription 
factor binding site V$HIF1_Q3 
(v7.4 TRANSFAC) in the 
regions spanning up to 4 kb 










1232 Genes having at least one 
occurrence of the highly 
conserved motif M72 
TTCYRGAA in the region 
spanning up to 4 kb around their 
transcription start sites. The 
motif does not match any 










Table 9.8 – List of genes found overlapped between hypoxia and IOX2 (not 
VH032) containing at least one conserved motifs stated in Appendix Table 9.7.  
Entrez gene ID for each gene is listed. Number 1-10 correspond to # in Appendix 
Table 9.7, which contains details of conserved motifs. X indicates that the gene contains 
the conserved motif. 
Entrez Gene Id Gene Symbol 1 2 3 4 5 6 7 8 9 10 
2597 GAPDH X X X X  X    X 
4035 LRP1 X X X  X      
30008 EFEMP2 X X X        
9066 SYT7 X X  X  X X    
222171 PRR15 X X  X       
3861 KRT14 X X    X  X   
8541 PPFIA3 X X        X 
9770 RASSF2 X  X X X X  X   
6261 RYR1 X  X X X      
28951 TRIB2 X  X X       
3201 HOXA4 X  X    X X  X 
901 CCNG2 X  X     X   
205428 C3orf58 X  X     X   
5460 POU5F1 X  X       X 
1026 CDKN1A X  X        
6920 TCEA3 X  X        
84929 FIBCD1 X  X        
4607 MYBPC3 X   X   X    
9744 ACAP1 X   X       
139728 PNCK X   X       
1852 DUSP9 X   X       
154743 C7orf60 X    X   X X  
9094 UNC119 X    X     X 
8642 DCHS1 X         X 
54890 ALKBH5 X          
242 ALOX12B X          
8572 PDLIM4  X X  X   X   
139596 UPRT  X X        
4582 MUC1  X X        
7511 XPNPEP1  X   X    X  
1755 DMBT1  X    X     
5493 PPL  X         
963 CD53  X         
1132 CHRM4  X         
84251 SGIP1   X X X  X X  X 
92359 CRB3   X X       
50619 DEF6   X X       
64866 CDCP1   X X       
7138 TNNT1   X  X X     
56901 NDUFA4L2   X  X      
8325 FZD8   X   X     
151556 GPR155   X    X    
5794 PTPRH   X        
3300 DNAJB2   X        
91373 UAP1L1   X        
9022 CLIC3   X        
23480 SEC61G   X        




113791 PIK3IP1    X    X X  
10865 ARID5A    X    X  X 
10529 NEBL    X       
79152 FA2H    X       
5604 MAP2K1    X       
2706 GJB2    X       
54852 PAQR5    X       
113828 FAM83F    X       
5737 PTGFR    X       
5054 SERPINE1     X X     
54541 DDIT4     X   X X  
5066 PAM     X   X  X 
51760 SYT17     X      
5365 PLXNB3     X      
2825 GPR1     X      
9241 NOG      X X   X 
55279 ZNF654      X  X   
4783 NFIL3      X   X X 
4093 SMAD9      X     
3237 HOXD11      X     
3868 KRT16      X     
50506 DUOX2      X     
7036 TFR2       X X   
164633 CABP7        X  X 
3484 IGFBP1        X   
79858 NEK11        X   
8780 RIOK3        X   
55760 DHX32        X   
5507 PPP1R3C         X  
771 CA12          X 
 
